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SUMMARY
Survivin belongs to the inhibitor of apoptosis protein family and is also a regulator of
mitosis as it is a member of the chromosomal passenger complex (CPC). While it is
not expressed in differentiated adult tissue (Adida et al., 1998), it was found to be up-
regulated in virtually all types of human cancers (Ambrosini et al., 1997; Adida et al.,
2000). Its overexpression is associated with resistance of tumors against chemo- and
radiotherapy, frequent recurrences and decreased patient survival (Engels et al., 2007;
Capalbo et al., 2007; Xu et al., 2014; Chen et al., 2014). Thus, Survivin is a potential
target for cancer therapy. In order to develop strategies for the therapeutic inhibition of
Survivin, the mechanisms underlying its dual role have to be clarified in detail. While
Survivin fulfills some of its cellular tasks as a homodimer (Pavlyukov et al., 2011), other
functions require the monomer (Jeyaprakash et al., 2007). A further layer of complexity
is introduced by the fact that Survivin shuttles between the nucleus and the cytoplasm
as it is able to passively diffuse into the nucleus and is actively exported by the sol-
uble receptor CRM1 (Rodriguez et al., 2002; Knauer et al., 2006). The mechanisms
regulating Survivin’s functions, its localization as well as its dimerization state are still
not completely resolved and a matter of scientific disagreement. Recently, Wang et al.
(2010b) reported that acetylation of Survivin at lysine 129 facilitates its dimerization,
thus causing an accumulation of the protein in the nucleus as only the monomer is
able to interact with CRM1 for nuclear export. As lysine acetylation has emerged as
a major post-translational modification capable of altering the functions and interac-
tions of proteins, it is conceivable that Survivin’s function might be regulated by the
acetylation of any of its 16 lysine residues.
Thus, as a preliminary work to our study, which aimed to identify further acetylation
sites in Survivin and the effect of a potential acetylation on some of Survivin’s functions,
we first set out to verify the findings obtained by Wang et al. (2010b). Accordingly, we
cloned the four SurvK129 mutants investigated in their study and characterized them
performing comprehensive molecular and structural analyses. Wang et al. (2010b)
reported a facilitated nuclear export and a reduced tendency to form dimers for the
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SurvK129E mutant, which they refered to as a mimicking mutant for Survivin unmod-
ified at K129. They also claimed that this mutant was comparable to the SurvK129R
mutant bearing a lysine to arginine mutation typically introduced to mimic an unmodi-
fied lysine. In contrast to their results, we found that SurvK129E is unique among the
analyzed SurvK129 mutants and not comparable to SurvK129R. Taken together, our
results suggest that the effects observed for SurvK129E are not caused by the lack
of acetylation at K129, but might be due to the emergence of a potential high-affinity
export signal by the exchange of a positively charged lysine with a negatively charged
glutamate at position 129. Moreover, our findings indicate that acetylation of Survivin
at K129 impairs dimerization rather than facilitating it.
Furthermore, we wanted to find out whether Survivin acetylated at K129 is involved in
mitosis. Our analyses indeed indicate that acetylated Survivin might be incorporated
into the CPC.
Finally, potential further acetylation sites within the Survivin protein were identified by
in situ acetylation prediction. Fifteen Survivin mutants were cloned in which probably
acetylated lysine residues were either mutated to arginine or to glutamine in order to
mimic an unmodified or an acetylated lysine residue. These mutants were analyzed
accordingly to the SurvK129 mutants in order to reveal potential effects on Survivin’s
cellular and mitotic localization as well as on its dimerization. However, the character-
ization of the mutants could not identify lysine residues potentially involved in Survivin
regulation. Nevertheless, we could show that, although K90 is located within Survivin’s
classical export signal, its acetylation is unlikely to affect the protein’s dimerization.
In summary, our results indicate that further comprehensive studies are required in
order to understand the complex regulation of Survivin’s various functions and the role
that lysine acetylation plays in it.
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Survivin gehört zur Proteinfamilie der Apoptose-Inhibitoren, ist aber als Mitglied des
chromosomalen Passenger-Complexes (CPC) ebenso an der Regulation der Mitose
beteiligt. Während es in differenziertem, adulten Gewebe nicht exprimiert wird (Adida
et al., 1998), wurde eine Hochregulation in nahezu allen humanen Krebsarten nach-
gewiesen (Ambrosini et al., 1997; Adida et al., 2000). Seine Überexpression steht in
Verbindung mit der Resistenz von Tumoren gegen Chemo- und Strahlentherapie, ei-
nem häufigen Wiederauftreten von Tumoren und einer verringerten Überlebenszeit der
Patienten (Engels et al., 2007; Capalbo et al., 2007; Xu et al., 2014; Chen et al., 2014).
Demzufolge stellt Survivin ein mögliches Angriffsziel für die Krebstherapie dar. Die Ent-
wicklung von Strategien zur therapeutischen Inhibition von Survivin setzt jedoch ein
grundlegendes Verständnis der molekularen Mechanismen, die seiner Doppelfunktion
zugrunde liegen, voraus. Seine duale Rolle führt Survivin innerhalb der Zelle teilweise
als Monomer, zum Teil aber auch als Homodimer aus. Survivin ist zudem in der La-
ge, zwischen Zellkern und Cytoplasma hin und her zu wandern, indem der durch den
Exportrezeptor CRM1 vermittelte, aktive Export aus dem Kern der passiven Diffusion
entgegenwirkt (Rodriguez et al., 2002; Knauer et al., 2006). Die Mechanismen, welche
die Funktion, Lokalisation und Dimerisierung von Survivin regulieren, konnten bisher
nicht vollständig aufgeklärt werden und sind Gegenstand kontroverser wissenschaftli-
cher Diskussionen. Einer Studie von Wang et al. (2010b) zufolge fördert die Acetylie-
rung von Survivin an Lysin 129 dessen Dimerisierung. Dies führt zu einer Ansammlung
des Proteins im Zellkern, da nur das Survivin-Monomer an den Exportrezeptor CRM1
binden kann. Da die Lysin-Acetylierung zudem als eine bedeutende post-translationale
Modifikation gilt, welche die Funktionen und Interaktionen von Proteinen beeinflussen
kann, ist eine Regulation von Survivin durch die Acetylierung einiger seiner 16 Lysin-
Reste durchaus denkbar.
Zunächst wurden zur Verifizierung der Ergebnisse von Wang et al. (2010b) die dort
verwendeten vier SurvK129-Mutanten kloniert und mittels umfassender molekularer
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und struktureller Analysen charakterisiert. Wang et al. (2010b) beschreiben einen er-
leichterten Kernexport sowie eine verringerte Dimerisierungstendenz der SurvK129E-
Mutante, welche in dieser Studie als an Lysin 129 nicht modifizierbar charakterisiert
wird. Auch sei diese Mutante vergleichbar mit der SurvK129R-Mutante, die eine Lysin-
zu-Arginin-Mutation trägt, welche typischerweise zur Nachahmung eines unmodifizier-
ten Lysins eingeführt wird. Im Gegensatz zu Wang et al. (2010b) konnten wir zeigen,
dass SurvK129E einzigartig unter den betrachteten SurvK129-Mutanten und nicht ver-
gleichbar mit SurvK129R ist. Insgesamt weisen unsere Ergebnisse darauf hin, dass
die Effekte, die für die SurvK129E-Mutante beobachtet wurden, nicht durch die feh-
lende Acetylierung an K129, sondern durch die Entstehung eines möglichen Exportsi-
gnals mit einer hohen Affinität zu CRM1 hervorgerufen werden könnten. Die Erhöhung
der Affinität des möglicherweise bestehenden, schwachen Exportsignals käme dabei
durch den Austausch des positiv geladenen Lysins an Position 129 durch ein negativ
geladenes Glutamat zustande. Darüberhinaus deuten unsere Erkenntnisse eher auf
eine Beeinträchtigung als auf eine Begünstigung der Dimerisierung durch die Acetylie-
rung an K129 hin.
Im Rahmen unserer Untersuchungen zur Rolle von acetyliertem Survivin in der Mito-
se deutete sich weiterhin an, dass im CPC gebundenes Survivin acetyliert vorliegen
könnte.
Weitere mögliche Acetylierungsstellen innerhalb von Survivin wurden durch eine in situ
Acetylierungsvorhersage identifiziert. Darauf basierend wurden 15 Survivin-Mutanten
kloniert, in welchen mit hoher Wahrscheinlichkeit acetylierte Lysin-Reste zu Arginin
oder Glutamin mutiert wurden, um entweder ein unmodifiziertes oder ein acetyliertes
Lysin zu imitieren. Diese Mutanten wurden analog zu den SurvK129-Mutanten ana-
lysiert, um mögliche Effekte auf die zelluläre und mitotische Lokalisation sowie die
Dimerisierung von Survivin nachzuweisen. Anhand dieser Untersuchungen konnten
allerdings keine Lysin-Reste identifiziert werden, welche eine tragende Rolle in dessen
Regulation spielen. Allerdings ist davon auszugehen, dass eine Beeinträchtigung der
Dimerisierung durch die Acetylierung von Lysin 90 unwahrscheinlich ist, obwohl sich
dieses innerhalb des klassischen Exportsignals von Survivin befindet.
Zusammenfassend implizieren unsere Ergebnisse, dass weitere umfassende Studien
nötig sind, um die komplexe Regulation der verschiedenen Funktionen von Survivin
und insbesondere die Rolle der Lysin-Acetylierung im Detail zu verstehen.
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1 INTRODUCTION
1.1 Cancer
Cancer is the second most common cause of death in Germany following diseases of
the circulatory system. In 2012, 222,000 people died from cancer, which corresponds
to 25.5 % of all cases of death (Federal Statistical Office Germany, 2014). According
to estimates, approx. 252,000 men and 225,000 women were newly diagnosed with
cancer in 2010 (Robert Koch Institute and the Association of Population-based Cancer
Registries in Germany, 2014). While the most frequently occurring cancer types in men
were prostate (26.1 %), lung (13.9 %) and colorectal cancer (13.4 %), in women almost
one third of new cancer cases were caused by breast cancer, followed by colorectal
(12.7 %) and lung cancer (7.6 %) (Figure 1.1).
Figure 1.1: Estimated incidence of different tumor types in Germany 2010. Most frequent
tumor sites as a percentage of all new cancer cases. (Robert Koch Institute and the Association
of Population-based Cancer Registries in Germany, 2014).
With 24.9 % lung cancer is the major cause of cancer death cases in men, whereas
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breast cancer causes the highest mortality in women (17.4 %) (Figure 1.2). The prob-
ability to develop cancer rises with increasing age. The median age at which cancer is
diagnosed is 69 years for both sexes. Today, every second man and 43 % of all women
have to expect to develop cancer in the course of their life.
Figure 1.2: Estimated mortality of different tumor types in Germany 2010. Most frequent
tumor sites as a percentage of all cases of death caused by cancer. (Robert Koch Institute and
the Association of Population-based Cancer Registries in Germany, 2014).
1.1.1 Carcinogenesis
The term "cancer" is a generic term used for all malignant tumors. A tumor is defined
as an abnormal growth of new tissue (neoplasia), which can be benign or malignant. In
contrast to a benign tumor, which only ousts the surrounding tissue, but stays localized,
cells of a malignant tumor can breach the basal membrane and invade adjacent tissue.
Furthermore, they are capable of forming metastases in other parts of the body, distant
from the primary tumor (Weinberg, 2013). The ability of malignant tumors to invade and
metastasize is one of the six "hallmarks of cancer" proposed by Hanahan and Weinberg
in 2000 describing the biological capabilities of malignant tumors acquired during their
multistep development. As further hallmarks, the ability of cancers to enable replicative
immortality, induce angiogenesis, resist cell death, sustain proliferative signaling as
well as to evade growth suppressors were suggested. In 2011, Hanahan and Weinberg
have revisited and expanded their concept of cancer hallmarks due to new insights in
cancer research (Figure 1.3). The capability to deregulate cellular energetics and to
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avoid destruction by the immune system were added to the list as emerging hallmarks,
which have to be validated by further research. Genome instability and mutations as
well as a tumor-promoting inflammation were described as characteristics enabling a
tumor to become malignant.
Figure 1.3: The hallmarks of cancer. Acquired capabilities of malignant cancer cells (modified
after Hanahan and Weinberg, 2011).
As mentioned before, carcinogenesis is a multistep process. It is characterized by the
successive accumulation of genomic alterations caused by inherited and/or sponta-
neous mutations, chromosomal rearrangements and epigenetic changes (Hanahan
and Weinberg, 2011). Alterations in different types of genes have been shown to con-
tribute to cancer development. Tumor suppressor genes (TSGs), also called "gatekeep-
ers" (Kinzler and Vogelstein, 1997), are genes whose products govern cell proliferation,
promote differentiation or induce apoptosis (Weinberg, 2013). Their inactivation (loss
of function), for example by point mutation, chromosomal deletion or promotor methyla-
tion, enables a defective cell to override these control mechanisms and further prolifer-
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ate, thus increasing the probability that the cell will undergo neoplastic transformation.
The loss of function phenotype is usually recessive, implying that it only occurs when
both alleles have become inactivated. The most prominent and initially identified TSGs
are tumor protein 53 (TP53) (Finlay et al., 1989; Levine et al., 2004) and retinoblastoma
1 (RB1) (Lee, 1989).
Another group of genes behaving similar to TSGs are the genome maintenance genes,
also known as "caretakers" (Kinzler and Vogelstein, 1997). Their gene products are in-
volved in sensing DNA damage and activating the repair machinery (e.g. breast cancer
type 1/2 susceptibility protein (BRCA1/2)), or they directly repair DNA lesions or inacti-
vate mutagenic molecules, thus sustaining genomic integrity (Hanahan and Weinberg,
2011).
Oncogenes, a third type of genes contributing to carcinogenesis, are former normal
cellular genes (proto-oncogenes) which have been activated by mutations, chromoso-
mal translocations or amplifications, or transcriptionally by a virus. Consequences of
the activation of a proto-oncogene are the overexpression of the gene product or the
expression of a protein with altered function (Weinberg, 2013). Most oncogenes code
for proteins involved in mitogenic signaling pathways, for example growth factors (e.g.
transforming growth factor α (TGF-α)), their receptors (e.g. epidermal growth factor
receptor (EGFR)), GTPases (e.g. hRas), or transcription factors (e.g. Myc).
In addition to genome instability outlined above, the second characteristic enabling
normal cells to become malignant is the tumor-promoting inflammation (Hanahan and
Weinberg, 2011). It has been observed that many tumors are infiltrated by immune
cells, already in early stages of neoplasia (Dvorak, 1986). Such immune responses,
reflecting the attempt of the immune system to eradicate tumors, paradoxically, not al-
ways lead to the destruction of the tumors, but can even promote tumorigenesis by
helping incipient neoplasms to acquire hallmark capabilities. Tumor-promoting inflam-
matory cells, like macrophages, mast cells, neutrophils as well as B and T lymphocytes,
contribute to the transformation of neoplastic cells in several ways, for example by sup-
plying growth or survival factors (e.g. epidermal growth factor (EGF), vascular endothe-
lial growth factor (VEGF)), which facilitate proliferation and prevent apoptosis, or by se-
creting extracellular matrix (ECM)-modifying enzymes (e.g. matrix metalloproteinase-9
(MMP-9)) fostering invasion and angiogenesis. They can also release mutagenic reac-
tive oxygen species, which increase the rate of genomic alterations in the tumor cells
(Colotta et al., 2009; Grivennikov et al., 2010; DeNardo et al., 2010).
The definition of the tumor-promoting inflammation as an enabling characteristic of
cancer development is due to a new understanding of cancer. While earlier a tumor
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was considered to be nothing more than an accumulation of cancer cells, it is now clear
that all cell types surrounding the cancer cells play a crucial role in carcinogenesis.
Among these are the already mentioned cells of the immune system, but also other
mesenchymal cells like endothelial cells, pericytes and cancer-associated fibroblasts,
forming the tumor stroma (Figure 1.4A). A complex heterotypic signaling occurs in the
tumor microenvironment, in which reciprocal interactions between tumor and stroma
cells promote the transformation of normal tissue to cancer (Figure 1.4B) (Hu and
Polyak, 2008; Goubran et al., 2014; Landskron et al., 2014).
Figure 1.4: The tumor microenvironment. A) Cell types constituting the tumor microenvi-
ronment of most solid tumors. B) Examples of reciprocal heterotypic signaling interactions in
the tumor microenvironment (modified after Hanahan and Weinberg, 2011). EGF: epidermal
growth factor, CSF-1: colony stimulating factor 1, IL-1β: interleukin 1β, VEGF: vascular en-
dothelial growth factor, TGF-β: transforming growth factor β, CXCL12: C-X-C motif chemokine
12, Ang-1: angiopoietin 1, PDGF: platelet-derived growth factor, HGF: hepatocyte growth factor,
Hh: hedgehog, FGF2: fibroblast growth factor 2.
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1.2 Survivin
Survivin, with 16.5 kDa the smallest member of the inhibitor of apoptosis protein (IAP)
family and a member of the chromosomal passenger complex (CPC), is up-regulated
in various human cancers (Ambrosini et al., 1997; Adida et al., 2000). Its overexpres-
sion is associated with resistance of tumors against chemo- and radiotherapy, frequent
recurrences and decreased patient survival (Engels et al., 2007; Capalbo et al., 2007;
Xu et al., 2014; Chen et al., 2014). Besides its up-regulation in cancer cells, Survivin is
highly expressed during embryonic and fetal development, but absent in differentiated
adult tissue (Adida et al., 1998).
The gene coding for Survivin, BIRC5 (baculoviral IAP repeat containing 5), contains
four exons and three introns and is located on chromosome 17q25 (Ambrosini et al.,
1997). Alternative splicing of the pre-mRNA gives rise to five different transcripts: Sur-
vivin, Survivin∆Ex3, Survivin3B, Survivin2B and Survivin2α. In normal dividing cells,
BIRC5 expression is tightly regulated in a cell cycle-dependent manner peaking at the
G2/M transition of the cell cycle (Li et al., 1998). Also epigenetic regulation through
DNA (cytosine-5)-methyltransferase 1 (DNMT1) or histone deacetylase 1 (HDAC1) as
well as post-transcriptional control by microRNAs has been reported (Smallwood et al.,
2007; Alajez et al., 2011; Ma et al., 2013). Survivin overexpression in cancer is due to
mutations in its promotor (Xu et al., 2004; Boidot et al., 2010), gene duplication (Tajiri
et al., 2001) or deregulation of its related transcription factors. Among them are several
known as products of TSGs, such as the retinoblastoma protein (pRb) and p53, as
well as oncogenes, for example Myc (Jiang et al., 2004; Hoffman et al., 2002; Mirza
et al., 2002; Cosgrave et al., 2006). Hence, in many tumors Survivin is found not only
in dividing, but also in interphase cells (Engels et al., 2007).
The gene product of BIRC5, the Survivin protein, has a unique structure (Figure 1.5).
The monomer contains three regions enabling the protein to interact with other proteins
and conduct its various functions. The N-terminal BIR domain (amino acid (aa) 15-88)
characterizes Survivin as a member of the IAP family as this domain is common to
all IAPs. It is a globular zinc finger domain stabilized by the tetrahedral coordination
of a Zn2+ ion by the amino acids C57, C60, H77 and C84. Survivin’s long C-terminal
α-helix (aa 99-142) extends out and away from the BIR domain. Hydrogen bonds as
well as hydrophobic contacts between the BIR domain and the first turns of the helix
stabilize it and fix its direction. It contains a cluster of hydrophobic amino acids between
F124 and L138 which functions as an adaptor for protein-protein interactions. Between
the BIR domain and Survivin’s C-terminal helix, a linker region is located containing two
overlapping, functionally important features: the nuclear export signal (NES)(aa 89-98),
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Figure 1.5: Structure of the Survivin protein. A) Domain organization of Survivin. B) Ribbon
representation of the Survivin homodimer (Chantalat et al., 2000; PDB ID: 1E31). C) The view
in B rotated by 90° around the horizontal axis. The N-terminal BIR domain is depicted in blue,
the NES in orange and the C-terminal α-helix in red. The dimer interface is indicated by a black
bar. The Zn2+ion is shown as a cyan sphere.
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which serves as the binding site for the nuclear export receptor chromosome region
maintenance 1 (CRM1), and one part of the dimer interface (aa 6-10 and 89-102). The
dimer interface is formed by hydrophobic contacts of L98 from one monomer with a
hydrophobic pocket composed of L6, W10, F93, F101 and F102 of the other monomer.
The Survivin homodimer formed in solution has a bow tie shape with the C-terminal
α-helices forming a 110° angle (Chantalat et al., 2000; Verdecia et al., 2000).
In addition to the transcriptional control of BIRC5, Survivin is also regulated on the
protein level by post-translational modifications (PTMs). The stability of the protein is
regulated by proteasomal degradation dependent on the cell cycle. Increased degra-
dation due to K48-linked ubiquitination has been observed at the end of mitosis (Zhao
et al., 2000). It has also been reported that XIAP-associated factor 1 (XAF1), a pro-
apoptotic factor that can bind to X-linked inhibitor of apoptosis protein (XIAP) and inhibit
its anti-caspase function, induces Survivin ubiquitination and the subsequent protea-
somal degradation by activating XIAP’s E3 ubiquitin ligase activity (Arora et al., 2007).
The interaction of Survivin with the chaperones Hsp60 and Hsp90 (heat shock pro-
teins 60 and 90), in contrast, retains its stability against degradation by the proteasome
(Fortugno et al., 2003; Ghosh et al., 2008). Further PTMs, such as phosphorylation and
acetylation, have been found to regulate Survivin (Figure 1.6). These are discussed in
detail below, according to their function.
Figure 1.6: Post-translational modifications regulating Survivin. Schematic representation
of Survivin’s domain structure indicating sites of known post-translational modifications. While
phosphorylation occurs at amino acids within the BIR domain (blue), acetylated residues are
mainly located in Survivin’s α-helix (red) and the NES (orange). Ubiquitination is not depicted
as the targeted positions have not yet been identified. Kinases are indicated as green spheres,
acetyltransferases as yellow spheres (O’Connor et al., 2000a; Wheatley et al., 2004; Dohi et al.,
2007; Colnaghi and Wheatley, 2010; Wang et al., 2010b; Barrett et al., 2011). BIR: baculoviral
IAP repeat, NES: nuclear export signal, PLK1: polo-like kinase 1, PKA: protein kinase A, CDK1:
cyclin-dependent kinase 1, CK2: casein kinase 2, AurB: Aurora B, CBP: CREB-binding protein.
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As mentioned above, Survivin belongs to the inhibitor of apoptosis protein family since
it contains a baculoviral IAP repeat (BIR) domain. The human IAP family consists of
eight proteins: Apollon, inhibitor of apoptosis-like protein 2 (ILP2), Livin, Survivin, neu-
ronal apoptosis inhibitory protein (NAIP), cellular inhibitor of apoptosis proteins 1 and
2 (c-IAP1/2) and XIAP (Riedl and Shi, 2004) (Figure 1.7). Unlike the seven other IAPs,
Survivin contains only one BIR domain and no further protein domains like CARD (cas-
pase recruitment domain) or RING (really interesting new gene) domains.
Figure 1.7: The human members of the IAP family. Schematic representation of the human
inhibitor of apoptosis proteins including Apollon, ILP2, Livin, Survivin, NAIP, c-IAP1, c-IAP2 and
XIAP. A conserved linker peptide that precedes the BIR2 domain of XIAP, c-IAP1 and c-IAP2
and is responsible for inhibiting caspases-3 and -7 is indicated in red (modified after Riedl and
Shi, 2004). NAIP: neuronal apoptosis inhibitory protein, c-IAP1/2: cellular inhibitor of apoptosis
proteins 1/2, XIAP: X-linked inhibitor of apoptosis protein, BIR: baculoviral IAP repeat, RING:
really interesting new gene, CARD: caspase recruitment domain.
BIR domains mediate protein recognition and protein-protein interactions (Altieri, 2010).
XIAP, c-IAP1 and c-IAP2, for example, bind proteins containing an IAP-binding mo-
tif (IBM) via one of their BIR domains. IBMs are present in caspases as well as in
certain apoptosis inducers for instance second mitochondria-derived activator of cas-
pase/direct IAP-binding protein with low pI (Smac/DIABLO). Caspase inhibition by di-
rect interaction was originally proposed for all IAPs including Survivin (Deveraux and
Reed, 1999; Tamm et al., 1998; Shin et al., 2001). Recent studies, however, revealed
that only XIAP can directly interact with caspases in vivo (Eckelman et al., 2006;
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Srinivasula and Ashwell, 2008). For Survivin, various modes of indirect inhibition of
caspase-dependent cell death have been reported. Survivin can form a complex with
XIAP resulting in an increased stability of XIAP against proteasomal degradation. This
complex, but not Survivin alone, is able to suppress caspase-9 activity. Phosphoryla-
tion of Survivin at S20 by protein kinase A (PKA) disrupts the interaction of Survivin
with XIAP (Dohi et al., 2004, 2007). A similar function has been shown for a Survivin-
HBXIP (hepatitis B X-interacting protein) complex, which precludes pro-caspase-9 re-
cruitment to activated apoptotic protease activating factor 1 (APAF-1), thus preventing
the formation of the apoptosome (Marusawa et al., 2003). Song et al. (2003) have
reported that Survivin binds to the pro-apoptotic factor Smac/DIABLO in the cytosol.
Consequently, XIAP is released from an inhibiting complex with Smac/DIABLO and
can conduct its anti-apoptotic function. In addition, mitochondrial Survivin, which can
be released from mitochondria upon apoptotic stimuli, has been described as a regu-
lator of Smac/DIABLO release from mitochondria as it can sequester the pro-apoptotic
factor in the intermembrane space (Ceballos-Cancino et al., 2007). Barrett et al. (2011)
have demonstrated that the phosphorylation of cytoplasmic Survivin at T48 by ca-
sein kinase 2 (CK2) is also required to inhibit caspases. Besides abrogating caspase-
dependent apoptosis, Survivin is also involved in the inhibition of caspase-independent
cell death. A study by Pavlyukov et al. (2011) revealed that Survivin prevents the re-
lease of apoptosis-inducing factor (AIF), a marker for caspase-independent apoptosis,
from mitochondria. Survivin’s cytoprotective activity conferring therapy resistance to
tumor cells is assumed to be conducted by cytoplasmic Survivin, whereas nuclear Sur-
vivin seems to be involved in regulating cell division (Lippert et al., 2007). However,
it has been shown that Survivin phosphorylated at T34 by cyclin-dependent kinase 1
(CDK1) is able to protect cells from cell death by inhibiting caspase-9 during mitosis
(O’Connor et al., 2000a; Barrett et al., 2009).
As aforementioned, Survivin has a dual role. Besides its anti-apoptotic function as an
IAP, it is also a key regulator of cell division as a member of the chromosomal pas-
senger complex (see subsection 1.3.4). During mitosis, the CPC regulates chromo-
some condensation, correction of erroneous kinetochore-microtubule attachments as
well as the activation of the spindle assembly checkpoint (SAC). In cytokinesis, it con-
trols the formation and function of the contractile ring that drives the abscission of the
two daughter cells (Carmena et al., 2012). The CPC is composed of a localization mod-
ule and a kinase module linked together by the central region of the inner centromere
protein (INCENP). The localization module, which comprises INCENP’s N-terminus,
Borealin and Survivin, targets the CPC first to centromeres, later to the mitotic spindle,
and last to the midbody. All three proteins contain stretched α-helices which interact
with each other to form a stable three-helical bundle, the core of the CPC (Figure 1.8)
10
1 INTRODUCTION
(Jeyaprakash et al., 2007). The kinase module consisting of Aurora B kinase and the
C-terminus of INCENP provides the enzymatic activity of the complex (Adams et al.,
2000). Together, both modules allow spatially restricted phosphorylation of Aurora B
substrates via dynamic changes in the localization of the CPC during mitosis and cy-
tokinesis.
Figure 1.8: Structure of the chromosomal passenger complex. A) Schematic representa-
tion of the CPC (modified after Carmena et al., 2012). The domains and functions of the CPC
members are indicated. B) Ribbon representation of the three-helical bundle forming the core
of the CPC (Jeyaprakash et al., 2007; PDB ID: 2QFA). Survivin is shown in green, Borealin in
blue and INCENP in yellow. HP1: heterochromatin protein 1, CPC: chromosomal passenger
complex.
Survivin is responsible for targeting the CPC to centromers in early prophase. Its BIR
domain has been shown to directly bind the N-terminus of histone H3 phosphorylated
at T3 (H3T3Ph), a mitosis-specific phosphorylation mark most prominent at the inner
centromer (Jeyaprakash et al., 2011; Carmena et al., 2012). Additionally, it has been
demonstrated that the interaction of the nuclear export receptor CRM1 with Survivin’s
NES (aa 89-98) is important for tethering the CPC to centromeres as well as for CPC
function, but not for its assembly (Knauer et al., 2006). For the association of Sur-
vivin to centromeres, furthermore, its ubiquitination through K63 ubiquitin linkages by
ubiquitin fusion degradation protein 1 (UFD1) is necessary, while its deubiquitination
by hFAM (fat facets in mammals) is required for its dissociation (Vong et al., 2005).
Besides Survivin’s function in CPC localization, its phosphorylation at S20 by polo-
like kinase 1 (PLK1) is required for accurate chromosome alignment since it causes a
complete activation of Aurora B (Colnaghi and Wheatley, 2010; Chu et al., 2011). The
phosphorylation of Survivin at T117 by Aurora B during mitosis has been reported to
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regulate localization and stability of the CPC, and its dephosphorylation is crucial for
progression to anaphase (Wheatley et al., 2004, 2007; Delacour-Larose et al., 2007).
In general, Survivin inhibition results in mitotic defects for instance cell cycle arrest at
prometaphase, abberant spindle formation, cytokinesis failure and multinucleated cells
(Conte and Altieri, 2006). Aside from Survivin which is part of the CPC, there is another
pool of the protein conducting a critical role in mitosis: Survivin bound to polymerized
microtubules has been shown to depress microtubule dynamics, sustain their stability,
and thus, support the assembly of mitotic spindles (Altieri, 2006).
In addition to its roles in apoptosis and mitosis, several other functions have recently
been indicated for Survivin. Capalbo et al. (2010) and Reichert et al. (2011) reported
that Survivin is linked to DNA repair as it rapidly accumulates in nuclear foci after ir-
radiation and forms complexes with members of the DNA double strand break repair
machinery. Survivin has also been related to inhibiting autophagy and promoting an-
giogenesis (Niu et al., 2010; Wang et al., 2011; O’Connor et al., 2000b; Tran et al.,
2002).
While originally only the Survivin homodimer was considered to be functionally active
(Muchmore et al., 2000; Song et al., 2004), recent studies have demonstrated that the
dimer as well as the monomer play distinct roles in critical cellular processes. It has
been shown that only the Survivin monomer can be part of the CPC (Jeyaprakash
et al., 2007), and interact with CRM1 for its nuclear export (Engelsma et al., 2007).
Moreover, Pavlyukov et al. (2011) found that monomeric Survivin prevents caspase-
dependent apoptosis by interacting with Smac/DIABLO and XIAP, and that it can also
inhibit caspase-independent cell death by preventing AIF release from mitochondria.
They could also show that only the Survivin dimer is able to stabilize microtubules. A
further function attributed to the Survivin homodimer is the inhibition of signal trans-
ducer and activator of transcription 3 (STAT3) transactivation (Wang et al., 2010b).
Wang et al. (2010b) suggested that acetylation of Survivin at K129 in the nucleus func-
tions as a switch between the momoneric and dimeric state of the protein: while CREB-
binding protein (CBP)-mediated acetylation facilitates Survivin homodimerization and
inhibits its interaction with the export receptor CRM1, its deacetylation by HDAC6 fa-
vors the monomeric state of Survivin which shows enhanced binding to CRM1, and
consequently, is exported to the cytoplasm (Wang et al., 2010b; Riolo et al., 2012).
It has been demonstrated before that the homodimerization of Survivin antagonizes its
nuclear export (Engelsma et al., 2007; Jeyaprakash et al., 2007). This is due to the
overlap of a classical leucine-rich nuclear export signal (89VKKQFEELTL98) identified
by Knauer et al. (2006) with one part of Survivin’s dimer interface. The NES is recog-
nized by the soluble export receptor CRM1, which mediates active export of Survivin
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from the nucleus. However, as mentioned above, the NES is not only required for Sur-
vivin’s nuclear export, but also for its targeting to centromeres in mitosis. Survivin lack-
ing the NES, or containing a NES in which two critical hydrophobic residues (L96 and
L98) are mutated to alanine, does not localize to centromeres, thus impairing the cor-
rect localization and function of the CPC. Inhibition of the Survivin-CRM1 interaction by
leptomycin B (LMB) also leads to mislocalization of Survivin and other CPC members
(Knauer et al., 2006). In addition to the classical NES, Rodriguez et al. (2002) proposed
a non-classical CRM1-dependent export motif in the α-helix of Survivin. Their study re-
vealed that Surv119-142, like the NES-containing fragment Surv89-136, predominantly
localized to the cytoplasm and relocated to the nucleus upon CRM1 inhibition by LMB.
However, the exact sequence of this export motif has not been further defined. They
speculated that CRM1-dependent export of Survivin via this motif could be mediated
by a NES-containing adapter protein, rather than via direct interaction.
1.3 The cell cycle
The cell cycle, a process in which cells undergo the replication of their DNA, the di-
vision of their nucleus, and last, the division of their cytoplasm, is the mechanism by
which all living cells reproduce. The cell cycle of eukaryotic cells is divided into four
phases: G1 (gap 1), S (synthesis), G2 (gap 2) and M (mitosis) (Figure 1.9). G1, S and
G2 together are named interphase. In many types of cultured mammalian cells, G1
lasts 12-15 h, S phase 6-8 h, G2 3-5 h and M phase only 1 h (Weinberg, 2013). In G1
and G2 phase, the cell prepares for the upcoming critical phases of the cell cycle, S
and M phase, and monitors whether the extra- and intracellular conditions are favor-
able, before it proceeds with the cell cycle. In S phase, the DNA is replicated yielding
duplicated chromosomes. The M phase is divided into two processes: mitosis, in which
the duplicated chromosomes are segregated, and cytokinesis, the partitioning of the
cytoplasm, which finally results in the formation of two daughter cells.
1.3.1 Regulation of the cell cycle
The cell cycle is a highly complex process which is tightly regulated, and controlled by
a series of checkpoints preventing cells from entering a new phase until they have suc-
cessfully completed the previous one. The central players that drive the cell cycle are
the cyclin-dependent kinases CDK1, CDK2, CDK4 and CDK6. These serine/threonine
kinases require binding to their regulatory subunits, the cyclins, to become catalytically
13
1 INTRODUCTION
Figure 1.9: The cell cycle. The eukaryotic cell cycle is divided into four phases: G1, S, G2
and M. Cells can also exit the cell cycle to reach a quiescent, non-proliferating state (G0), from
which they can re-enter the cell cycle at a later time point (modified after Weinberg, 2013).
active and recognize their substrates (Murray, 2004; Massagué, 2004). In addition,
CDK activity is also regulated by phosphorylation. The CDK-activating kinase (CAK)
provides activating CDK phosphorylation, while the phosphorylation by Wee1 kinase
has an inhibitory effect (Malumbres and Barbacid, 2001). A third mode of CDK regu-
lation is by CDK inhibitors (CDKIs). The strictly regulated timing and extend of CDK-
cyclin complex activity drives the progression of the cell cycle from one phase to the
next (Figure 1.10A).
In early and mid G1, CDK4 and CDK6 bind to D-type cyclins. After the restriction point
(R point) (see below) CDK2 associates with E-type cyclins to enable the phosphoryla-
tion of substrates required for S phase entry. In early S phase, E cyclins are replaced
by A cyclins as binding partners of CDK2, which leads to the progression of S phase.
Later in S phase and during G2, A cyclins are bound to CDK1. Finally, at the onset of
M phase, CDK1-cyclin B complexes form triggering the events in all phases of mitosis
(Weinberg, 2013). While the levels of most CDKs are constant, the levels of cyclins
fluctuate dramatically during the different phases of the cell cycle (Figure 1.10B). Cy-
clin D expression is dependent on extracellular mitogenic signaling, for example on the
hRas or phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathways, and its nu-
clear level is regulated by export from the nucleus after G1/S transition. The levels of
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Figure 1.10: Regulation of the cell cycle by CDK-cyclin complexes. Cell cycle progress is
driven by the activity of various CDK-cyclin complexes in different phases of the cell cycle. A)
The period of activity of each CDK-cyclin complex. B) The fluctuating levels of cyclins during the
cell cycle regulating CDK activation (modified after Weinberg, 2013). CDC2: cell division control
protein 2 homolog (also known as CDK1), CDK: cyclin-dependent kinase, R point: restriction
point.
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the other cyclins, however, are independent from the cell’s environment and are tightly
coordinated with the advance of the cell cycle. Their rapid decrease at specific points
is due to ubiquitination, and subsequent proteasomal degradation.
Figure 1.11: Cell cycle-dependent phosphorylation of pRb. The phosphorylation state of
pRb (red circle) is controlled by CDK-cyclin complexes and increases throughout the cell cycle
from G1 to M phase. Its dephosphorylation is conducted by PP1 at the end of mitosis (modi-
fied after Weinberg, 2013). pRb: retinoblastoma protein, CDC2: cell division control protein 2
homolog (also known as CDK1), CDK: cyclin-dependent kinase, R point: restriction point, PP1:
protein phosphatase 1.
An important substrate of CDK-cyclin complexes is the retinoblastoma protein (pRb),
a master regulator of the cell cycle. pRb becomes hypophosphorylated by CDK4/6-
cyclin D complexes in early and mid G1. In its unphosphorylated or hypophosphory-
lated state, it binds to E2F transcription factors, hence repressing the transcription of
E2F-controlled genes. When CDK2-cyclin E is activated in late G1, it further phospho-
rylates pRb (Figure 1.11). In its hyperphosphorylated state, pRb releases E2F and
allows expression of the repressed genes, whose products, for instance proteins in-
volved in DNA replication, guide the cell into S phase. The hyperphosphorylation of
pRb is maintained throughout the remaining cell cycle, until it is dephosphorylated at
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the end of mitosis by protein phosphatase 1 (PP1) (Sears and Nevins, 2002; Stevaux
and Dyson, 2002; Kolupaeva and Janssens, 2013).
Five checkpoints are integrated in the cell cycle that monitor the conditions required
for proceeding to the next phase, and can halt the cell cycle when necessary. The first
checkpoint, G1 checkpoint or R point, occurs in late G1. At this point, the cell decides
whether to stay in G1, proceed to S phase, or even exit from the cell cycle and reach a
quiescent state (G0) (Malumbres and Barbacid, 2001; Massagué, 2004). This decision
is based on the integration of intra- and extracellular signals providing information on
the cell’s metabolic state, stress and the availability of nutrients and growth factors.
The R point is a "point of no return" as once the cell has decided to enter S phase, this
decision cannot be reversed. The transition from G1 to S phase is controlled by the G1/S
checkpoint, which deters the cell from replicating its DNA in case of DNA damage. The
next checkpoint occurs in S phase. Here, the ongoing DNA synthesis is slowed down
or halted if DNA damage is sensed. The G2/M checkpoint at the transition from G2 to
M phase deters the cell from initiating mitosis in case of DNA lesions. All three DNA
damage checkpoints are controlled by the ATM (ataxia telangiectasia mutated)/ATR
(ataxia telangiectasia and Rad3-related protein)-Chk1/Chk2 (checkpoint kinase 1/2)
pathway (Kastan and Bartek, 2004). The spindle assembly checkpoint, occurring at
the metaphase-to-anaphase transition, blocks anaphase onset if mitotic chromosomes
are not properly attached to spindle microtubules (see subsection 1.3.4).
1.3.2 Interphase
In both gap phases, the cell grows and produces components required to conduct
DNA replication or mitosis, for example nucleotides, RNA and proteins. It also has
to increase the amount or size of organelles and cytosol, in order to establish two
daughter cells.
In S phase, the chromosomes are duplicated. DNA replication begins at multiple ori-
gins of replication, special regions on the chromosomes on which replication is initiated.
The initiation of replication is divided into two steps. Already at the end of mitosis of the
previous cell cycle, and in early G1 when CDK activity is low, the replication origins are
loaded with the pre-replicative complex (preRC), which consists of the origin recogni-
tion complex (ORC), cell division cycle 6 (CDC6) kinase, chromatin licensing and DNA
replication factor 1 (CTD1) and mini-chromosome maintenance (MCM) proteins (Mas-
sagué, 2004). At S phase onset, activated CDK2 phosphorylates MCM proteins, thus
initiating the recruitment of DNA helicases, primases and polymerases to the preRCs to
form even larger protein complexes, the pre-initiation complexes (preICs) (Costa et al.,
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2013). They unwind the DNA double helix and initiate DNA synthesis. Simultaneously
to the initiation of replication, CDK2 triggers the disassembly of the PRC by phosphory-
lating ORC and CDC6. Hence, preRC re-assembly is inhibited at the newly replicated
origin until CDK activity drops at the end of mitosis (Kelly and Brown, 2000; Prasanth
et al., 2004). Chromosome duplication not only requires replication of the DNA, but
also the duplication of chromatin proteins and their proper assembly on the DNA. The
synthesis of chromatin proteins increases during S phase, and CDK2-cyclin E com-
plexes have been shown to stimulate expression of the four histone subunits (Kelly and
Brown, 2000). At the end of S phase, each duplicated chromosome consists of two
identical sister chromatids held together along their chomosome arms by cohesin pro-
tein complexes. This sister-chromatid cohesion is required for successful mitosis as it
facilitates attachment of the chromatids to the spindles (Zou, 2011).
1.3.3 Mitosis and cytokinesis
In mitosis, the duplicated sister chromatids are segregated and packed into two new
daughter nuclei. This process is divided into five phases: prophase, prometaphase,
metaphase, anaphase, and telophase (Figure 1.12). In prophase, the chromosomes
condense yielding the mitotic chromosome structure, and the mitotic spindle begins to
assemble. Prometaphase begins with nuclear envelope break down (NEBD). Subse-
quently, the chromosomes attach to spindles via their kinetochores. In metaphase, the
chromosomes align at the spindle equator, and their kinetochores achieve a bi-polar
attachment to kinetochore microtubules. In anaphase, the formation of central spin-
dles occurs, and the sister chromatids are pulled to opposite spindle poles. Telophase
is characterized by the decondensation of the segregated chromosomes and the re-
assembly of the nuclear envelope.
Mitosis is regulated by the cell cycle machinery in two major steps. The abrupt increase
of CDK1-cyclin B activity at the G2/M transition induces the events of early mitosis,
while activation of the anaphase-promoting complex/cyclosome (APC/C) facilitates the
processes from metaphase-to-anaphase transition onward.
At the G2/M transition, the CDK1-cyclin B complex is activated. It phosphorylates con-
densin, a protein complex involved in chromosome condensation and sister chromatid
resolution, which facilitates the re-organization of the chromosomes to gain their mitotic
structure (Ono et al., 2003). Parallel with chromosome restructuring, CDK1-cyclin B in-
duces spindle assembly. The centrosome duplication, however, already begins when
the cell enters S phase triggered by CDK2-cyclin E (Winey, 1999). The mitotic spin-
dle apparatus is a bipolar array of microtubules, which spread between the two spin-
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Figure 1.12: The phases of mitosis. Mitosis, the division of the nucleus containing the dupli-
cated DNA, occurs in five subsequent steps: prophase, prometaphase, metaphase, anaphase
and telophase. Shortly after the end of telophase, cytokinesis, the partitioning of the cytoplasm,
is completed yielding two new daughter cells (modified after Scholey et al., 2003).
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dle poles organized by centrosomes. Three types of microtubules emanate from the
spindle poles where they are anchored with their minus ends: interpolar microtubules
interacting with microtubules from the opposite pole, kinetochore microtubules, which
attach to the kinetochores of the metaphase chromosomes, and astral microtubules
radiating outward to contact the cell cortex. The assembly and function of spindles
depend on microtubule-dependent motor proteins, for example kinesins and dyneins
(Glotzer, 2009).
As centrosomes and microtubules are located in the cytoplasm, the attachment of spin-
dles to the chromosomes in prometaphase requires the disassembly of the nuclear en-
velope. NEBD is initiated by the phosphorylation of subunits of the nuclear pore com-
plexes and the nuclear lamina by CDK1-cyclin B (Alvarez-Fernández and Malumbres,
2014). During prometa- and metaphase, the stability of microtubules decreases, while
the ability of centrosomes to nucleate new microtubules increases, creating a dense
and dynamic array of spindles. These changes are also induced by CDK1-cyclin B
phosphorylation of motor proteins and microtubule-associated proteins (Glotzer, 2009).
The attachment of microtubules to kinetochores is conducted by a search-and-capture
mechanism. Stable attachment occurs when the kinetochores of each sister chromatid
bind to spindles from opposite spindle poles (bipolar or amphitelic attachment). Incor-
rect attachments, such as syntelic (both kinetochores bind to microtubules emanating
from the same pole) and merotelic (a single kinetochore binds to microtubules from
both spindle poles) attachments, are not stabilized (Ruchaud et al., 2007; Cheeram-
bathur and Desai, 2014; Pavin and Tolic´-Nørrelykke, 2014).
Sensing and correction of erroneous microtubule-kinetochore attachments occurs at
the spindle assembly checkpoint in metaphase. The mitotic kinase Aurora B, the enzy-
matic subunit of the chromosomal passenger complex (see subsection 1.3.4), senses
proper attachments via the presence of tension at the kinetochore. In the absence of
tension, Aurora B phosphorylates components of the microtubule attachments sites on
kinetochores, thus decreasing the sites’ affinity for microtubule plus ends. The SAC
also blocks the APC/C until all chromosomes have achieved a correct bi-orientation
(Foley and Kapoor, 2013). Once all chromosomes are attached correctly, chromosome
congression can take place: the chromosomes are positioned at the spindle equator
forming the metaphase plate, and the cell can progress to anaphase.
Anaphase begins with the sudden disruption of sister chromatid cohesion induced by
the APC/C, which is also activated by CDK1-cyclin B. The APC/C targets securin, an
inhibitor of the protease separase, for degradation allowing separase-mediated cohesin
cleavage. In addition, the APC/C mediates degradation of cyclins A and B, thus inac-
tivating CDKs. Anaphase proceeds in two steps: in anaphase A, the chromatids move
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polewards, accompanied by the shortening of kinetochore microtubules. In anaphase
B, the spindle poles are separated. Completion of anaphase requires dephosphory-
lation of CDK substrates resulting from the APC/C-dependent degradation of cyclins
(Kim and Yu, 2011).
In telophase, the mitotic spindle disassembles and the nuclear envelope is rebuilt. First,
fragments of the nuclear membrane associate with the chromosomes, then fuse to
form a continuous membrane. Nuclear pore complexes are incorporated, and last, the
nuclear lamina is re-assembled. The chromosomes decondense to allow gene tran-
scription. For these processes, also the APC/C-induced dephosphorylation of CDK
substrates is necessary (Schooley et al., 2012).
Cytokinesis, the division of the cytoplasm, already begins in anaphase and is com-
pleted shortly after telophase. During chromosome segregation in anaphase, actin and
myosin filaments as well as various structural and regulatory proteins dynamically as-
semble to form a contractile ring at the equatorial cell cortex. After anaphase is com-
pleted, the ring contracts gradually, while intracellular vesicles fuse with the plasma
membrane adjacent to the ring promoting cleavage furrow ingression. When cleavage
is completed, the plasma membrane of the cleavage furrow forms the midbody. It also
contains remains of the central spindle and functions as an intercellular bridge between
the two daughter cells until they are completely separated by abscission. The assem-
bly and function of the contractile ring is controlled by the small GTPase ras homolog
family member A (RhoA), which in turn is regulated by the CPC (Carmena et al., 2012;
Agromayor and Martin-Serrano, 2013; Chircop, 2014).
1.3.4 The CPC in mitosis and cytokinesis
As mentioned above, the CPC regulates crucial events in mitosis and cytokinesis, for
instance the correction of kinetochore-microtubule attachment errors, the activation of
the SAC as well as the formation and function of the contractile ring (Carmena et al.,
2012) (Figure 1.13). It consists of a kinase module comprising Aurora B and the C-
terminus of INCENP, and a localization module consisting of Survivin, Borealin and
INCENP’s N-terminus which form a stable three-helical bundle (Jeyaprakash et al.,
2007) (Figure 1.8).
Aurora B, together with Aurora A, which functions at the spindle poles, and Aurora C,
which regulates meiosis and mitosis in early development, belongs to a family of highly
conserved serine/threonine kinases (Glover et al., 1995; Carmena et al., 2009). It re-
quires INCENP binding to become activated, a mechanism similar to the activation of
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Figure 1.13: Localization and function of the CPC during mitosis. The CPC (green) is lo-
calized to chromosome arms and centromeres in prophase. In prometaphase, it concentrates
at centromeres, where it remains during metaphase. The relocalization of the CPC to the spin-
dle midzone and the cell cortex occurs in anaphase. In telophase, the CPC localizes to the
cleavage furrow. The functions of the CPC during the different phases of mitosis are indicated in
blue boxes. Tubulin is depicted in red, chromosomes are shown in blue (modified after Ruchaud
et al., 2007).
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CDKs by cyclins. Besides being a regulator of Aurora B activity, INCENP also serves
as a scaffold for CPC assembly, and is required for proper localization of the CPC to-
gether with Survivin and Borealin (Ainsztein et al., 1998; Jeyaprakash et al., 2007). The
activation of Aurora B is a complex multistep process. Once the CPC has assembled,
Aurora B is partially active due to its binding to INCENP’s C-terminus. This enables
Aurora B to phosphorylate INCENP’s TSS motif and T232 in the T-loop of its kinase
domain in trans resulting in further Aurora B activation (Bishop and Schumacher, 2002;
Sessa et al., 2005). The necessity of a second CPC for Aurora B activation explains its
density-dependent activation at inner centromers and the spindle midzone (Kelly et al.,
2007; Fuller et al., 2008) (Figure 1.14). Complete activation of Aurora B requires its
phosphorylation by Chk1 and phosphorylation of Survivin at S20 by PLK1 (Petsalaki
et al., 2011; Chu et al., 2011). In early mitosis, Aurora B phosphorylates multiple sub-
strates at the kinetochore to destabilize and correct erroneous kinetochore-microtubule
attachments. To gain stable attachments, which are required in prometaphase and tran-
sition to anaphase, the phosphorylation has to be removed from Aurora B substrates.
This is achieved by the recruitment of antagonistic phosphatases like PP1 or PP2A
(Meadows et al., 2011; Foley et al., 2011). It has been proposed that the concentra-
tions of Aurora B and its counteracting phosphatases are spatially regulated: upon the
formation of a bipolar kinetochore-microtubule attachment, tension is generated which
stretches the kinetochore. Hence, Aurora B substrates are pulled away from the inner
centromer where Aurora B activity is high (Lampson and Cheeseman, 2011).
In interphase, the CPC localizes to heterochromatin via the interaction of INCENP with
heterochromatin protein 1 (HP1). HP1 directly binds to histone H3 tri-methylated at K9
(H3K9Me3), which is a typical histone modification found in transcriptionally silenced
heterochromatin (Ainsztein et al., 1998; Zeng et al., 2010). At onset of mitosis, Aurora B
phosphorylates H3 at the adjacent S10, which causes dissociation of HP1 from H3 (Hi-
rota et al., 2005). The following enrichment of the CPC at centromeres is achieved by
direct and indirect binding to mitosis-specific phosphorylation marks: Haspin kinase,
located at the inner centromer, phosphorylates histone H3 at T3, which is recognized
and bound by Survivin’s BIR domain. Additionally, the kinetochore-associated kinase
budding uninhibited by benzimidazoles 1 (BUB1) phosphorylates histone H2A at T120
(H2AT120Ph). Subsequently, Shugoshin 1 (Sgo1) and Shugoshin 2 (Sgo2) are re-
cruited to H2AT120Ph and interact with Borealin that has been phosphorylated by
CDK1 (Yamagishi et al., 2010; Kawashima et al., 2007) (Figure 1.15). In addition, a
recent study by Liu et al. (2014) has revealed that Borealin can directly bind to HP1α
and that this interaction is required for targeting the CPC to centromeres.
One proposed role of the CPC in prophase is the regulation of chromosome conden-
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Figure 1.14: Aurora B kinase activation. Activation of Aurora B is coupled to CPC formation
and function. A) Aurora B requires binding to INCENP to become partially activated. Subse-
quently, it phosphorylates INCENP and itself to gain full activity. Both phosphorylation events
are catalyzed in trans. B) Autophosphorylation of Aurora B requires a second CPC. This prereq-
uisite is fulfilled at sites of high CPC density like the inner centromere and the spindle midzone
(modified after Carmena et al., 2012).
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Figure 1.15: Recruitment of the CPC to centromeres in early mitosis. In interphase, the
CPC is recruited to heterochromatin via the interaction of INCENP with HP1. In prophase,
phosphorylation of centromeric histone tails by the mitotic kinases Aurora B, Haspin and BUB1
induces displacement of HP1, and the recruitment of the CPC to inner centromers via the in-
teraction of Survivin with H3T3Ph by prophase (modified after Carmena et al., 2012). MIS14:
Mum2p-Ime4p-Slz1p protein 14, HP1: heterochromatin protein 1, CPC: chromosomal passen-
ger complex, SGO1: Shugoshin 1, H3K9me3: histone H3 tri-methylated at lysine 9, CDK1:
cyclin-dependent kinase 1, H3S10: histone H3 serine 10, H3T3: histone H3 threonine 3,
H2AT120: histone H2A threonine 120, KNL1: kinetochore-null protein 1, BUB1: budding un-
inhibited by benzimidazoles 1 kinase, MPS1: metallopan-stimulin 1.
sation by targeting condensin (Collette et al., 2011). As mentioned above, in prometa-
phase, the function of the CPC is to destabilize and correct erroneous kineto-
chore-microtubule attachments. The KMN (KNL1-MIS12-NDC80) network, a microtu-
bule-binding module of the outer kinetochore comprising the KNL1 (kinetochore-null
protein 1), MIS12 (named after the yeast proteins Mum2p, Ime4p and Slz1p) and
NDC80 (nuclear division cycle 80) complexes, captures plus-ends of dynamic micro-
tubules. Aurora B weakens its affinity for microtubules by phosphorylating the N-termi-
nus of NDC80 at multiple sites (Powers et al., 2009; DeLuca et al., 2006; Cheeseman
et al., 2006). It also regulates other microtubule stabilizing or destabilizing proteins at
the kinetochore, for example the mitotic centromere-associated kinesin (MCAK) (Lan
et al., 2004).
In metaphase, the CPC controls the spindle assembly checkpoint. A proposed mecha-
nism for SAC activation by Aurora B is the recruitment of SAC proteins, for instance mi-
totic arrest deficient 1-like proteins 1 and 2 (MAD1/2), to kinetochores in the absence of
bipolar attachments (Ditchfield et al., 2003; Vigneron et al., 2004; Saurin et al., 2011).
The interaction of these two proteins at kinetochores results in the binding of MAD2 to
the APC/C activator CDC20, thus preventing it from activating the APC/C. The accu-
mulation of further proteins results in the formation of the mitotic checkpoint complex
(MCC), which additionally blocks the APC/C (Musacchio and Salmon, 2007; Luo and
Yu, 2008). Once a bipolar kinetochore-microtubule attachment is achieved, Aurora B
activity decreases at kinetochores, while PP1 is recruited (Welburn et al., 2010; Liu and
25
1 INTRODUCTION
Mitchell, 2010). PP1 promotes SAC silencing in different ways, for example it reverses
the Aurora B-dependent phosphorylation of several SAC proteins releasing them from
kinetochores. One result is the activation of the APC/C by CDC20 and the subsequent
ubiquitination of its targets cyclin B and securin (Peters, 2006). This indicates that the
spatial regulation of phosphorylation/dephosphorylation is essential for SAC activation
and silencing.
During metaphase-to-anaphase transition, the CPC leaves the inner centromere to re-
locate to the spindle midzone, and subsequently to the equatorial cortex (Figure 1.16A).
The relocation is initiated by the APC/C-mediated decrease of CDK1 activity and driven
by three different processes: the termination of CPC targeting to centromeres, its active
removal from chromosomes, and its targeting to the central spindle (Carmena et al.,
2012). The centromeric localization of the CPC is abrogated by the dephosphoryla-
tion of H3T3Ph by PP1 (Qian et al., 2011). Its active removal from chromosomes upon
ubiquitination is conducted by the AAA+ ATPase p97. This process also facilitates chro-
mosome decondensation as well as nuclear reformation in telophase (Ramadan et al.,
2007; Dobrynin et al., 2011). The targeting to the central spindle requires interaction of
INCENP and Aurora B with mitotic kinesin-like protein 2 (MKLP2), which binds to micro-
tubules at the central spindle only during anaphase, when CDK1-mediated inhibitory
phosphorylation is removed (Hümmer and Mayer, 2009). Central spindle formation is
facilitated by the CPC by recruiting the protein complex centralspindlin. Phosphory-
lation of a centralspindlin component by Aurora B increases its microtubule-bundling
activity, thus stabilizing the central spindle (Kaitna et al., 2000; Douglas et al., 2010).
During cytokinesis, the CPC contributes to the maturation and constriction of the con-
tractile ring by indirectly regulating the small GTPase RhoA via centralspindlin recruit-
ment to the spindle midzone (Figure 1.16B). RhoA fosters actin polymerization and
myosin activation (Nishimura and Yonemura, 2006; Touré et al., 2008). Another role of
the CPC in contractile ring constriction is the phosphorylation of intermediate filament
components which facilitates their disassembly (Kawajiri et al., 2003). During abscis-
sion, the final step of cytokinesis, Aurora B is involved in the abscission checkpoint,
which delays the separation of the daughter cells in case lagging chromatin is present
in the intercellular bridge (Steigemann et al., 2009). The CPC can possibly also inhibit
components of the ESCRT-III complex, which mediates membrane fission at the end of
cytokinesis, thus deferring premature cytokinesis (Capalbo et al., 2012; Carlton et al.,
2012).
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Figure 1.16: Localization and function of the CPC in late mitosis. At anaphase onset, the
CPC relocalizes from chromosomes to the spindle midzone, and subsequently to the cell cor-
tex. In telophase and cytokinesis, the CPC is found at the cleavage furrow. A) CPC targeting to
the central spindle in anaphase requires its interaction with MKLP2. Central spindle formation is
promoted by the CPC as it recruits centralspindlin to the spindle midzone. B) During telophase
and cytokinesis, the CPC contributes to the maturation and constriction of the contractile ring
as it indirectly regulates RhoA via the recruitment of centralspindlin. It also mediates intermedi-
ate filament phosphorylation, thus facilitating their disassembly (modified after Carmena et al.,
2012). PLK1: polo-like kinase 1, MKLP1/2: mitotic kinesin-like protein 1/2, MgcRacGAP: male
germ cell RacGAP, ECT2: epithelial cell-transforming 2, CPC: chromosomal passenger com-
plex, GEF-H1: guanine nucleotide exchange factor H1, CHMP4C: charged multivesicular body
protein 4C.
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1.4 Nucleo-cytoplasmic transport
The cell nucleus is separated from the cytoplasm by the nuclear envelope (NE). It is
formed of the outer nuclear membrane (ONM), which is continuous with the endoplas-
mic reticulum (ER), and the inner nuclear membrane (INM) separated from the ONM
by a luminal space. Nuclear pore complexes (NPCs) are distributed throughout the NE
at fusion sites between the outer and inner nuclear membrane (Schooley et al., 2012;
Grossman et al., 2012). The NPCs contribute to the function of the NE as a selective
physical barrier. They allow free diffusion of all small molecules up to a size of 20 kDa,
for example water, ions, metabolites and small proteins. Dependent on their surface
properties, even larger molecules up to a size of approx. 60 kDa can passively diffuse
through NPCs. Despite the possibility to passively diffuse into the nucleus, proteins
with a molecular weight between 20 and 60 kDa mostly undergo active transport as it
is more efficient and can be regulated by the cell. Molecules larger than 60 kDa like
proteins or RNAs must be actively transported through the pore with the assistance of
soluble transport receptors (Yoneda, 2000).
The NPC is a large cylindrical protein complex with octagonal symmetry comprising ap-
prox. thirty different nucleoporin proteins (Nups), which are present in multiple copies
(Figure 1.17). Its core scaffold consists of two inner and outer rings of Nups. Two
transmembrane rings connected to the core scaffold anchor the NPC to the nuclear
envelope. Attached to the inside of this scaffold are linker Nups which, together with
the inner ring, serve as attachment sites for Nups with phenylalanine-glycine repeats
(FG Nups). A gel-like matrix of FG Nups inside the central tube of the NPC serves
as a mechanical barrier and mediates translocation of transport receptor-cargo com-
plexes. Eight large filaments protrude into the cytoplasm, whereas a basket structure
is attached to the nuclear face of the central core. Both structures mediate transport
receptor-cargo docking to the NPC (Wente and Rout, 2010; Turner et al., 2012).
Active transport of a cargo protein through the NPC requires three prerequisites: exis-
tence of a localization signal, binding to a transport receptor, and energy (Figure 1.18).
For the import into the nucleus, a nuclear localization signal (NLS) is needed. The
classical NLS is a cluster of basic amino acids and can be mono- or bipartite (Goldfarb
et al., 1986; Hodel et al., 2001). Proteins undergoing nuclear export contain a nuclear
export signal (NES), a leucine-rich stretch of hydrophobic amino acids (Kutay and Güt-
tinger, 2005). Some proteins shuttling between nucleus and cytoplasm possess NLSs
as well as NESs which can also function in a cooperative manner. Most of the trans-
port receptors are karyopherins. Except for NLS-mediated import, which often requires
cargo recognition by an adapter protein, for example Importin-α, the karyopherins di-
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Figure 1.17: Structure of the nuclear pore complex. The NPC is a cylindrical, octagonal
protein complex comprised of specialized nucleoporins that form distinct structures. The FG
Nups of the cytoplasmic filaments, the nuclear basket and those filling the central tube medi-
ate the selective passage of transport receptor-cargo complexes through the NPC (modified
after Strambio-De-Castillia et al., 2010). NPC: nuclear pore complex, Nup: nucleoporin, FG:
phenylalanine-glycine, ONM: outer nuclear membrane, INM: inner nuclear membrane.
rectly bind to their cargo proteins. In addition, they interact with the small GTPase Ran,
which produces the energy necessary for the transport. The different concentrations
of GTP-bound Ran (RanGTP) – high in the nucleus and low in the cytoplasm – form
the RanGTP gradient driving transport via the NPC. The gradient is maintained by the
nuclear Ran guanine nucleotide exchange factor (RanGEF) regulator of chromosome
condensation 1 (RCC1) , which is tethered to chromatin, and the cytoplasmic Ran GT-
Pase activating protein (RanGAP) RanGAP1 (Fung and Chook, 2014). To be imported,
a cargo protein must be recognized by its specific import receptor, e.g. Importin-β,
which mediates docking and passage through the NPC. In the nucleus, dissociation
of the complex is stimulated by RanGTP. Subsequently, the RanGTP-bound import
receptor is recycled to the cytoplasm and released from RanGTP following RanGAP1-
induced GTP hydrolysis. For export, a specific export receptor, for example CRM1 (also
known as Exportin1), binds its cargo protein in the presence of RanGTP. This trimeric
complex can then pass the central channel of the NPC to reach the cytoplasm. Here,
RanGAP1 activates Ran to hydrolyze GTP to GDP resulting in the dissociation of the
complex. The cargo is released and the export receptor as well as RanGDP are recy-
cled back to the nucleus, where RCC1 exchanges GDP by GTP (Turner et al., 2012;
Tran et al., 2014; Mor et al., 2014).
The docking and passage of transport receptor-cargo complexes through the NPC is
mediated by interactions of the FG repeats of FG Nups inside the NPC and HEAT
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Figure 1.18: Nucleo-cytoplasmic transport. Schematic representation of the export of NES-
containing proteins and the import of NLS-containing proteins. Cargo proteins (here exem-
plarily CDK-cyclin complexes) bind to their transport receptors, Exportin 1 (or CRM1) for ex-
port and a complex of Importin-α and Importin-β for import, which mediate passage through
the nuclear pore. Transport is driven by a Ran-GTP gradient, which is maintained by the cy-
toplasmic GAP RanGAP1 and the nuclear GEF RCC1 (modified after Moore, 2013). CDK:
cyclin-dependent kinase, NLS: nuclear localization signal, NES: nuclear export signal, GTP:
guanosine triphosphate, GDP: guanosine diphosphate, GAP: GTPase activating protein, GEF:
guanine nucleotide exchange factor.
repeat domains (named after the proteins Huntingtin, elongation factor 3, protein phos-
phatase 2A, and the yeast kinase target of rapamycin kinase 1) of the receptors. The
FG repeat regions of FG Nups are disordered and form a dense mesh of filaments
that fills the central tube and serves as a barrier for larger molecules. Karyopherins
overcome this barrier by binding to the FG Nups and passing from one Nup to the
next. Several models have been proposed describing how passage might occur. The
hydrogel model is based on crosslinks of FG repeats forming a dense hydrophobic gel.
Transport receptors can pass through the gel by binding the FG repeats, therefore tran-
siently and locally dissolving the crosslinks (Frey et al., 2006). In the brush model FG
Nups are understood as polymer brushes: by rapid diffusion-driven movements their
filaments sweep away macromolecules, but transport receptors can overcome this by
binding to FG Nups (Lim et al., 2007).
In addition to its role as a highly selective, bidirectional transporter, the NPC, or its
components, are also involved in other processes. In mitosis, for instance, Nups are
important for kinetochore function (Roux and Burke, 2006). In interphase, Mad pro-
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teins, which are involved in the spindle assembly checkpoint, are docked to the NPC,
but are released in mitosis (Iouk et al., 2002; Lee et al., 2008).
1.4.1 CRM1
CRM1 (also known as Exportin 1) is an ubiquitous nuclear export receptor for NES-
containing proteins (Fornerod et al., 1997; Daelemans et al., 2005). It consists of 21
HEAT repeats arranged in a distorted toroid structure. RanGTP is enclosed in the ring
and stabilizes it. Cargo proteins bind to the exterior of the toroid at a hydrophobic cleft
whose accessibility for the cargo is regulated by RanGTP binding (Monecke et al.,
2009). The components of the export complex – CRM1, RanGTP and the cargo pro-
tein – interact with positive cooperativity: the affinity of CRM1 to either RanGTP or a
NES protein is weak. However, when both proteins bind to CRM1, the affinity for both
increases by 500-1000 fold (Turner et al., 2012).
In addition to its role as an export receptor in interphase, CRM1 also has crucial func-
tions during mitosis. Arnaoutov et al. (2005) have reported that CRM1-RanGTP com-
plexes localize to kinetochores in mitosis, and that this localization is essential for the
formation of stable kinetochore fibers as well as for proper chromosome segregation
during anaphase. Moreover, as shown by Knauer et al. (2006), the interaction of CRM1
with its cargo Survivin is required for the correct localization and function of the CPC.
1.5 Post-translational modifications
The post-translational modification (PTM) of proteins allows eukaryotic cells to rapidly
alter the functions of existing proteins by transmitting chemical signals across divers
cellular pathways. Prominent PTMs are the phosphorylation of serine, threonine and
tyrosine residues, proline isomerization, arginine and lysine methylation as well as
ubiquitination, sumoylation and acetylation also occurring at lysine residues. Hence,
the lysine side chain is a target of different PTMs which are mutually exclusive on the
same lysine residue (Yang and Seto, 2008; Arif et al., 2010).
1.5.1 Acetylation
In addition to phosphorylation, the acetylation of the ε-amino group of lysine residues
has emerged as a major PTM in eukaryotes. Like phosphorylation, acetylation is able to
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influence various protein functions for instance protein-DNA and protein-protein inter-
actions, activation or inactivation of enzymes as well as protein localization and stability
(Arif et al., 2010). Lysine acetylation has originally been associated with the regulation
of gene transcription as it was first identified in nuclear core histones in the 1960s (All-
frey et al., 1964). The acetylation of histone tails of promotor-proximal nucleosomes
results in a lower binding affinity of histones to DNA. Thus, the chromatin packaging
is loosened and DNA becomes accessible for transcription factors and coactivators.
Only the development of Tubulin as the first cytoplasmic target of lysine acetylation
in 1985 revealed that this modification is not restricted to the nucleus (L’Hernault and
Rosenbaum, 1985).
Acetylation neutralizes the positive charge of the lysine side chain, thus inhibiting the
formation of ionic interactions with other amino acids, and additionally impairs the ability
of the lysine side chain to form hydrogen bonds (Figure 1.19). The functional impact
of lysine acetylation is context-dependent and varies from protein to protein. Three
modes of acetylation events have been identified so far: first, acetylation occurs at
one or a few lysine residues and functions as an on/off switch. Second, acetylation
occurs at multiple residues within lysine clusters that form charged patches. The third
mechanism describes the interplay of acetylation with other PTMs in a site-specific
manner, for example acetylation of H3K9 crosstalks with phosphorylation of H3S10
(Yang and Seto, 2008).
Lysine acetylation is a reversible process (Figure 1.19). The transfer of an acetyl group
from acetyl-CoA to a lysine residue is catalyzed by lysine acetyltransferases (KATs).
KATs are classified into three families according to their homology with yeast proteins:
the general control of amino acid synthesis protein 5 (Gcn5)-related N-acetyltransferase
(GNAT) family containing for example the human KATs GCN5 and PCAF, the p300/CBP
family and the MYST family (named after monocytic leukemia zinc finger protein, Ybf2/
Sas3 (something about silencing protein 3), Sas2 and 60 kDa Tat-interactive protein).
Although most KATs are predominantly localized in the nucleus, recent studies demon-
strated that some of them, for example PCAF and GCN5, undergo nucleo-cytoplasmic
transport (Sadoul et al., 2011). Deacetylation is carried out by lysine deacetylases
(KDACs), which are divided into four classes according to their relation to yeast pro-
teins. The class I (similar to Rpd3 (reduced potassium dependency 3)), class II (related
to Hda1 (histone deacetylase 1)) and class IV KDACs belong to the classical family of
Zn2+-dependent KDACs, whereas class III KDACs, also called sirtuins (homologs of
Sir2 (silent information regulator 2)), require the cofactor NAD+ for their activity. Many
KDACs contain NES as well as NLS sequences enabling them to shuttle between nu-
cleus and cytoplasm. As KATs and KDACs are acetylated themselves, they are able to
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regulate each other’s activity by a direct interplay, thus controling the dynamic acety-
lation state of their target proteins (Yang and Seto, 2008; Peserico and Simone, 2011;
Sadoul et al., 2011).
Figure 1.19: Lysine acetylation/deacetylation. Schematic representation of lysine acetylation
by KATs and its deacetylation by KDACs. A target protein containing a lysine residue is indicated
in red. The KAT and the KDAC are shown as blue spheres. The transferred acetyl group is
depicted in green. Deacetylase activity can be inhibited by KDAC inhibitors, such as trichostatin
A. K: lysine, KAT: lysine acetyltransferase, KDAC: lysine deacetylase, KDACi: KDAC inhibitor,
TSA: trichostatin A.
1.6 Aims of the thesis
Survivin is up-regulated in various human cancers (Ambrosini et al., 1997; Adida et al.,
2000). Due to its dual role as an inhibitor of apoptosis and a member of the chromoso-
mal passenger complex, Survivin on the one hand is able to protect tumor cells from
therapy-induced apoptosis, and on the other hand provides a proliferative advantage
(Engels et al., 2007; Capalbo et al., 2007; Xu et al., 2014; Chen et al., 2014). This
makes Survivin an interesting therapeutic target. In order to develop strategies for the
therapeutic inhibition of Survivin, the mechanisms underlying the different functions of
the protein have to be understood in detail. In case of Survivin this is complicated as
some of its functions are conducted by the homodimer (Wang et al., 2010b; Pavlyukov
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et al., 2011), while other roles critically rely on the monomer (Jeyaprakash et al., 2007;
Engelsma et al., 2007; Pavlyukov et al., 2011). In addition, Survivin’s functions are spa-
tially controlled as it is able to shuttle between nucleus and cytoplasm (Rodriguez et al.,
2002; Knauer et al., 2006). However, the mechanisms by which Survivin’s functions, its
localization as well as its dimerization state are regulated are still not clarified in detail.
Recently, Wang et al. (2010b) reported that acetylation of Survivin at lysine 129 func-
tions as a switch between its monomeric and dimeric state, and that it also regulates
Survivin’s interaction with the export receptor CRM1.
In this study, we first aimed to verify the results of Wang et al. (2010b) concerning
the influence of SurvK129 acetylation on Survivin’s dimerization and nuclear export.
Therefore, the four SurvK129 mutants also used in this study should be cloned and their
properties analyzed by means of immunofluorescence stainings, immunoprecipitation,
gel filtration as well as CD spectroscopy. Furthermore, we aimed to investigate the role
of Survivin acetylated at K129 in mitosis.
In order to gain further insight into the complex regulation of Survivin, we intended to
find out whether other lysine residues in Survivin might be subjected to acetylation,
and thus to examine the effects of a potential acetylation on Survivin’s divers functions.
Therefore, the lysine residues most likely to be acetylated should be identified and
mutated to arginine or glutamine in order to mimic unmodified or acetylated lysine,
respectively. The properties of the mutants should then be analyzed accordingly to the
analysis of the SurvK129 mutants.
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2.1 Materials
2.1.1 Chemicals
The chemicals and reagents used in this thesis are listed in Table 2.1.
Table 2.1: Chemicals and reagents.
Chemical/ Reagent Manufacturer
Acetic acid Applichem GmbH, Darmstadt
Acrylamide solution (30 %) - Mix
37.5:1
Applichem GmbH, Darmstadt
Agarose Applichem GmbH, Darmstadt
Ammonium persulfate (APS) Applichem GmbH, Darmstadt
Ampicillin sodium salt Applichem GmbH, Darmstadt
Antibiotic-Antimycotic Life Technologies GmbH, Darmstadt
Bovine serum albumin (BSA) Applichem GmbH, Darmstadt
Bromophenol blue sodium salt Applichem GmbH, Darmstadt
Carbenicillin disodium salt Applichem GmbH, Darmstadt
Chloramphenicol Applichem GmbH, Darmstadt
Coomassie Brilliant Blue G-250 Applichem GmbH, Darmstadt
Deoxynucleotide (dNTP) Solution Mix New England BioLabs GmbH,
Frankfurt am Main
Disodium hydrogen phosphate
dihydrate
Applichem GmbH, Darmstadt
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Table 2.1 continued
Chemical/ Reagent Manufacturer
Dithiothreitol (DTT) Applichem GmbH, Darmstadt
DNA Loading Dye (6x) Thermo Fisher Scientific, Waltham
Dulbecco’s Modified Eagle Medium
(DMEM), high glucose, GlutaMax
supplement
Life Technologies GmbH, Darmstadt
Dulbecco’s Phosphate-Buffered
Saline (DPBS)
Life Technologies GmbH, Darmstadt
Ethylenediaminotetraacetic acid
(EDTA) disodium salt dihydrate
Applichem GmbH, Darmstadt
Ethanol VWR International GmbH, Darmstadt
Ethanol technical grade Applichem GmbH, Darmstadt
Fetal calf serum (FCS) Life Technologies GmbH, Darmstadt
GelRed Biotium Inc, Hayward
Glutathione Sepharose 4B GE Healthcare Life Sciences,
Freiburg
Glycerol 87 % Applichem GmbH, Darmstadt
Glycine Applichem GmbH, Darmstadt
Hoechst 33342 Applichem GmbH, Darmstadt
Hydrochloric acid 1 M Applichem GmbH, Darmstadt
Hydrochloric acid 37 % Applichem GmbH, Darmstadt
Isopropanol Applichem GmbH, Darmstadt
Isopropanol technical grade Applichem GmbH, Darmstadt
Isopropyl β-D-1-
thiogalactopyranoside (IPTG)
Applichem GmbH, Darmstadt
Kanamycin sulfate Applichem GmbH, Darmstadt
Luria-Bertani (LB)-Agar powder Applichem GmbH, Darmstadt
LB-Medium powder Applichem GmbH, Darmstadt
Leptomycin B (LMB) Enzo Life Sciences, Lörrach
Lipofectamine 2000 Life Technologies GmbH, Darmstadt
Magnesium chloride hexahydrate Applichem GmbH, Darmstadt
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Table 2.1 continued
Chemical/ Reagent Manufacturer
β-Mercaptoethanol Applichem GmbH, Darmstadt
Methanol Applichem GmbH, Darmstadt
Methanol technical grade Applichem GmbH, Darmstadt
Milk powder Applichem GmbH, Darmstadt
Nocodazole Enzo Life Sciences, Lörrach
Nonidet P40 (NP40) Applichem GmbH, Darmstadt
Normal goat serum (NGS) Dako Deutschland GmbH, Hamburg
Opti-MEM Life Technologies GmbH, Darmstadt
Phenylmethanesulfonylfluoride
(PMSF)
Applichem GmbH, Darmstadt
Polyethylenimine (PEI) Sigma-Aldrich Chemie Gmbh,
Munich
Potassium chloride Applichem GmbH, Darmstadt
Potassium dihydrogen phosphate Applichem GmbH, Darmstadt
Protease inhibitor cocktail tablets
Complete
Roche, Mannheim
Roti-Histofix 4 % Carl Roth GmbH & Co. KG, Karlsruhe
Sodium azide Applichem GmbH, Darmstadt
Sodium chloride Carl Roth GmbH & Co. KG, Karlsruhe
Sodium deoxycholate Applichem GmbH, Darmstadt
Sodium dihydrogen phosphate
monohydrate
Carl Roth GmbH & Co. KG, Karlsruhe
Sodium dodecyl sulfate (SDS) Applichem GmbH, Darmstadt
Sodium hydroxide pellets Applichem GmbH, Darmstadt
Sodium sulfate anhydrous Applichem GmbH, Darmstadt
N,N,N’,N’-Tetramethyl-
ethylenediamine (TEMED)
Applichem GmbH, Darmstadt
Trichostatin A (TSA) Sigma-Aldrich Chemie Gmbh,
Munich
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Table 2.1 continued
Chemical/ Reagent Manufacturer
Tris(hydroxymethyl)aminomethane
(Tris)
Applichem GmbH, Darmstadt
Tris acetate Applichem GmbH, Darmstadt
Tris hydrochloride Applichem GmbH, Darmstadt
Triton X-100 Applichem GmbH, Darmstadt
TrypLE Express Life Technologies GmbH, Darmstadt
Tween 20 Applichem GmbH, Darmstadt
Zinc sulfate heptahydrate Applichem GmbH, Darmstadt
2.1.2 Buffers, solutions and media
The buffers, solutions and media used in this thesis are listed in Table 2.2. Unless
otherwise stated, the ingredients were dissolved in ultra-pure water (ddH2O).
Table 2.2: Buffers, solutions and media.
Buffer/Solution/
Medium
Ingredients Final
concentration
Acetylation IP lysis
buffer
Tris-HCl 50 mM
Sodium chloride 150 mM
EDTA 1 mM
SDS 1 % (w/v)
Sodium deoxycholate 1 % (w/v)
Triton X-100 1 % (v/v)
DTT 1 mM
PMSF 1 mM
Protease inhibitor cocktail
tablet Complete
1x
TSA 1 µM
pH 6.8
APS 10 % (w/v)
Antibody dilution buffer BSA 1 % (w/v)
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Table 2.2 continued
Buffer/Solution/
Medium
Ingredients Final
concentration
Triton X-100 0.3 % (v/v)
in PBS
Carbenicillin 100 mg/mL
CD buffer Sodium dihydrogen
phosphate
20 mM
Sodium sulfate 20 mM
Zinc sulfate 10 mM
pH 7.7
Cleavage buffer Tris-HCl 50 mM
Sodium chloride 150 mM
DTT 1 mM
EDTA 1mM
pH 7.5
Coomassie destaining
solution
Ethanol 40 %
Acetic acid 10 % (v/v)
Coomassie staining
solution
Coomassie brilliant blue G250 0.1 % (w/v)
Ethanol 40 % (v/v)
Acetic acid 10 % (v/v)
DMEM++ FCS 10 % (v/v)
Antibiotic-Antimycotic 1x
in DMEM, high
glucose, GlutaMax
supplement
Gel filtration buffer β-Mercaptoethanol 2.5 mM
in PBS
Hoechst solution Hoechst 33342 1 mg/ml
Ethanol 25 % (v/v)
in PBS
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Table 2.2 continued
Buffer/Solution/
Medium
Ingredients Final
concentration
IF blocking buffer Normal goat serum 5 % (v/v)
Triton X-100 0.3 % (v/v)
in PBS
Interaction IP lysis buffer Tris 50 mM
Sodium chloride 150 mM
EDTA 5 mM
NP40 0.5 % (v/v)
DTT 1 mM
PMSF 1 mM
Protease inhibitor cocktail
tablet Complete
1x
pH 8
IPTG 1 M
Kanamycin 50 mg/mL
LB-Agar LB-Agar powder 40 g/L
pH 7.5
LB-Medium LB-Medium powder 25 g/L
pH 7.5
Lysis buffer Tris-HCl 50 mM
Sodium chloride 150 mM
DTT 1 mM
PMSF 1 mM
pH 7.5
Magnesium chloride 1 M
Nocodazole 1 mg/mL
in DMSO
PBS Sodium chloride 137 mM
Potassium chloride 2.7 mM
Disodium hydrogen
phosphate
10 mM
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Table 2.2 continued
Buffer/Solution/
Medium
Ingredients Final
concentration
Potassium dihydrogen
phosphate
2 mM
pH 7.4
PEI 10 mM
pH 6.8
RIPA buffer Tris-HCl 50 mM
Sodium chloride 150 mM
EDTA 5 mM
NP40 1 % (v/v)
Sodium deoxycholate 1 % (w/v)
DTT 1 mM
Protease inhibitor cocktail
tablet Complete
1x
PMSF 1 mM
SDS-PAGE running
buffer
Tris 25 mM
Glycine 192 mM
SDS 0.1 % (w/v)
SDS sample buffer (5x) EDTA 5 mM
Glycerol 30 % (v/v)
Tris-HCl 60 mM
SDS 15 % (w/v)
β-Mercaptoethanol 7.5 % (v/v)
Bromophenol blue 0.1 % (w/v)
pH 6.8
Separating gel buffer
(4x)
Tris 1.5 M
SDS 0.8 %
pH 8.8
Sodium azide 0.1 % (w/v)
in PBS
Stacking gel buffer (4x) Tris-HCl 0.5 M
SDS 0.8 %
pH 6.8
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Table 2.2 continued
Buffer/Solution/
Medium
Ingredients Final
concentration
TAE buffer Tris acetate 40 mM
EDTA 1 mM
pH 8.3
TBS Tris-HCl 50 mM
Sodium chloride 150 mM
pH 7.4
TBST Tris-HCl 50 mM
Sodium chloride 150 mM
Tween 20 0.1 %
pH 7.4
TE Tris-HCl 10 mM
EDTA 1 mM
pH 8
Transfer buffer Tris 25 mM
Glycine 192 mM
SDS 0.01 % (w/v)
Methanol 20 % (v/v)
pH 8.3
WB blocking buffer Milk powder 5 % (w/v)
in TBST
2.1.3 Protein and DNA standards
The protein and DNA standards used in this thesis are listed in Table 2.3.
Table 2.3: Protein and DNA standards.
Size standard Manufacturer
GeneRuler 1 kb DNA Ladder Thermo Fisher Scientific, Waltham
GeneRuler 100 bp DNA Ladder Thermo Fisher Scientific, Waltham
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Table 2.3 continued
Size standard Manufacturer
Spectra Multicolor Broad Range
Protein Ladder
Thermo Fisher Scientific, Waltham
2.1.4 Enzymes
The enzymes used in this thesis are listed in Table 2.4.
Table 2.4: Enzymes.
Enzyme class Enzyme Manufacturer/Received from
Endonucleases ApaI New England BioLabs GmbH,
Frankfurt am Main
BamHI-HF New England BioLabs GmbH,
Frankfurt am Main
DNase I Applichem GmbH, Darmstadt
EcoRI-HF New England BioLabs GmbH,
Frankfurt am Main
HindIII-HF New England BioLabs GmbH,
Frankfurt am Main
KpnI-HF New England BioLabs GmbH,
Frankfurt am Main
NcoI-HF New England BioLabs GmbH,
Frankfurt am Main
NdeI New England BioLabs GmbH,
Frankfurt am Main
NheI-HF New England BioLabs GmbH,
Frankfurt am Main
SacII New England BioLabs GmbH,
Frankfurt am Main
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Table 2.4 continued
Enzyme class Enzyme Manufacturer/Received from
Proteases Lysozyme Applichem GmbH, Darmstadt
PreScission
Protease
Bayer group, University of
Duisburg-Essen
2.1.5 Antibodies
The primary and secondary antibodies used in this thesis are listed in Table 2.5 and
Table 2.6, respectively.
Table 2.5: Primary antibodies.
Antigen Host Dilution
WB
Dilution
IF
Manufacturer
Acetylated
lysine
Rabbit 1:1,000 Cell Signaling Technology
Europe, Leiden
Acetylated
SurvivinK129
Rabbit 1:1,000 1:400 Novus Biologicals Ltd,
Cambridge
Aurora B Mouse 1:500 BD Transduction
Laboratories, Heidelberg
Aurora B Rabbit 1:2,000 Sigma-Aldrich Chemie
Gmbh, Munich
Borealin Mouse 1:200 MBL International, Woburn
CRM1 Rabbit 1:10,000 Novus Biologicals Ltd,
Cambridge
Flag Mouse 1:2,000 Sigma-Aldrich Chemie
Gmbh, Munich
GAPDH Mouse 1:1,000 Santa Cruz Biotechnology
Inc, Heidelberg
GFP Rabbit 1:2,000 Santa Cruz Biotechnology
Inc, Heidelberg
HA Mouse 1:1,000 Covance Inc, Munster
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Table 2.5
continued
Antigen Host Dilution
WB
Dilution
IF
Manufacturer
INCENP Mouse 1:150 Life Technologies GmbH,
Darmstadt
Myc Mouse 1:1,000 1:1,500 Cell Signaling Technology
Europe, Leiden
Survivin Rabbit 1:1,000 1:500 Novus Biologicals Ltd,
Cambridge
α-Tubulin Mouse 1:8,000 1:4,000 Sigma-Aldrich Chemie
Gmbh, Munich
Table 2.6: Secondary antibodies.
Antibody Host Dilution
WB
Dilution
IF
Manufacturer
Anti-mouse
IgG-Alexa
Fluor 488
Goat 1:1,000 Life Technologies GmbH,
Darmstadt
Anti-rabbit
IgG-Alexa
Fluor 568
Goat 1:1,000 Life Technologies GmbH,
Darmstadt
Anti-mouse
IgG-HRP
Sheep 1:10,000 GE Healthcare Life
Sciences, Freiburg
Anti-rabbit
IgG-HRP
Donkey 1:10,000 GE Healthcare Life
Sciences, Freiburg
2.1.6 Plasmids
The plasmids used in this thesis are listed in Table 2.7 to Table 2.9. Vector maps for
pc3-Survivin-GFP (Figure A.1), pc3-myc-Survivin (Figure A.2) and pET41-PreSc-GST-
Survivin (Figure A.3) can be found in the appendix.
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Table 2.7: Cloning vectors.
Vector Description Received from
pc3-SDSurvivinVL
N-term-myc
Eukaryotic expression vector,
ampr, used for cloning Survivin
mutants with C-terminal myc tag
Stauber group,
University Medical
Center Mainz
pc3-myc-TFIIA-
GFP
Eukaryotic expression vector,
ampr, used for cloning Survivin
mutants with N-terminal myc tag
Stauber group,
University Medical
Center Mainz
pc3-DDX3
N-term-HA
Eukaryotic expression vector,
ampr, used for cloning Survivin
mutants with C-terminal HA tag
Stauber group,
University Medical
Center Mainz
pET41-GST-PreSc Empty prokaryotic expression
vector, kanr, used for cloning
Survivin mutants with
N-terminal GST tag and
PreScisson protease cleavage
site
Bayer group, University
of Duisburg-Essen
Table 2.8: Eukaryotic expression vectors.
Vector Description Received from/
Supplier/Reference
pc3-Aurora B-GFP Aurora B C-terminally fused
with GFP
Stauber group,
University Medical
Center Mainz
pc3-Borealin-GFP Borealin C-terminally fused with
GFP
Stauber group,
University Medical
Center Mainz
pc3-CRM1-HA CRM1 C-terminally fused with
HA
Stauber group,
University Medical
Center Mainz
pc3-Flag-GCN5 GCN5 N-terminally fused with
Flag
PhD thesis
Carolin Bier
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Table 2.8 continued
Vector Description Received from/
Supplier/Reference
pc3-GFP GFP Stauber group,
University Medical
Center Mainz
pc3-HA-p300 p300 N-terminally fused with HA PhD thesis
Carolin Bier
pc3-myc-Survivin
F101AL102A
Dimerization-deficient
SurvivinF101AL102A mutant
N-terminally fused with myc
Master’s thesis
Cecilia Vallet
pc3-myc-
SurvivinK78Q
SurvivinK78Q mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK78R
SurvivinK78R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK90E
SurvivinK90E mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK90Q
SurvivinK90Q mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK90R
SurvivinK90R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK90,91R
SurvivinK90,91R mutant
N-terminally fused with myc
This thesis
pc3-myc-Survivin
K110,112,115Q
SurvivinK110,112,115Q mutant
N-terminally fused with myc
This thesis
pc3-myc-Survivin
K110,112,115R
SurvivinK110,112,115R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK112Q
SurvivinK112Q mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK112R
SurvivinK112R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK115Q
SurvivinK115Q mutant
N-terminally fused with myc
This thesis
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Table 2.8 continued
Vector Description Received from/
Supplier/Reference
pc3-myc-
SurvivinK115R
SurvivinK115R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK120-122Q
SurvivinK120-122Q mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK120-122R
SurvivinK120-122R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK129R
SurvivinK129R mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK129E
SurvivinK129E mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK129Q
SurvivinK129Q mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK129A
SurvivinK129A mutant
N-terminally fused with myc
This thesis
pc3-myc-
SurvivinK129,130R
SurvivinK129,130R mutant
N-terminally fused with myc
This thesis
pc3-myc-Survivin wt Survivin wildtype N-terminally
fused with myc
This thesis
pc3-Survivin
1-119-GFP
truncated Survivin1-119
C-terminally fused with GFP
Stauber group,
University Medical
Center Mainz
pc3-
SurvivinF101AL102A-
GFP
Dimerization-deficient
SurvivinF101AL102A mutant
C-terminally fused with GFP
This thesis
pc3-SurvivinK129Q-
GFP
SurvivinK129Q mutant
C-terminally fused with GFP
This thesis
pc3-SurvivinK129R-
GFP
SurvivinK129R mutant
C-terminally fused with GFP
This thesis
pc3-
SurvivinNESmut-
GFP
CRM1 binding-deficient
SurvivinNES mutant
C-terminally fused with GFP
Stauber group,
University Medical
Center Mainz
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Table 2.8 continued
Vector Description Received from/
Supplier/Reference
pc3-Survivin wt-GFP Survivin wildtype C-terminally
fused with GFP
Stauber group,
University Medical
Center Mainz
pc3-Survivin
F101AL102A-HA
Dimerization-deficient
SurvivinF101AL102A mutant
C-terminally fused with HA
This thesis
pc3-SurvivinK129E-
HA
SurvivinK129E mutant
C-terminally fused with HA
This thesis
pc3-SurvivinK129Q-
HA
SurvivinK129Q mutant
C-terminally fused with HA
This thesis
pc3-SurvivinK129R-
HA
SurvivinK129R mutant
C-terminally fused with HA
This thesis
pc3-Survivin wt-HA Survivin wildtype C-terminally
fused with HA
This thesis
pc3-SurvivinK129Q-
myc
SurvivinK129Q mutant
C-terminally fused with myc
This thesis
pc3-SurvivinK129R-
myc
SurvivinK129R mutant
C-terminally fused with myc
This thesis
pc3-Survivin wt-myc Survivin wildtype C-terminally
fused with myc
This thesis
pcDNA3.1(+) Used as empty vector in
transfections
Life Technologies
GmbH, Darmstadt
pcDNA3.1-INCENP-
GFP
INCENP C-terminally fused with
GFP
Schramm group,
University Children’s
Hospital Essen
pcDNA3.1-myc-
INCENP
INCENP N-terminally fused with
myc
Meyer group,
University of
Duisburg-Essen
pCMV-CBP-Flag CBP C-terminally fused with
Flag
PhD thesis
Carolin Bier
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Table 2.8 continued
Vector Description Received from/
Supplier/Reference
pcX-Flag-PCAF PCAF N-terminally fused with
Flag
PhD thesis
Carolin Bier
Table 2.9: Prokaryotic expression vectors.
Vector Description Reference
pET41-GST-PreSc-
SurvivinF101AL102A
Dimerization-deficient
SurvivinF101AL102A mutant
N-terminally fused with GST and
PreScisson protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK90Q
SurvivinK90Q mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK90R
SurvivinK90R mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK129A
SurvivinK129A mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK129E
SurvivinK129E mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK129Q
SurvivinK129Q mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
SurvivinK129R
SurvivinK129R mutant N-terminally
fused with GST and PreScisson
protease cleavage site
This thesis
pET41-GST-PreSc-
Survivin wt
Survivin wildtype N-terminally fused
with GST and PreScisson protease
cleavage site
This thesis
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2.1.7 Oligonucleotides
The PCR primers used in this thesis were purchased from Eurofins Genomics (Ebers-
berg) and are listed in Table 2.10. The sequencing primers were provided by the cor-
responding sequencing company and are listed in Table 2.11.
Table 2.10: PCR primers.
Primer Sequence (5’→3’)
3’-EcoRI-Surv TTTGAATTCTTAATCCATGGCAGCCAG
Apa-Surv for AAAGGGCCCGGTGCCCCGACGTTGCCC
Bam-Surv rev TTTGGATCCTTAATCCATGGCAGCCAG
Bam-Surv(ATG) for TTTGGATCCACATGGGTGCCCCGACGTTG
Bam-Surv(-ATG) for TTTGGATCCACGGTGCCCCGACGTTGCCCC
GFP5-Sequ-new GTGGCATCGCCCTCGCCCTC
pc3-F-Sequ GGAGGTCTATATAAGCAGAGCTC
pc3’-Sequ CAACTAGAAGGCACAGTCGAG
Surv-Bam for AAAGGATCCACATGGGTGCCCCGACGTTG
SurvF101AL102A-1P GTCCAGTTTCGCAGCTTCACCAAG
SurvF101AL102A-2P CTTGGTGAAGCTGCGAAACTGGAC
SurvK78Q-1P CGAATGCTTTTGATGTTCCTC
SurvK78Q-2P GAGGAACATCAAAAGCATTCG
SurvK78R-1P CGAATGCTTTCTATGTTCCTC
SurvK78R-2P GAGGAACATAGAAAGCATTCG
SurvK90E-1P CAAACTGCTTCTCGACAGAAAG
SurvK90E-2P CTTTCTGTCGAGAAGCAGTTTG
SurvK90Q-1P CAAACTGCTTCTGGACAGAAAG
SurvK90Q-2P CTTTCTGTCCAGAAGCAGTTTG
SurvK90R-1P CAAACTGCTTCCTGACAGAAAG
SurvK90R-2P CTTTCTGTCAGGAAGCAGTTTG
SurvK90,91R-1P TTCTTCAAACTGCCTCCTGACAGAAAG
SurvK90,91R-2P CTTTCTGTCAGGAGGCAGTTTGAAGAA
SurvK110,112,115Q-1P GGTTTCCTGTGCAATTTGGTTCTGGGCTCT
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Table 2.10 continued
Primer Sequence (5’→3’)
SurvK110,112,115Q-2P AGAGCCCAGAACCAAATTGCACAGGAAACC
SurvK110,112,115R-1P GGTTTCCCTTGCAATTCTGTTCCTGGCTCT
SurvK110,112,115R-2P AGAGCCAGGAACAGAATTGCAAGGGAAACC
SurvK112Q-1P CTTTGCAATTTGGTTCTTGGC
SurvK112Q-2P GCCAAGAACCAAATTGCAAAG
SurvK112R-1P CTTTGCAATTCTGTTCTTGGC
SurvK112R-2P GCCAAGAACAGAATTGCAAAG
SurvK115Q-1P GTTGGTTTCCTGTGCAATTTT
SurvK115Q-2P AAAATTGCACAGGAAACCAAC
SurvK115R-1P GTTGGTTTCCCTTGCAATTTT
SurvK115R-2P AAAATTGCAAGGGAAACCAAC
SurvK120-122Q-1P CTCAAATTCTTGCTGCTGATTGTTGGT
SurvK120-122Q-2P ACCAACAATCAGCAGCAAGAATTTGAG
SurvK120-122R-1P TTCCTCAAATTCTCTCCTCCTATTGTTGGT
SurvK120-122R-2P ACCAACAATAGGAGGAGAGAATTTGAGGAA
SurvK129A-1P GCGCACTTTTGCCGCAGTTTC
SurvK129A-2P GAAACTGCGGCAAAAGTGCGC
SurvK129E-1P GCGCACTTTCTCCGCAGTTTC
SurvK129E-2P GAAACTGCGGAGAAAGTGCGC
SurvK129Q-1P GCGCACTTTCTGCGCAGTTTC
SurvK129Q-2P GAAACTGCGCAGAAAGTGCGC
SurvK129R-1P GCGCACTTTCCTCGCAGTTTC
SurvK129R-2P GAAACTGCGAGGAAAGTGCGC
SurvK129,130R-1P GCGCACTCTCCTCGCAGTTTC
SurvK129,130R-2P GAAACTGCGAGGAGAGTGCGC
Surv-Nhe rev TTTGCTAGCATCCATGGCAGCCAGCTGC
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Table 2.11: Sequencing primers.
Primer Sequence (5’→3’) Sequencing company
T7 TAATACGACTCACTATAGGG GATC Biotech AG,
Konstanz
pcDNA3.1-FP CTCTGGCTAACTAGAGAAC GATC Biotech AG,
Konstanz
CMV-F CGCAAATGGGCGGTAGGCGTG LGC Genomics GmbH,
Berlin
T7term GCTAGTTATTGCTCAGCGG LGC Genomics GmbH,
Berlin
2.1.8 Bacterial strains
The bacterial strains used in this thesis are listed in Table 2.12.
Table 2.12: Bacterial strains.
Strain Genotype Manufacturer
E. coli SoluBL21 F- ompT hsd SB (rB- mB-) gal
dcm (DE3) + further
uncharacterized mutations
Genlantis, San Diego
E. coli XL2-Blue endA1 supE44 thi-1 hsdR17
recA1 gyrA96 relA1 lac [F’
proAB lacIqZ∆M15 Tn10 (Tetr)
Amy Camr]
Agilent Technologies,
Waldbronn
53
2 MATERIALS & METHODS
2.1.9 Eukaryotic cell lines
The cell lines used in this thesis are listed in Table 2.13. All cell lines were cultivated in
DMEM++.
Table 2.13: Eukaryotic cell lines.
Cell line Origin Growth property ATCC number
293T H. sapiens, fetal kidney adherent CRL-11268
HeLa H. sapiens, cervical
adenocarcinoma
adherent CCL-2
HeLa Kyoto H. sapiens, cervical
adenocarcinoma
adherent
2.1.10 Kits
The kits used in this thesis are listed in Table 2.14.
Table 2.14: Kits.
Kit Manufacturer
Expand High Fidelity PLUS PCR
System
Roche, Mannheim
Gel Filtration LMW Calibration kit GE Healthcare Life Sciences,
Freiburg
µMACS c-myc Isolation kit Miltenyi Biotec GmbH,
Bergisch-Gladbach
µMACS GFP Isolation kit Miltenyi Biotec GmbH,
Bergisch-Gladbach
µMACS HA Isolation kit Miltenyi Biotec GmbH,
Bergisch-Gladbach
NucleoBond Xtra Midi kit Macherey-Nagel GmbH & Co. KG,
Düren
NucleoSpin 8 Plasmid kit Macherey-Nagel GmbH & Co. KG,
Düren
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Table 2.14 continued
Kit Manufacturer
NucleoSpin Gel and PCR Clean-up
kit
Macherey-Nagel GmbH & Co. KG,
Düren
Pierce ECL plus Western blotting
Substrate kit
Thermo Fisher Scientific, Waltham
Protein Assay Kit Bio-Rad Laboratories GmbH, Munich
Takara DNA Ligation kit Clontech, Saint-Germain-en-Laye
2.1.11 Consumables
The consumables used in this thesis are listed in Table 2.15.
Table 2.15: Consumables.
Item Manufacturer
Beaker 50 mL VWR International GmbH, Darmstadt
Cell culture dish 10 cm Sarstedt AG & Co., Nümbrecht
Cell culture flask T-75 Sarstedt AG & Co., Nümbrecht
Cell scraper 25 cm Sarstedt AG & Co., Nümbrecht
Erlenmeyer flask 25/50 mL Technische Glaswerke Ilmenau
GmbH, Ilmenau
Erlenmeyer flask 250/500 mL DURAN Group GmbH, Wertheim
µ Column Miltenyi Biotec GmbH,
Bergisch-Gladbach
PCR tubes 0.2 mL Bio-Rad Laboratories GmbH, Munich
Pipette tip 10/20/200/1250 µL Sarstedt AG & Co., Nümbrecht
Poly-Prep chromatography column Bio-Rad Laboratories GmbH, Munich
Polyvinylidene fluoride (PVDF)
transfer membrane BioTrace
Pall GmbH, Dreieich
PVDF transfer membrane Amersham
Hybond P 0.45
GE Healthcare Life Sciences,
Freiburg
Semi-micro cuvette 10 x 4 mm Sarstedt AG & Co., Nümbrecht
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Table 2.15 continued
Item Manufacturer
µ-Slide 8 well ibidi GmbH, Planegg
Reaction tubes 1.5/2 mL Sarstedt AG & Co., Nümbrecht
Reaction tubes 15/50 mL Sarstedt AG & Co., Nümbrecht
Serological pipettes 2/5/10/25 mL Sarstedt AG & Co., Nümbrecht
UV micro cuvette Sarstedt AG & Co., Nümbrecht
Vacuum filter Techno Plastic Products AG,
Trasadingen
2.1.12 Instruments
The instruments and devices used in this thesis are listed in Table 2.16.
Table 2.16: Instruments and devices.
Instrument Manufacturer
Agarose gel electrophoresis chamber Peqlab Biotechnologie GmbH,
Erlangen
BioPhotometer Plus Eppendorf AG, Hamburg
CD spectropolarimeter J-715 Jasco Inc, Easton
Centrifuge 5417 C/R Eppendorf AG, Hamburg
Centrifuge Allegra X-22 Beckman Coulter GmbH, Krefeld
Centrifuge ROTINA 380/380 R Andreas Hettich GmbH & Co. KG,
Tuttlingen
Chemistry pumping unit Vacuubrand GmbH & Co. KG,
Wertheim
Chromatography column Superdex
75 10/300 GL
GE Healthcare Life Sciences,
Freiburg
CO2 incubator Binder GmbH, Tuttlingen
CO2 incubator INC153 Memmert GmbH & Co. KG,
Schwabach
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Table 2.16 continued
Instrument Manufacturer
Confocal laser scanning microscope
(inverse) TCS SP5
Leica Microsystems GmbH,
Mannheim
Epifluorescence microscope
(inverse) Axio Observer Z.1
Carl Zeiss, Oberkochen
Epifluorescence microscope
(inverse) CKX41
Olympus Europa SE & Co. KG,
Hamburg
Film processor Cawomat 2000 IR Cawo, Schrobenhausen
Freezer (-80 °C) Forma 900S-RIFS Thermo Fisher Scientific, Waltham
Freezer (-20 °C) Liebherr Premium
BioFresh
Liebherr GmbH, Biberach
Gel caster Bio-Rad Laboratories GmbH, Munich
Gel documentation system E-Box
VX2
Vilber Lourmat Deutschland GmbH,
Eberhardzell
Heating plate Gesellschaft für Labortechnik mbH,
Burgwedel
Heating plate Medax GmbH & Co. KG, Rendsburg
Liquid chromatography system
ÄKTApurifier
GE Healthcare Life Sciences,
Freiburg
µMACS separator Miltenyi Biotec GmbH,
Bergisch-Gladbach
Magnetic stirrer Hei-Mix L Heidolph Instruments GmbH & Co.
KG, Schwabach
Magnetic stirrer HI 180 Hanna Instruments Deutschland
GmbH, Kehl
Microscope Primo Vert Carl Zeiss, Oberkochen
Microwave Severin Elektrogeräte GmbH,
Sundern
Mini centrifuge Spectrafuge Labnet International Inc, Edison
Multichannel Pipette Plus Eppendorf AG, Hamburg
Orbital shaker Forma 420 series Thermo Fisher Scientific, Waltham
Orbital shaker POS-300 Grant Instruments Ltd, Royston
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Table 2.16 continued
Instrument Manufacturer
Pipettes Research Plus Eppendorf AG, Hamburg
Pipetting aid Pipetus Hirschmann Laborgeräte GmbH &
Co. KG, Eberstadt
pH meter Hanna Instruments Deutschland
GmbH, Kehl
Polyacrylamide gel electrophoresis
chamber Mini-Protean Tetra Cell
Bio-Rad Laboratories GmbH, Munich
Power supply Peqpower 300 Peqlab Biotechnologie GmbH,
Erlangen
Power supply PowerPac Basic Bio-Rad Laboratories GmbH, Munich
Precision balance Kern & Sohn GmbH, Balingen
Quarz glass cuvette (path length
1mm
Hellma Analytics, Müllheim
Refrigerator Liebherr Comfort Liebherr GmbH, Biberach
Refrigerator Liebherr Medline Liebherr GmbH, Biberach
Rotator PTR-30 Grant Instruments Ltd, Royston
Safety cabinet NuAire NU-437-400E Integra Biosciences GmbH, Fernwald
Safety cabinets HERAsafe Thermo Fisher Scientific, Waltham
Shaker ST5 neoLab Migge Laborbedarf-Vertriebs
GmbH, Heidelberg
Spectrophotometer Nanodrop 1000 Thermo Fisher Scientific, Waltham
Thermal mixer ThermoMixer Comfort Eppendorf AG, Hamburg
Thermal mixer MHR 11 HLC BioTech, Bovenden
Thermal printer DPU-414 Seiko Instruments GmbH,
Neu-Isenburg
Thermal printer P95D Mitsubishi Chemical Europe GmbH,
Düsseldorf
Thermoblock Eppendorf AG, Hamburg
Thermocycler TProfessional standard
gradient 96
Biometra GmbH, Göttingen
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Table 2.16 continued
Instrument Manufacturer
Ultrasonic homogenizer mini20 Bandelin electronic GmbH & Co. KG,
Berlin
Ultrasonic homogenizer Sonopuls
HD2200
Bandelin electronic GmbH & Co. KG,
Berlin
UV Sterilizing PCR Workstation Peqlab Biotechnologie GmbH,
Erlangen
Vacuum removal system AZ 02 HLC BioTech, Bovenden
Vortexer PV-1 Grant Instruments Ltd, Royston
Vortexer Vortex-Genie 2 Scientific Industries, Bohemia
Water bath 1002-1013 Gesellschaft für Labortechnik mbH,
Burgwedel
2.1.13 Software
The software used in this thesis is listed in Table 2.17.
Table 2.17: Software.
Software Manufacturer
Adobe Photoshop CC 2014 Adobe Systems GmbH, Munich
AxioVision Carl Zeiss, Oberkochen
BioEdit 7.2.5 Ibis Biosciences, Carlsbad
Canvas 11 ACD Systems International Inc., Seattle
Gene Construction Kit 3.0 Textco BioSoftware, Inc, New Hampshire
Image Studio Lite 4.0 LI-COR Biosciences GmbH, Bad Homburg
Jasco Spectra Manager 2.0 Jasco Inc, Easton
Leica Application Suite
Advanced Fluorescence
Leica Microsystems GmbH, Mannheim
PyMOL 1.3 Schrödinger LCC, Portland
Unicorn 5.20 GE Healthcare Life Sciences, Freiburg
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2.2 Methods
2.2.1 Molecular biology
2.2.1.1 Polymerase chain reaction
Polymerase chain reaction (PCR) is used to amplify DNA sequences. In addition to the
DNA template, also a sequence-specific pair of oligonucleotides (primer), deoxynu-
cleotide triphosphates (dNTPs) as well as a temperature-resistant DNA polymerase
are required. A PCR cycle contains three steps: denaturation of the double-stranded
DNA template and the primers, annealing of the primers, and primer elongation. It is
repeated 30 to 40 times in order to gain a sufficient amount of the template. Denatura-
tion is performed at 94 °C. The annealing temperature should be 2 to 5 °C lower than
the melting temperature of the used primers in order to allow specific hybridization of
the primers with the template. The elongation step requires 72 °C as this is the optimal
temperature for the used DNA polymerase. Its duration depends on the length of the
template and the amplification rate of the polymerase.
Table 2.18 summarizes the ingredients of a 50 µL PCR reaction mixture using the Ex-
pand High Fidelity PLUS PCR System (Roche Diagnostics). The standard PCR program
for Survivin cDNA amplification is displayed in Table 2.19. The PCR cycle was repeated
30 times.
Table 2.18: PCR reaction mixture.
Reagents Volume [µL]
Buffer 2 (5x) 10.0
Primer 1 (10 µM) 2.0
Primer 2 (10 µM) 2.0
dNTPs (10 mM each) 1.0
DNA polymerase 0.5
DNA template (10 ng/µL) 2.0
H2O 32.5
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Table 2.19: Standard PCR program for Survivin amplification.
Step Temperature Duration
Initial denaturation 94 °C 2 min
Denaturation 94 °C 30 s
Annealing 53-65 °C 30 s 30x
Elongation 72 °C 45 s
Final elongation 72 °C 5 min
2.2.1.2 Splice overlap extension PCR
For the site-directed mutagenesis of the Survivin cDNA, splice overlap extension (SOE)
PCR was applied. This method allows the generation of point mutations as well as the
deletion or insertion of nucleotides into a DNA sequence. A pair of complementary
mutagenesis primers bearing the mutation and a pair of primers that flank the DNA
template are required for the two-step PCR. In the first step of SOE PCR, the template
is amplified in two separate reaction mixtures containing either the forward flanking
primer and the reverse mutagenic primer, or the reverse flanking primer and the forward
mutagenic primer. In the second step, both PCR products are mixed allowing their
hybridization along the complementary regions derived from the mutagenic primers.
Thus, each DNA strand serves as a template for the completion of the other one. The
addition of the flanking primers then leads to the amplification of the mutated DNA
strands.
SOE PCR was performed using the same reagents and PCR program as for standard
PCR (see Table 2.18 and Table 2.19). The elongation time was increased to 1 min.
2.2.1.3 Agarose gel electrophoresis
Agarose gel electrophoresis is used to separate nucleic acids according to size. The
method utilizes the fact that charged molecules migrate within an electric field depen-
dent on their conformation, size, and charge density. As DNA is negatively charged it
moves to the anode. In order to achieve a size-dependent separation, the DNA moves
through an agarose gel that is placed in an electric field. Agarose is a polysaccharide
which forms a polymer gel upon boiling. The agarose concentration determines the
61
2 MATERIALS & METHODS
pore size of the gel and, thus, its separation capability as small DNA fragments mi-
grate faster through the pores than large fragments. After separation, DNA bands are
visualized by fluorescent DNA-binding dyes.
For an analytic gel, 30 mL 1x TAE buffer containing 1 to 2 % (w/v) agarose were
boiled. The DNA-staining dye GelRed (Biotium) was added (1:10,000), and the gel was
poured. After polymerization, the gel was placed in the electrophoresis chamber. The
samples were mixed with 6x DNA sample buffer and loaded on the gel. Electrophoresis
was conducted at 100 to 120 V for 45 to 90 min in 1x TAE buffer. After that, the DNA
bands were visualized with UV light using the gel documentation system E-Box VX2
(Vilber Lourmat). GeneRuler 1 kb DNA Ladder and GeneRuler 100 bp DNA Ladder
(Thermo Fisher Scientific) were used as DNA size standards.
2.2.1.4 Purification of DNA fragments
To remove impurities like salts, enzymes and primers from PCR products, and to extract
DNA from agarose gels, the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel)
was used according to the manufacturer’s instructions. The mechanism is based on
binding of DNA to a silica membrane followed by washing steps to remove contamina-
tions and, finally, the elution of the purified DNA.
2.2.1.5 Photometric determination of DNA concentration
Double stranded DNA (dsDNA) exerts an absorption maximum at a wavelength of
260 nm due to the strong absorption of the aromatic purine and pyrimidine bases at
this wavelength. Thus, applying Lambert-Beer’s law (see Equation 2.1, page 72) the
concentration of a dsDNA solution can be determined photometrically by measuring
its absorbance at 260 nm (A260). Measured at a neutral pH in a quartz cuvette of a
path length of 1 cm the absorbance of 1.0 corresponds to a dsDNA concentration of
50 µg/mL. The A260/A280 ratio provides information about the purity of the DNA. Pure
DNA exhibits a ratio of 1.8 to 2.0. While lower values hint at contamination with proteins
or phenol, higher values indicate RNA contamination. The A260/A230 ratio informs about
contamination with phenol or other organic substances. For pure DNA the value should
be 2.0
For the photometric quantification of the DNA concentration, 1 µL DNA was mixed with
70 µL ddH2O in a UV micro cuvette (Sarstedt) and the absorbance of the solution was
measured with a BioPhotometer (Eppendorf).
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2.2.1.6 Restriction of DNA
Restriction endonucleases are used to cut dsDNA at distinct sites as they catalyze the
hydrolysis of phophodiester bonds within the sugar phosphate backbone of DNA. For
molecular biological applications type II endonucleases are relevant as they cut dsDNA
within or near their mostly palindromic recognition sites. Depending on the restriction
enzyme the cleavage yields 3’ or 5’ cohesive ends, or blunt ends. The vector and
the PCR product serving as an insert have to be digested with the same restriction
enzymes in order to allow proper ligation.
For an analytic digest, 0,5 to 2 µL DNA were digested with suitable restriction enzymes
(New England BioLabs) in a buffer recommended by the manufacturer. The 10 µL re-
action mixture was incubated at 37 °C for 1 h. For a preparative digest, 4 µg DNA were
digested in a total volume of 50 µL for 4 h at 37 °C.
2.2.1.7 Ligation of DNA
Ligases are used to join DNA strands together as they catalyze the formation of phos-
phodiester bonds of the sugar phosphate backbone of DNA. An enzyme commonly
used to insert a DNA fragment into a linearized plasmid is the T4 DNA ligase derived
from the bacteriophage T4. It can ligate cohesive as well as blunt ends and requires
adenosine triphosphate (ATP) as a cofactor.
Ligation of an insert into a linearized plasmid was performed using the Takara DNA
Ligation Kit, Version 2.1 (Clontech), which also utilizes T4 DNA ligase. 0,5 µL plasmid,
2 µL insert and 2,5 µL Solution I of the kit were mixed and incubated for 30 min at
room temperature (RT). A negative control was also included in which the insert was
exchanged by ddH2O in order to test for re-ligation of the linearized plasmid.
2.2.1.8 Isolation of plasmids
Depending on the required amount of DNA a mini or midi preparation was performed in
order to isolate plasmid DNA from E.coli cells in which the plasmids were amplified.
For the mini preparation of plasmids, overnight cultures of E. coli XL2-Blue (Agilent
Technologies) containing positive clones were inoculated in 4 mL LB medium contain-
ing 100 µg/mL carbenicillin (Carb) or 50 µg/mL kanamycin (Kan) depending on the an-
tibiotic resistance coded on the plasmid. The cultures were incubated for approx. 16 h
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at 37 °C under constant shaking at 180 rpm. 3 mL of the bacterial cultures were cen-
trifuged for 10 min at 1,000 x g and the plasmids were isolated from the pellets with the
NucleoSpin 8 Plasmid kit (Macherey-Nagel) according to the manufacturer’s instruc-
tions. The kit is based on the principle of alkaline lysis of the bacterial cells (Birnboim
and Doly, 1979) and the subsequent loading of the neutralized, cleared lysate on a
column containing a silica membrane. Plasmid DNA binds to the silica membrane in
the presence of chaotropic salts. Contaminants are removed by several washing steps,
and the purified plasmids are eluted with a low salt buffer.
For the midi preparation, 150 mL overnight cultures were inoculated in antibiotic-con-
taining LB medium and incubated for 16 h at 37 °C under constant shaking at 120 rpm.
After harvesting the cells by centrifugation for 15 min at 3,900 x g and 4 °C the the
plasmids were isolated from the pellets using the NucleoBond Xtra Midi kit (Macherey-
Nagel) according to the manufacturer’s instructions. This kit is also based on the prin-
ciple of alkaline lysis of the bacterial cells followed by binding of the plasmids to a silica
resin under high salt conditions. However, elution of the plasmids is also conducted in
the presence of a high salt concentration by a shift from neutral to acidic pH. Thus, the
eluted plasmids have to be precipitated with isopropanol, and subsequently washed
with ethanol in order to remove salts.
2.2.1.9 DNA sequencing and sequence analysis
Sequencing of purified plasmid DNA was carried out by GATC Biotech or LGC Ge-
nomics according to the chain termination method (Sanger and Coulson, 1975). To
this end, 20 µL plasmid DNA with a concentration of 80 to 100 ng/µL were sent to the
companies. Sequencing primers (see Table 2.11) were provided by the companies. The
alignment of the sequences obtained from the sequencing companies with the virtual
constructs was performed using the cloning software Gene Construction Kit (Textco
BioSoftware) as well as the alignment software BioEdit (Ibis Biosciences).
2.2.2 Cell biology
2.2.2.1 Transformation of competent E. coli cells
Transformation describes the genetic alteration of cells due to the uptake of exogenous
DNA. Cells that are capable of taking up naked DNA are called competent. Not all bac-
teria strains possess a natural competence. E. coli, for example, which is commonly
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used to amplify recombinant plasmids, has to be made competent by chemical treat-
ment. Competent cells can be forced to incorporate DNA either by electroporation or
by a heat shock. Both methods cause the temporary appearance of pores in the cell
membrane enabling the DNA to enter.
For a heat shock transformation of chemically competent E. coli XL2-Blue or E. coli
SoluBL21 cells (Genlantis), 10 to 20 µL bacteria suspension were mixed with 1 to 2 µL
of the ligation product or a purified plasmid, and incubated for 20 min on ice. Then, the
mixture was incubated for 45 s at 42 °C and immediately placed on ice again where
it was incubated for further 10 min. After the heat shock, the cells were resuspended
in 200 µL LB medium. E. coli cells transformed with plasmids carrying an ampicillin
resistance were directly resuspended in LB-Carb medium and plated on LB-Carb agar
plates. E. coli cells transformed with plasmids carrying a kanamycin resistance were
first resuspended in LB medium without antibiotics, and incubated for 1 h at 37 °C under
shaking at 180 rpm in order to enable the expression of the resistance gene. After
that, they were plated on LB-Kan agar plates. The plates were incubated over night at
37 °C
2.2.2.2 Heterologous expression of recombinant GST fusion proteins
The heterologous expression of recombinant proteins in E. coli offers protein produc-
tion within a short time and with a high yield. The most commonly used expression
system consisting of an expression vector and a suitable E. coli host strain is based
on the bacteriophage T7. In this system, the expression vector containing the gene of
interest cloned downstream of the T7 promotor is introduced into a T7 expression host
strain. These host strains carry a chomosomal copy of the T7 RNA polymerase gene,
the expression of which is controlled by the lac operon. The addition of an inducer,
e.g. isopropyl β-D-1-thiogalactopyranoside (IPTG), leads to the expression of the RNA
polymerase which, in turn, transcribes the gene of interest.
In this thesis, an expression system comprising the E. coli SoluBL21 strain and the
pET41-GST-PreSc vector was used. In order to test the expression conditions for re-
combinant proteins, a protein mini expression was performed. To this end, overnight
cultures of clones grown on LB agar plates were inoculated in 5 mL LB-Kan medium
and incubated at 37 °C under shaking at 180 rpm. Each culture was splitted into four
1 mL aliquots and diluted with 4 mL LB-Kan medium and the cultures were again in-
cubated for 1 h. 500 µL of the suspensions were taken as a negative control sample.
IPTG was added to the remaining suspensions in varying concentrations (0,1 to 1 mM)
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in order to induce protein expression, and the cultures were incubated at different tem-
peratures for different durations in order to evaluate the best expression conditions.
500 µL of each culture were taken as a positive control. The samples were pelleted, and
the pellets were resuspended in 50 µL 2x SDS (sodium dodecylsulfate) sample buffer.
After sonication for 1 min with the ultrasonic homogenizer Sonopuls mini20 (Bandelin)
the samples were heated to 95 °C for 5 min. 10 µL of the samples were analyzed by
SDS polyacrylamide gel electrophoresis (subsubsection 2.2.3.5).
For a preparative protein maxi expression, 50 mL LB-Kan medium were inoculated
with 50 µL of a 5 mL overnight culture and incubated overnight at 37 °C under shaking
at 120 rpm. 20 mL of the pre-culture were diluted with 280 mL LB-Kan medium and
the culture was grown until its absorbance at 600 nm reached a value around 0.6.
Then, protein expression was induced by adding IPTG and was conducted under the
conditions evaluated by mini expression.
2.2.2.3 Cultivation of mammalian cell lines
The cultivation of mammalian cells requires special conditions. In order to enable cell
proliferation, cells are incubated at 37 °C and 5 % CO2 in approx. 90 % relative humidity.
In addition, the cells have to be continuously supplied with fresh growth medium, and
the cell density has to be regulated by regular splitting and transfer of the cells to new
culture vessels. The cultivation of the cells must be conducted under sterile conditions
in order to prevent infections with viruses, bacterial and fungi.
The mammalian adherent cell lines used in this thesis (HeLa, HeLa Kyoto and 293T)
were cultivated in DMEM++ growth medium in T-75 cell culture flasks. They were pas-
saged twice or three times a week with a ratio of 1:10 to 1:20. To this end, old growth
medium was aspirated and the cell layer was carefully rinsed with 5 mL DPBS to re-
move remaining fetal calf serum (FCS) which inhibits the enzymatic detachment of
the cells from the bottom of the cell culture flask. This was done by adding 2 mL of
the trypsin replacement TrypLE Express (Life Technologies), which cleaves the adhe-
sion proteins on the cell surface, and incubating the cells on a heating plate until they
were detached. 8 mL DMEM++ were added and the cells were resuspended. 0,5 to
1 mL of the cell suspension was transferred to a new culture flask which was filled with
DMEM++ up to 10 mL.
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2.2.2.4 Transient transfection of eukaryotic cells
Transient transfection describes the temporally introduction of nucleic acids into eu-
karyotic cells. Eukaryotic cells can be transfected chemically, for example by using
cationic polymers like polyethylenimine (PEI) or liposomal transfection reagents like
Lipofectamine 2000 (Life Technologies), to transport nucleic acids through the cell
membrane. PEI forms complexes with negatively charged nucleic acids, which are
taken up into cells via endocytosis. Lipofectamine 2000 forms liposomes around the
nucleic acids, which are capable of fusing with the cell membrane. Another method to
introduce nucleic acids into cells is by physical transfection, e.g. by means of electro-
poration or via particles. Irrespective of the transfection method used, the nucleic acids
must enter the cell and, subsequently, the nucleus in order to be transcribed. As they
are not integrated into the cell genome the are diluted upon cell division or degraded.
293T cells were used for the production of cell lysates and transfected with PEI. To
this end, 0.8 to 1 mL of the cell suspension produced during cell passage was diluted
with 9 mL DMEM++ and plated on a 10 cm cell culture dish. 24 h later, two solutions
were prepared: solution A comprised 240 µL DPBS and 44 µL 10 mM PEI, solution B
consisted of 240 µL DPBS and 15 µg plasmid DNA. The solutions were mixed together,
centrifuged and the mixture was incubated for 5 min at RT. Then, the transfection mix-
ture was applied to the cell layer in drops and the cells were incubated for 24 h.
For microscopic analyses, proteins were expressed in HeLa or HeLa Kyoto cells. Cells
were plated in 8 well µ-slides (ibidi) and transfected with Lipofectamine 2000. For
the transfection of one well, 20 to 25 µL of the cell suspension produced during cell
passage were diluted with 300 µL DMEM++ and seeded. 24 h later, the transfection
solutions were prepared: solution A comprised 12.5 µL Opti-MEM (Life Technologies)
and 0.2 µL Lipofectamine 2000, solution B consisted of 12.5 µL Opti-MEM and 150 ng
plasmid DNA. The solutions were mixed together, centrifuged and the mixture was
incubated for 5 min at RT. Then, the transfection mixture was applied to the cell layer in
drops and the cells were incubated for 24 h.
2.2.2.5 Inhibitor treatment of eukaryotic cells
Leptomycin B (LMB) is a secondary metabolite of the actinobacterium Streptomyces
spp. While it was originally discovered as an anti-fungal antibiotic (Hamamoto et al.,
1983), Kudo et al. (1999) found that LMB irreversibly inhibits the nuclear export receptor
CRM1 in eukaryotic cells.
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HeLa or HeLa Kyoto cells were incubated with DMEM++ containing 10 nM LMB for
3.5 h in order to inhibit CRM1 and, thus, analyze whether the export of the expressed
Survivin variants is CRM1-dependent.
Trichostatin A (TSA) is a metabolite of the actinobacterium Streptomyces hygroscopi-
cus and was originally identified as an anti-fungal antibiotic (Tsuji et al., 1976). In 1990,
Yoshida et al. reported that TSA is capable of inhibiting lysine deacetylases. It is now
known that it is a selective inhibitor of the mammalian class I and class II KDACs, but
not of the sirtuins (class III KDACs).
In order to enhance the general acetylation level, thus, gaining a higher amount of
acetylated Survivin, 293T cells were incubated in DMEM++ containing 100 nm TSA for
16 h.
Nocodazole was patented in 1972 by Gelder et al.. Soon is was discovered that it
is a potent anti-cancer drug due to its ability to inhibit microtubule polymerization, thus
preventing cell division (Atassi and Tagnon, 1975; Hoebeke et al., 1976). In cell biology,
nocodazole is used to synchronize the cell cycle of cells as treatment with nocodazole
arrests them in prometaphase of mitosis.
In order to arrest 293T cells in prometaphase, thus gaining a higher amount of assem-
bled CPCs in IP experiments, cells were treated with DMEM++ containing 50 ng/mL
nocodazole for 16 h.
2.2.2.6 Immunofluorescence staining
Immunofluorescence (IF) stainings are performed to label proteins within samples, for
example cells or tissues, with fluorescence dyes in order to allow the analysis of their
distribution within the sample by fluorescence microscopy. The method is based on the
specific recognition of an antigen by an appropriate antibody. In indirect immunofluores-
cence, the protein of interest is first recognized by a specific primary, non-fluorescing
antibody which, in turn, is detected by a secondary antibody labeled with a fluores-
cence dye.
For IF stainings of HeLa or HeLa Kyoto cells plated in 8 well µ-slides, the medium was
aspirated and the cells were fixed with 200 µL 4 % Roti-Histofix (Carl Roth) per well for
15 min at RT. The fixative was then aspirated and the cells were rinsed three times with
PBS for 5 min each. Afterwards, the cells were incubated in 200 µL blocking buffer for
1 h. While blocking, the primary antibodies were diluted in antibody dilution buffer as
indicted in Table 2.5. The blocking buffer was aspirated and the cells were incubated
in 120 µL primary antibody dilution at 4 °C over night. After rinsing the cells three times
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with PBS for 5 min each, 120 µL of the secondary antibody dilution (see Table 2.6)
containing 1 µg/µL of the DNA staining dye Hoechst 33342 (AppliChem) were applied
and incubated for 1 h at RT in the dark. Subsequently, the cells were rinsed again. For
conservation, the PBS was exchanged with PBS containing 0.1 % (w/v) sodium azide
and the samples were stored at 4 °C in the dark. In case another antigen was to be
stained, the entire procedure was repeated using a primary antibody derived from a
different species.
2.2.2.7 Fluorescence microscopy
Fluorescence microscopy takes advantage of the property of a fluorophore to enter
an excited state when it absorbs light of a distinct wavelength, and, after a short time,
emit light of a longer wavelength when returning to the ground state. With this method
the localization of proteins either indirectly labeled with fluorophore-coupled antibod-
ies during IF stainings (see subsubsection 2.2.2.6), or directly labeled via their fusion
with fluorescent proteins, can be analyzed in cells or tissues using epifluorescence or
confocal fluorescence microscopes.
In an epifluorescence microscope, the excitation light is reflected on the fluorophore-
labeled specimen through the objective by a dichroic beamsplitter. In addition to guiding
the excitation light from the light source to the specimen, the beamsplitter ensures that
only the fluorescence light emitted by the specimen, but not the reflected excitation
light are focused on the detector. An additional downstream emission filter prevents
transmission of light with wavelengths different from the wavelength of the light emitted
by the used fluorophore.
Epifluorescence microscopy was conducted using the inverted microscopes Axio Ob-
server Z.1 (Carl Zeiss Microscopy) and CKX41 (Olympus) with filter sets for imaging the
fluorophores Hoechst 33342, green fluorescent protein (GFP)/Alexa Fluor 488 (AF488)
and AF568.
In epifluorescence microscopy a great volume of the specimen is excited as the ex-
citation light can penetrate into the specimen, and light emitted by all planes of the
specimen reaches the detector. In a confocal microscope, however, only one small
focal volume within the specimen is excited and its emitted fluorescence is detected
increasing the contrast as well as the lateral resolution in comparison to conventional
fluorescence microscopy. This is achieved by two additional apertures, or pinholes,
within the light path. The first pinhole is located between the light source and the beam
splitter in order to create a point-like light source. The excitation light is focused to the
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specimen via the objective and excites only on a small volume of the specimen in the
focus plane. Fluorescence light emitted by the specimen passes the objective and the
beam splitter and reaches a second pinhole. Only light emitted from the focus plane is
focused on that pinhole, thus, passing the pinhole to reach the detector. Light emitted
from planes above or below the focus plane is not focused on the pinhole and, thus,
cannot reach the detector.
Localization and co-localization studies were conducted using the laser scanning mi-
croscope TCS SP5 (Leica Microsystems) controlled by the Leica Application Suite Ad-
vanced Fluorescence software. The samples were imaged by sequential scans at ex-
citation wavelengths of 405 nm (Hoechst 33342), 488 nm (GFP or AF488) and 561 nm
(AF568) with a scan speed of 100 Hz and a resolution of 1024 x 1024 pixels. For mi-
croscopy with the 63x water objective, the diameter of the pinhole was set to 111,4 µm.
2.2.3 Biochemistry
2.2.3.1 Purification of recombinant GST fusion proteins
Proteins tagged with glutathione S-transferase (GST) can be purified from bacterial
lysates via affinity chromatography using an affinity medium, e.g. sepharose beads,
coupled to the GST ligand glutathione (GSH). At low flow rates GST-tagged proteins
bind to immobilized GSH, and impurities can be removed by several washing steps.
The bound GST-fusion proteins are then either eluted from the GSH-beads by adding
reduced glutathione or, in case a protease cleavage site is located between the tag
and the protein, they can be released from the chromatography medium by proteolytic
cleavage. The pET41-GST-PreSc vector used to express the recombinant Survivin vari-
ants contains a PreScission protease cleavage site. PreScission protease is a fusion
protein consisting of human rhinovirus 3C protease and GST. It specifically cleaves
between the Q and G residues of its recognition sequence (LEVLFQ/GP).
E. coli SoluBL21 cells expressing the GST-tagged Survivin variants (see subsubsec-
tion 2.2.2.2) were harvested in a 50 mL reaction tube by subsequent steps of cen-
trifugation for 15 min at 3,900 x g and 4 °C. Then, the bacterial cells were lyzed. Af-
ter freezing in liquid nitrogen and re-thawing on ice, the bacterial pellet was resus-
pended in 15 mL cold lysis buffer and incubated on ice for 10 min. 150 µL of 50 mg/mL
Lysozyme were added and the suspension was incubated on ice for 20 min. Next, 75 µL
of 10 mg/mL DNase I as well as 75 µL of 1 M magnesium chloride were added and the
lysate was transferred to a 25 mL beaker placed on ice. The complete disruption of the
cells was achieved by sonication (four times for 7 s and once for 10 s with a break of
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90 s each) with the ultrasonic homogenizer Sonopuls HD2200 (Bandelin). The bacterial
lysate was cleared by centrifugation for 45 min at 3,900 x g and 4 °C. The supernatant
was transferred to a 15 mL reaction tube.
The GST-tagged Survivin proteins were purified from the supernatant with Glutathione
Sepharose 4B beads (GE Healthcare Life Sciences). To this end, 1 mL of the GSH
beads was transferred to a 15 mL reaction tube and the beads were washed twice
by resuspension in 5 mL cold PBS and subsequent centrifugation for 5 min at 500 x g
and 4 °C. The bacterial supernatant was mixed with the beads and binding occurred
for 2 h at 4 °C on an overhead shaker. After binding, the beads were separated from
the supernatant by centrifugation and washed twice with 5 mL cold cleavage buffer
containing 1 % (v/v) Triton X-100 (AppliChem).
The GST tag was removed from the recombinant Survivin proteins by proteolytical
cleavage with PreScission protease. The beads were resuspended in 500 µL cleavage
buffer and transferred to a 2 mL reaction tube. 10 µL PreScission protease (10 mg/mL)
were added, and cleavage occurred over night at 4 °C on an overhead shaker. In order
to separate the tag-free Survivin proteins from the beads, the suspension was trans-
ferred to a Poly-Prep chromatography column (Bio-Rad), and the first fraction of eluted,
tag-free protein was collected. Successively, the proteins were eluted twice with 400
and 300 µL of cleavage buffer, respectively.
2.2.3.2 Preparation of whole cell lysates from eukaryotic cells
Whole cell lysates of mammalian cells can be prepared in several ways. One com-
monly used method is the chemical lysis using RIPA buffer. RIPA buffer, which derives
its name from the radio-immunoprecipitation assay for which it has originally been de-
veloped, lyses cells effectively as it contains different detergents.
In order to prepare cell extracts from 293T cells plated on 10 cm cell culture dishes,
the dishes were placed on ice for 5 min. Then, the cells were detached with a cell
scraper, and the cell suspension was transferred to a 15 mL reaction tube. Cells were
pelleted by centrifugation for 5 min at 400 x g and 4 °C, resuspended in 1 mL cold PBS
and transferred to an 1.5 mL reaction tube. After further centrifugation, the PBS was
aspirated. The cells were lyzed by resuspending the cell pellet in 100 to 150 µL RIPA
buffer followed by a 15 min incubation on ice. To remove cell debris, the lysate was
centrifuged for 20 min at 20,000 x g and 4 °C. Finally, the supernatant was transferred
to a fresh 1.5 mL reaction tube. For SDS-PAGE analysis, 40 µg of protein were made
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up to 15 µL with ddH2O and 3.8 µL 5x SDS sample buffer were added. The samples
were denatured by boiling at 95 °C for 5 min.
2.2.3.3 Photometric determination of protein concentration
There are several methods to determine the protein concentration of samples, for ex-
ample the Bradford assay or the measurement of the absorbance at 280 nm (A280). All
of these methods have certain advantages and disadvantages. The Bradford assay is
rapid and sensitive (Bradford, 1976). It is based on the binding of the anionic triphenyl-
methane dye Coomassie brilliant blue G-250 to arginine, tryptophan, tyrosine, histidine
and phenylalanine residues of proteins under acidic conditions causing a shift in its
absorption maximum from 470 nm in the unbound state to 595 nm when it is bound to
proteins. Thus, in order to determine the protein concentration of a sample, it is mixed
with Coomassie brilliant blue G-250, and the absorbance at 595 nm is measured and
compared to a standard curve.
The protein concentration of cell lysates was determined by the Bradford micro assay
using the Bio-Rad Protein Assay Kit according to the manufacturer’s instructions.
The measurement of the absorbance at 280 nm in order to determine protein concen-
tration is quick, but error prone. It depends on the presence of the aromatic amino acids
tyrosine and tryptophan in the protein, which absorb at 280 nm. Similar to the concen-
tration determination of nucleic acids, the calculation of the protein concentration from
the A280 value is conducted according to Lambert-Beer’s law (Equation 2.1):
Aλ = lg(
I0
I
) = λ · c · l (2.1)
where Aλ is the absorbance at wavelength λ, I0 is the intensity of the incident light, I
is the intensity of the transmitted light, ελ is the molar absorption coefficient, c is the
concentration and l is the path length. Thus, if the sample contains a purified protein
with known absorption coefficient, this method yields reliable results. However, for the
concentration determination of proteins with unknown absorption coefficients or protein
mixtures, this is not the method of choice.
In order to determine the concentration of purified proteins, their absorption at 280 nm
was measured with the spectrophotometer NanoDrop 1000 (Thermo Fisher Scientific).
After entering the molar absorption coefficient as well as the molecular weight of the
protein, the instrument was calibrated by measuring a ddH2O sample. After that, 2 µL
cleavage buffer were applied to the sample pedestal and measured as a blank followed
by measurements of the purified proteins.
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2.2.3.4 Immunoprecipitation
Immunoprecipitation (IP) is a method to precipitate a protein from a solution using a
specific antibody. The technique requires that the antibody is coupled to a solid matrix,
e.g. sepharose or magnetic beads, in order to separate the antigen-antibody precipitate
from the solution by centrifugation or application of a magnetic field. Despite isolating
a single protein, IP experiments are also performed to investigate protein-protein inter-
actions by pulling on one member of a protein complex under conditions that prevent
its dissociation. This is called co-immunoprecipitation (co-IP). In this thesis, tagged
proteins were immunoprecipitated from 293T cell lysates using µMACS Isolation kits
(Miltenyi Biotec). These kits provide magnetic micro beads coupled to an antibody spe-
cific for the respective expression tag. The micro beads are incubated with the lysate,
and the mixture is loaded onto a µ column placed in a magnetic field. The magnetically-
labeled proteins are retained on the column while unspecifically binding molecules are
removed by several washing steps. The target proteins are then eluted from the column
with a denaturing elution buffer.
For co-IPs from 293T cells plated on 10 cm cell culture dishes, cell lysates were pre-
pared as described in subsubsection 2.2.3.2 using 1 mL interaction IP lysis buffer. The
lysate was incubated for 20 min at 37 °C and 500 rpm and placed on ice. 60 µL of the
lysate was mixed with 15 µL 5x SDS sample buffer and heated to 95 °C for 5 min to
serve as the input sample for western blot analysis. The remaining lysate was mixed
with 50 µL micro beads and incubated for 30 min on ice. A µ column was placed into the
magnetic field of a µMACS separator and equilibrated with 200 µL IP lysis buffer. Then,
the lysate-beads mixture was loaded to the column and allowed to flow through. After
washing the column four times with 200 µL IP lysis buffer each, and once with 100 µL
wash buffer 2, the precipitated proteins were eluted. To this end, first 20 µL, and after
a 5 min incubation, further 50 µL of elution buffer heated to 95 °C were applied. The
eluted samples were collected in 1.5 mL reaction tubes. 25 µL of the input and eluate
samples, respectively, were analyzed by SDS-PAGE (see subsubsection 2.2.3.5) and,
subsequently, by western blot (see subsubsection 2.2.3.7).
For acetylation IP, lysates were prepared using acetylation IP lysis buffer. Before clear-
ing the lysates by centrifugation, they were sonicated four times for 10 s using the
ultrasonic homogenizer Sonopuls mini20 (Bandelin) , and pressed through a 0.8 mm
hollow needle five times. All buffers were supplemented with 1 µM TSA in order to pre-
vent deacetylation. 25 µL of the input and 50 µL of the eluate samples were analyzed
by SDS-PAGE and, subsequently, by western blot.
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2.2.3.5 SDS-polyacrylamide gel electrophoresis
SDS-polyacrylamide gel electrophoresis (PAGE) is a technique that allows to separate
denatured proteins according to their mass within an electric field. To this end, the
protein samples are mixed with a sample buffer containing, among others, the anionic
detergent SDS (Laemmli, 1970). Binding of SDS to proteins leads to the disruption of
nearly all noncovalent inter- and intramolecular interactions and results in a linearized
conformation. In addition, a net negative charge is imparted to the proteins which is ap-
proximately proportional to their molecular mass. This allows the electrophoretic sep-
aration of proteins with different masses within a polyacrylamide gel. The acrylamide
concentration determines the pore size of the gel and, thus, its separation properties as
small proteins migrate faster through the gel than large proteins. The use of a discon-
tinuous system containing of a stacking and a separating gel with different acrylamide
and ion concentrations leads to the formation of distinct protein bands.
First, the components of the separating gel were mixed according to Table 2.20 and
poured between two glass plates separated by a 1 or 1.5 mm spacer. A layer of iso-
propanol was added in order to gain a separating gel with a straight upper edge. After
polymerization, isopropanol was removed and the stacking gel was poured on top of
the separating gel. A comb was inserted in order to create sample wells. After polymer-
ization, the gel was transferred to a vertical electrophoresis chamber and the chamber
was filled with 1x SDS-PAGE running buffer. After removing the comb, the samples
as well as 7 µL of the Spectra Multicolor Broad Range protein ladder (Thermo Fisher
Scientific) were loaded to the gel. Electrophoresis was started at 80 to 100 V. When
the samples had passed the stacking gel, the voltage was increased to 120 to 200 V.
Electrophoresis was stopped when a sufficient separation was achieved.
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Table 2.20: SDS-gel compositions. All volumes are given in mL.
Separating gel
1 mm
7.5 % 10.0 % 12.5 % 15.0 % 2 Stacking
gels 1mm
4.0 %
ddH2O 2.4 2.0 1.6 1.2 ddH2O 2.5
Separating gel
buffer
1.3 1.3 1.3 1.3 Stacking gel
buffer
1.35
Acrylamide
(30 % (v/v))
1.2 1.6 2.1 2.5 Acrylamide
(30 % (v/v))
0.65
APS (10 %
(w/v))
0.05 0.05 0.05 0.05 APS (10 %
(w/v))
0.05
TEMED 0.005 0.005 0.005 0.005 TEMED 0.005
Separating gel
1.5 mm
7.5 % 10.0 % 12.5 % 15.0 % 2 Stacking
gels 1.5 mm
4.0 %
ddH2O 4.3 3.6 2.9 2.0 ddH2O 2.5
Separating gel
buffer
2.4 2.4 2.4 2.4 Stacking gel
buffer
1.35
Acrylamide
(30 % (v/v))
2.3 3.0 3.7 4.4 Acrylamide
(30 % (v/v))
0.65
APS (10 %
(w/v))
0.096 0.096 0.096 0.096 APS (10 %
(w/v))
0.05
TEMED 0.010 0.010 0.010 0.010 TEMED 0.005
2.2.3.6 Coomassie staining of polyacrylamide gels
The unspecific staining of proteins within polyacrylamide gels after electrophoretic sep-
aration by SDS PAGE is based on the binding of the triphenylmethane dye Coomassie
brilliant blue G-250 to basic amino acids as explained in subsubsection 2.2.3.3.
Polyacrylamide gels were incubated in Coomassie staining solution over night at RT
under shaking. After staining, the gels were rinsed with water several times and incu-
bated in destaining solution for at least 3 h at RT under shaking in order to remove
background staining, and were again rinsed with water.
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2.2.3.7 Western blot
Western blotting (or immunoblotting) is a method used to electrophoretically transfer
proteins that have been separated by SDS-PAGE to a membrane allowing their de-
tection by specific antibodies. To this end, the polyacrylamide gel containing the sep-
arated proteins is placed in an electric field. As the proteins are negatively charged
due to treatment with SDS they migrate to the anode. The membrane is placed be-
tween the gel and the anode of the western blotting chamber, thus, when migrating
towards the anode, the proteins are immobilized on the membrane due to hydrophobic
and electrostatic interactions. After transfer, the proteins are accessible for detection
by specific primary antibodies. Primary antibodies are, in turn, detected by secondary
antibodies. The secondary antibody is derived from a different species than the primary
antibody and recognizes all antibodies derived from the same species by their identi-
cal Fc domain. Secondary antibodies are labeled, for instance with fluorescent dyes
or enzymes catalyzing light or color reactions, in order to locate their position on the
membrane. The proteins bands are then detected either by a fluorescence scanner,
X-ray films, or directly on the membrane due to the appearance of colored bands.
Western blotting was performed using the tank blot technique. First, the PVDF mem-
brane was activated in 100 % methanol for 15 s and, subsequently, equilibrated in 1x
transfer buffer together with the polyacrylamide gel. Four sheets of filter paper as well
as the pads of the blot cassette were also soaked with transfer buffer . The blot sand-
wich was assembled from the anode-facing side of the blot cassette to the cathode-
facing side as follows: a pad, two sheets of filter paper, the membrane, the gel, another
two sheets of filter paper and another pad. After inserting the blot cassette into the tank
blot chamber, the chamber was filled with transfer buffer. Western blotting occurred for
350 to 400 mA for 90 to 120 min at 4 °C. When transfer was finished, the membrane
was incubated in blocking buffer for 1 h at RT on a rocking shaker in order to block
free binding sites on the membrane, thus preventing unspecific binding of the primary
antibody. Primary antibodies were diluted in blocking buffer according to Table 2.5. In-
cubation of the membrane with the primary antibody dilution occurred for 1 h at RT or
over night at 4 °C. After washing the membrane three times with TBST, the secondary
antibody coupled to the enzyme horseradish peroxidase (HRP) was diluted in blocking
buffer (see Table 2.6) and incubated on the membrane for 1 h at RT. The membrane
was washed twice with TBST and once with TBS, before developing the blot with the
Pierce ECL Plus western blotting substrate (Thermo Fisher Scientific). This reagent
contains an acridan substrate that undergoes enzymatic oxidation by HRP to yield a
chemiluminescent acridinium ester. The chemiluminescence was detected by an X-ray
film which was developed using the film processor Cawomat 2000 IR (Cawo).
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2.2.3.8 Analytical gel filtration
Gel filtration (or size exclusion chromatography) is a chromatography technique that
separates molecules due to differences in their size as they pass through a gel filtra-
tion medium packed in a column. The medium is a matrix of porous beads which allows
small molecules to enter the pores resulting in a long retention time. Larger molecules
that cannot enter the pores migrate around the beads and are eluted earlier. Gel filtra-
tion is commonly applied to analyze the oligomerization state of native proteins.
The dimerization of the recombinant, purified Survivin variants was investigated using
the Superdex 75 10/300 GL gel filtration column together with the liquid chromatog-
raphy (LC) system ÄKTApurifier controlled by the Unicorn control software (all GE
Healthcare Life Sciences). Before the column was equilibrated with cold gel filtration
buffer, the buffer had to be sterile-filtered and degassed. The purified proteins were
diluted with the buffer to a final concentration of 1 to 2 mg/mL and 80 to 100 µL of
the samples were injected into the 500 µL sample loop of the LC system. The samples
passed through the column with a flow rate of 0.4 mL/min. The elution of the proteins
was monitored by measuring the absorbance at 280 nm. For calibration, a mixture of
the globular proteins Conalbumin (75 kDa), Ovalbumin (44 kDa), Carbonic anhydrase
(29 kDa), Ribonuclease A (13.7 kDa) and Aprotinin (6.5 kDa) as well as Blue Dextran
2000 (>2,000 kDa) was analyzed under the same conditions.
2.2.3.9 Circular dichroism spectroscopy
Circular dichroism (CD) spectroscopy is a technique to study chiral molecules by mea-
suring their CD over a range of wavelengths. CD is the difference in the absorption
of left-handed circularly polarised light and right-handed circularly polarised light and
is a characteristic of molecules containing one or more chiral chromophores. A com-
mon application of CD spectroscopy is the analysis of the structure or conformation of
macromolecules, in particular of proteins. Far-UV CD spectra recorded between 170
and 260 nm provide information on the conformation of the amide bonds within the pro-
tein backbone, thus allowing to identify secondary structure elements within a protein.
While randomly coiled regions of a protein exhibit a positive peak of the CD or the el-
lipticity at 212 nm and a negative peak at 195 nm, in case of β-sheets the peaks are
shifted to 218 and 196 nm, respectively. α-helical regions exhibit three peaks: a positive
one at 192 nm and two negative ones at 209 and 222 nm.
The integrity of the secondary structure of the purified, recombinant Survivin variants
was analyzed by measuring CD with a J-715 CD spectropolarimeter (Jasco). The pro-
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teins were diluted to a final concentration of 0.2 mg/mL with sterile-filtered CD buffer
and 200 µL of the dilutions were transferred to a quartz glass cuvette with a path lengths
of 1 mm (Hellma Analytics). For recording the far-UV CD spectra between 190 and
260 nm, the data interval was set to 0.1 nm, the scanning speed to 100 nm/min, the
response time to 0.5 s and the band width to 2 nm. 15 spectra were recorded of each
sample at 20 °C and accumulated. From each protein spectrum a buffer spectrum was
subtracted and the measured ellipticity was converted to specific ellipticity using path
length and protein concentration according to Equation 2.2
Ψspec =
Ψ
l · c (2.2)
where Ψspec is the specific ellipticity in deg · cm3 · dm-1 per gram of amino acid, Ψ is
the measured ellipticity in mdeg, l is the path length in cm and c is the concentration in
mg/ml.
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3.1 Relevance of Survivin acetylation for its
dimerization and cellular localization
In 2010, Wang et al. reported that the acetylation of Survivin at lysine 129 deter-
mines whether the protein forms homodimers or binds to the nuclear export receptor
CRM1, and thus, is also responsible for Survivin’s cellular localization. In the study,
four Survivin mutants were compared, two, which cannot be acetylated at lysine 129
(SurvK129R and SurvK129E), the others mimicking acetylation (SurvK129Q and
SurvK129A). By immunofluorescence (IF) stainings of the Survivin variants expressed
in HeLa cells they showed that myc-tagged SurvK129R and SurvK129E showed a
more cytoplasmic localization while the mimicking mutants localized mainly in the nu-
cleus like the wt protein. Furthermore, immunoprecipitation (IP) and Förster resonance
energy transfer (FRET) analyses revealed that SurvK129E formed less stable homod-
imers and that its binding affinity to CRM1 was increased compared to Survivin wt.
Survivin consists of three regions determining its various functions. The N-terminal BIR
domain (aa 15-88) is responsible for Survivin’s anti-apoptotic function, as it can bind
to, and thus, stabilize XIAP (Dohi et al., 2004). Between the BIR domain and Survivin’s
C-terminal α-helix (aa 99-142), a linker region is located containing two overlapping,
functionally important features: the nuclear export signal (aa 89-98) and one part of
the dimer interface (aa 89-102). The NES is the binding site for the nuclear export
receptor CRM1, thus mediating the nuclear export of Survivin. At the dimer interface,
two Survivin monomers can interact to form the bow tie-shaped dimer depicted in Fig-
ure 3.1. For the long C-terminal α-helix, two functions have been described so far: first,
it mediates the interaction of Survivin with microtubules (Li et al., 1998), and second, it
forms a stable helical bundle with helices of Borealin and INCENP to build up the core
of the CPC (Jeyaprakash et al., 2007). K129 is located within a hydrophobic cluster
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in the last third of Survivin’s C-terminal helix, a region which is likely to be involved in
protein-protein interactions.
Figure 3.1: Schematic representation of acetylated lysine 129 in the Survivin homodimer.
Ribbon representations of the bow tie-shaped Survivin homodimer (Chantalat et al., 2000; PDB
ID: 1E31). The N-terminal BIR domain is shown in blue and the C-terminal α-helix in red. K129
is depicted in green in stick representation. The Zn2+ ion is shown as a sphere in cyan. A) Bow
tie-shaped Survivin dimer. The NES is depicted in orange. B) The view in A rotated by 90°
around the horizontal axis. C) The same view as in A. The dimer interface is depicted in purple.
D) The view in C rotated by 90° around the horizontal axis. The dimer interface is depicted in
purple. The circle shows a close up view of K129.
It is noticeable about the abovementioned study by Wang et al. (2010b) that the re-
sults shown only included the SurvK129E mutant, which was described as unacetylat-
able, and thus, comparable to SurvK129R. For SurvK129R, however, except that it was
mentioned that its cellular localization resembled that of SurvK129E, no results were
shown at all. The SurvK129E mutant was chosen since a search in the NCBI single nu-
cleotide polymorphism (SNP) database revealed a SNP in the Survivin gene changing
lysine 129 to glutamate. Considering other studies analyzing protein acetylation, the
substitution of lysine with glutamate is not the typical mutation to abolish acetylation.
Conventionally, lysine is mutated to arginine on the one hand to inhibit acetylation and
other post-translational modifications, and on the other hand to mimic the structural as
well as biochemical properties of lysine.
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Figure 3.2: Chemical structures of the amino acids lysine and acetyllysine and the amino
acids used for their substitution.
The side chain of lysine consists of four methylen groups followed by an amino group
which makes lysine a basic, polar and positively charged amino acid at a neutral pH
value (Figure 3.2). The side chain of arginine contains three methylen groups fol-
lowed by a guanidino group which implicates that arginine is basic, polar and posi-
tively charged as well, and its side chain has a length comparable to that of lysine.
Glutamate, however, besides having a shorter side chain, belongs to the acidic amino
acids as its side chain ends with a negatively charged carboxyl group. This indicates
that SurvK129E might not be comparable to Survivin wt not acetylated at K129 or to
SurvK129R, and thus, might be inappropriate to gain information about the function of
Survivin acetylation at K129. The acetylation of a lysine residue leads to the loss of its
positive charge. Hence, an amino acid appropriate to mimic acetylated lysine must be
polar and uncharged. For this purpose, glutamine is used as standard, although its side
chain is shorter than that of lysine. The substitution of lysine with alanine is untypical
for mimicking an acetylated lysine residue since alanine is unpolar and its side chain
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consists only of one methyl group.
As a preliminary work to our studies, which were aimed at the identification of further
acetylation sites in Survivin and the influence of the potential acetylation on Survivin’s
various functions, we first wanted to verify the findings observed by Wang et al. (2010b),
and evaluate whether the results presented for the SurvK129E mutant allow to draw
conclusions on the relevance of Survivin acetylation for its dimerization and cellular
localization. Furthermore, we intended to analyze the effects of lysine 129 acetylation
on Survivin’s functions that were not addressed in the study, for example its role in
mitosis.
3.2 Characterization of Survivin acetylation at lysine
129
3.2.1 Optimization of the conditions to analyze Survivin
acetylation
As lysine to arginine and lysine to glutamine mutations are conventionally used to in-
vestigate protein acetylation, initially, the SurvK129R and SurvK129Q mutants were
analyzed. To generate these mutants, the pc3-Survivin-GFP plasmid was used as a
template for splice overlap extension PCR (subsubsection 2.2.1.2) with primers bear-
ing the mutation of lysine 129 to arginine or glutamine, respectively. To first examine
their general acetylation level, the Survivin variants were transiently expressed in 293T
cells and immunoprecipitated from the lysates. Lysine acetylation was determined by
western blot using an antibody specific for acetylated lysine (AcK) (Figure 3.3). For
Survivin wt-GFP (43 kDa), a low acetylation level could be detected which did not in-
crease upon treatment with the KDAC class I and II inhibitor trichostatin A (TSA) (Fig-
ure 3.3A). However, co-expression with the KATs p300 or CBP strongly enhanced the
overall acetylation. The acetylation levels of SurvK129R and SurvK129Q were com-
parable to that of Survivin wt. Further analysis by IP including the isolated GFP tag
(27 kDa) revealed that GFP also contains acetylated lysine residues (Figure 3.3B).
In order to investigate the cellular localization of the Survivin mutants, cDNAs coding
for the GFP-tagged Survivin variants were transiently transfected into HeLa cells, and
protein localization was assessed by IF staining (Figure 3.4). The wt protein and both
mutants predominantly localized to the cytoplasm. A minor protein amount could also
be detected in the nucleus.
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Figure 3.3: Acetylation of GFP-tagged Survivin by the KATs p300 and CBP. A) 293T cells
were (co-)transfected with GFP-tagged Survivin variants, and the lysine acetyltransferases
HA-p300 or CBP-Flag. Treatment with 100 nM trichostatine A (TSA) for 16 h was performed
where indicated. Lysates were immunoprecipitated (IP) with magnetic beads coupled to a GFP-
specific antibody using TSA-containing buffers and immunoblotted (WB). Membranes were
probed with antibodies specific for HA, Flag, GFP, or AcK. B) 293T cells were transfected with
cDNAs coding for GFP or Survivin wt-GFP. Lysates were immunoprecipitated with magnetic
beads coupled to a GFP antibody using TSA-containing buffers and immunoblotted. Mem-
branes were probed with antibodies specific for GFP or AcK.
Since GFP contains acetylated lysine residues, which was confirmed by the PAIL (Pre-
diction of acetylation on internal lysines) online tool (http://bdmpail.biocuckoo.org/index.
php, Li et al., 2006), and a huge tag like GFP (27 kDa) fused to the C-terminus of Sur-
vivin (16.5 kDa) might prevent acetylation in the C-terminal region, Survivin wt and both
mutants were cloned with smaller C-terminal expression tags (myc or HA). An acetyla-
tion prediction for the Survivin wt-myc sequence by PAIL revealed that although the myc
tag contains a lysine residue, its acetylation is improbable. The HA tag does not con-
tain lysine residues. The Survivin variants with smaller tags were expressed in HeLa
cells and again, their cellular localization was analyzed microscopically (Figure 3.5 and
data not shown). The results were comparable to that obtained for the GFP-tagged
Survivin variants (Figure 3.4), with the only difference that more protein was present in
the nucleus. In most cells, an intense membrane staining was observed.
Since no differences in the cellular localization of the C-terminally tagged mutants could
be observed, Survivin wt and both mutants were finally cloned with an N-terminal myc
tag in order to create the same conditions as reported by Wang et al. (2010b), although
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Figure 3.4: Cellular localization of GFP-tagged Survivin K129R/Q mutants. HeLa cells
were transiently transfected with Survivin-GFP variants (green), fixed, and DNA was stained
with Hoechst. Images were taken with a Zeiss AxioObserver fluorescence microscope. Scale
bar, 10 µm.
PAIL prediction revealed that the lysine within the myc tag is likely to be acetylated if
the tag is placed at the N-terminus of the protein. Also the unconventional SurvK129E
and SurvK129A mutants were included in our study. Furthermore, a different strain of
HeLa cells, HeLa Kyoto (HeLa K), was chosen for subsequent microscopic analyses
as these cells have a larger cell body, they form an ordered monolayer, and no staining
artifacts like membrane staining occur in IF experiments.
With Survivin wt and the four mutants available with an N-terminal myc tag, the differ-
ent properties of the Survivin variants could be analyzed. The subcellular localization
was assessed by IF stainings, while the dimerization was analyzed by IP as well as
gel filtration experiments. IP was also used to investigate the interaction of the Sur-
vivin mutants with CRM1 and with members of the CPC. Their involvement in mitosis
was additionally analyzed by IF staining, and CD spectra were recorded to survey the
integrity of the proteins’ secondary structure.
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Figure 3.5: Cellular localization of myc-tagged Survivin K129R/Q mutants. HeLa cells were
transiently transfected with Survivin-myc variants, fixed, and immunostained with a myc-specific
antibody (red). DNA was stained with Hoechst (blue). Images were taken with a Zeiss AxioOb-
server fluorescence microscope. Scale bar, 10 µm.
3.2.2 Effect of Survivin acetylation on its cellular localization
In order to investigate their cellular localization, the myc-tagged Survivin variants were
transiently expressed in HeLa K cells, and their localization was assessed by IF stain-
ing (Figure 3.6). The wt protein and both acetylation mimicking mutants, K129Q and
K129A, localized primarily in the cytoplasm, but a minor amount of protein was also
detectable in the nucleus. The same distribution was observed for the acetylation abol-
ishing K129R mutant. SurvK129E, however, showed an altered subcellular localization
as no protein could be detected in the nucleus.
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Figure 3.6: Cellular localization of myc-tagged Survivin K129 mutants. HeLa K cells were
transiently transfected with myc-Survivin variants and fixed 24 h later. After permeabilization,
they were immunostained with a myc-specific antibody (green). DNA was stained with Hoechst
(blue). Images were taken with a Leica SP5 confocal microscope. Scale bar, 20 µm (overview)
and 10 µm (zoom), respectively.
3.2.3 Effect of Survivin acetylation on its dimerization
As Wang et al. (2010b) argued that SurvK129E forms less stable dimers than wt Sur-
vivin, the homodimerization of the Survivin variants was investigated by IP experiments.
293T cells were co-transfected with myc-, HA- or GFP-tagged Survivin mutants and
lysed. The lysates were incubated for 20 min at 37 °C before adding the microbeads
coupled to an HA-specific antibody. HA-tagged Survivin was immunoprecipitated from
the lysates, and the interaction of the different Survivin mutants was then analyzed by
western blot (Figure 3.7). SurvF101AL102A, a dimerization deficient mutant described
by Engelsma et al. (2007), was used as negative control.
No dimerization of SurvF101AL102A with Survivin wt or with itself could be detected.
The non acetylatable SurvK129E mutant also preferentially existed as a monomer.
The second mutant that cannot be acetylated, SurvK129R, however, showed a strong
dimerization with Survivin wt similar to that of wt with wt protein. In comparison to that,
the homodimerization of SurvK129R was reduced by 38 %. Also a different interaction
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Figure 3.7: Dimerization of myc-tagged Survivin K129 mutants. A) Lysates from 293T cells
transiently transfected with myc-, HA- or GFP-tagged Survivin mutants were immunoprecipi-
tated (IP) with magnetic beads coupled to an HA-specific antibody and immunoblotted (WB).
Membranes were probed with antibodies specific for GFP, myc or HA. B) Quantification of the
immunoblot shown in A.
strength was found for the acetylation mimicking mutants SurvK129Q and SurvK129A.
While no dimerization of SurvK129A with wt Survivin was evident, the dimerization of
SurvK129Q with Survivin wt or with itself was enhanced (28 % and 25 %, respectively,
compared to Survivin wt with wt).
To verify the results obtained by IP experiments, gel filtration analyses were performed.
For recombinant expression in bacteria, the Survivin mutants were integrated into the
pET41-GST-PreSc vector system. The advantage of this system is that proteins can be
expressed with an N-terminal GST tag followed by the PreScission protease cleavage
site allowing to purify the proteins from bacterial lysates with Sepharose-GSH beads,
and subsequently, use PreScission protease to remove the tag. The expression of GST-
tagged Survivin wt in E.coli SoluBL21 bacteria (Genlantis) was tested under different
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conditions. Finally, expression at 30 °C for 7 h resulted in the highest yield of soluble
protein. Consequently, the expression of Survivin wt and the mutants was performed
under these conditions.
The purified, tag-free Survivin proteins were then analyzed in PBS containing 2.5 mM
β-mercaptoethanol using a Superdex 75 10/300 GL column (GE Healtcare Life Sci-
ences) (Figure 3.8A). The dimerization-deficient SurvF101AL102A mutant was again
used as negative control.
The gel filtration analysis revealed that for SurvF101AL102A (gray) indeed only one
peak was detectable at an elution volume of 10.4 mL, indicative for a monomer. In
contrast, the profiles of Survivin wt (green) and the mutants SurvK129R (dark blue)
and SurvK129Q (red) also showed a low monomer peak at approx. 10.3 mL, but the
major peak appeared at an elution volume of 9.5 mL indicating a Survivin dimer. The
profile of SurvK129E (blue) resembled that of Survivin wt and the other K129 mutants,
but both peaks eluted 0.1 mL earlier, at 9.4 and 10.2 mL, respectively. SurvK129A was
not included in this analysis. Gel filtration was repeated (data not shown), this time
including the K129A mutant.
As it was not possible to draw conclusions on the dimerization properties of the mu-
tants only by comparing their elution profiles due to the different height of the peaks,
the dimer and monomer peaks of each profile were integrated separately to obtain the
amount of dimer or momomer. The sum of both integrals was set to 100 %. Figure 3.8B
shows the results of both gel filtration analyses. As already apparent from its gel filtra-
tion profile, SurvF101AL102A did not form homodimers. The quantification revealed an
amount of 84 % monomeric protein. The results for Survivin wt and the SurvK129 mu-
tants differed from the distribution obtained for the dimerization-deficient variant. With
percentages of 75 % for Survivin wt, SurvK129R and SurvK129E, 76 % for SurvK129Q
and even 85 % for SurvK129A, the dimeric form was clearly predominant.
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Figure 3.8: Dimerization of recombinant, untagged Survivin K129 mutants. A) Gel filtration
profiles of purified, tag-free Survivin mutants in PBS containing 2.5 mM β-mercaptoethanol.
Only the elution range between 8.5 and 11.5 mL is shown. A 280: absorption at 280 nm; AU:
absorption units. B) Quantification of Survivin dimerization. Monomer and dimer peaks of the
gel filtration profiles shown in A were integrated and the sum of both integrals was set to 100 %.
The data are means of two experiments, except for SurvK129A (n=1). The error bars represent
s.d.
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3.2.4 Effect of Survivin acetylation on its interaction with the
export receptor CRM1
As also shown by Wang et al. (2010b), the SurvK129E mutant exhibited an altered
subcellular localization compared to the other mutants (Figure 3.6), which indicates
differences in their nucleo-cytoplasmic transport and their interaction patterns with the
export receptor CRM1. In order to investigate whether the nuclear export of the Survivin
variants is indeed CRM1-dependent, a cellular CRM1 inhibition assay was performed.
To this end, HeLa K cells transfected with the myc-Survivin variants were treated with
10 nM leptomycin B (LMB) for 3.5 h. LMB irreversibly inhibits CRM1 by alkylating C528
in its NES binding pocket, thus preventing the binding of NES-containing proteins (Kudo
et al., 1999). Then the cells were fixed, permeabilized, and immunostained with a myc-
specific antibody (Figure 3.9).
In the untreated control cells, myc-tagged Survivin wt and the different mutants showed
the same localization as already described in subsection 3.2.2 (Figure 3.6). Again, only
SurvK129E did not localized to the nucleus, but was exclusively found in the cytoplasm.
The SurvF101AL102A mutant, for which a stronger binding to CRM1 was described
(Engelsma et al., 2007), localized like Survivin wt in the untreated cells. SurvNESmut-
GFP, in contrast, exhibited a prominent nuclear accumulation. After LMB treatment, all
SurvK129 variants showed an increased nuclear localization, but still more protein was
detectable in the cytoplasm than in the nucleus. An equal protein distribution in both
compartments could be observed for the dimerization-deficient mutant. SurvNESmut-
GFP accumulated in the nucleus as before the treatment with LMB.
The CRM1 inhibition assay was accompanied by IP experiments in order to evaluate
the differences of the SurvK129 mutants in CRM1 binding reported by Wang et al.
(2010b). Therefore, 293T cells were transfected with CRM1-HA and the different myc-
SurvK129 mutants. The lysates were incubated for 20 min at 37 °C before adding the
microbeads coupled to an HA-specific antibody. CRM1-HA (125 kDa) was then im-
munoprecipitated from the lysates, and the co-IP of the Survivin variants was analyzed
by western blot (Figure 3.10).
Indeed, differences between the acetylation abolishing mutants K129R and K129E
could be observed. While the binding affinity of SurvK129R to CRM1 was reduced
by 16 % compared to wt Survivin, the interaction of SurvK129E with CRM1 was even
stronger than that of Survivin wt (1.11). The acetylation mimicking mutants SurvK129Q
and SurvK129A exhibited a 28 % and 48 % decreased binding affinity, respecticely,
compared to Survivin wt. A binding of Surv1-119-GFP, a truncated variant of Survivin
missing the C-terminal part of the helix in which Rodriguez et al. (2002) hypothesized a
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Figure 3.9: Effect of CRM1 inhibition on the cellular localization of myc-tagged Sur-
vivin mutants. HeLa K cells were transiently transfected with myc-Survivin variants (green)
or SurvNESmut-GFP. 24 h later they were treated with 10 nM LMB for 3.5 h. After permeabi-
lization, cells were immunostained with a myc-specific antibody. Untreated cells were used as
control. Images were taken with a Zeiss Axiovert epifluorescence microscope. Scale bar, 20 µm
(overview) and 10 µm (zoom), respectively.
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Figure 3.10: Interaction of myc-tagged Survivin K129 mutants with CRM1. A) Lysates from
293T cells transiently transfected with HA-tagged CRM1 and myc- or GFP-tagged Survivin
mutants were immunoprecipitated (IP) with magnetic beads coupled to an HA-specific antibody
and immunoblotted (WB). Membranes were probed with antibodies specific for CRM1, GFP,
myc or Surv. B) Quantification of the immunoblot shown in A.
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non-classical CRM1-dependent export motif, could not be detected. For SurvNESmut-
GFP, where the interaction with CRM1 is abolished by mutating two essential leucine
residues within the export signal (Knauer et al., 2006), an only 28 % reduced interaction
with CRM1 was observed, however.
Figure 3.11: Interaction of CRM1 with myc-tagged Survivin K129 mutants. A) Lysates from
293T cells transiently transfected with HA-tagged CRM1 and myc- or GFP-tagged Survivin
mutants were immunoprecipitated (IP) with magnetic beads coupled to antibodies specific for
myc or GFP and immunoblotted (WB). Membranes were probed with antibodies specific for
CRM1, GFP, myc or Surv. B) Quantification of the immunoblot shown in A.
In a further experiment, microbeads coupled to a myc- or GFP-specific antibody were
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used, so the Survivin mutants were precipitated from the lysates instead of CRM1-HA
(Figure 3.11). As positive control the dimerization-deficient myc-SurvF101AL102A mu-
tant was included, as Engelsma et al. (2007) reported an increased binding to CRM1.
For SurvK129E and SurvK129Q, the quantification of the western blot revealed results
similar to those shown in Figure 3.10 (1.02 and 0.68, respectively). For SurvK129R and
SurvK129A, however, a binding affinity comparable to Survivin wt was determined. The
interaction strength of SurvNESmut to CRM1 was reduced to 42 %. Even an interaction
of Surv1-119 with CRM1 could be observed, which was only decreased by 40 % com-
pared to Survivin wt. SurvF101AL102A, the positive control for an increased binding to
CRM1, showed a 55 % lower binding affinity compared to wt Survivin.
3.2.5 Analysis of the secondary structure of Survivin K129
mutants
The introduction of a mutation into a protein can cause conformational changes due
to different biochemical properties of the amino acids. To evaluate whether amino acid
substitutions introduced in the Survivin protein caused alterations in the protein sec-
ondary structure, far-UV CD spectroscopy was applied. CD spectroscopy allows to
draw conclusions on the conformation of peptide bonds from their optical activity, thus
providing insight into the secondary structure of proteins. The far-UV CD spectra of
the recombinant Survivin variants were recorded in phosphate buffer containing 10 µM
Zn2+ at 20 °C (Figure 3.12).
The spectra of all SurvK129 mutants showed a similar progression with one maximum
of the specific ellipticity at approx. 191 nm and two minima at 207 and 225 nm. All
spectra intersected the x-axis at approx. 200 nm. SurvF101AL102A (gray), however,
exhibited a spectrum clearly different from those of the other mutants. The specific
ellipticity decreased earlier with the curve intersecting the x-axis already at approx.
197 nm. Also the first minimum was slightly shifted to lower wavelengths, and a second
minimum at 225 nm could not be observed.
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Figure 3.12: CD spectra of recombinant, untagged Survivin K129 mutants. Far-UV circular
dichroism spectra of purified, tag-free Survivin mutants in 20 mM phosphate buffer containing
10 µM Zn2+ at 20 °C.
3.2.6 Involvement of acetylated Survivin in mitosis
Survivin, besides its role as an apoptosis inhibitor, is an essential regulator of cell
division since it is a member of the CPC (Lens et al., 2006). The CPC consists of a ki-
nase module comprising Aurora B and INCENP’s C-terminus, and a regulatory module
composed of Survivin, Borealin and the N-terminus of INCENP. These three proteins
interact with each other forming a helix bundle which stabilizes the complex. The two
modules are linked together by INCENP. A direct interaction of Survivin with Aurora B
occurs only temporarily, when Aurora B phosphorylates Survivin at T117 (Wheatley
et al., 2007). For the formation and the proper localization of the CPC, Survivin’s dimer-
ization state as well as its interaction with the export receptor CRM1 are of particular
importance: on the one hand Survivin is present as a monomer in the CPC since Bo-
realin and INCENP occupy its dimer interface (Jeyaprakash et al., 2007), and on the
other hand the interaction of Survivin with CRM1 is essential for targeting the CPC to
centromers (Knauer et al., 2006). Since Wang et al. (2010b) proposed that Survivin
K129 acetylation regulates both, the protein’s dimerization as well as its interaction
with CRM1, we aimed to analyze the involvement of Survivin acetylated at lysine 129
(SurvK129Ac) in mitosis.
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For this purpose, a primary antibody specific for SurvK129Ac, also described by Wang
et al. (2010b), was tested. This antibody offers the possibility to directly gain insight into
the functions of SurvK129Ac without having to use a mimicking mutant. First tests with
GFP-tagged Survivin wt and mutants showed that the antibody was only able to detect
endogenous Survivin in western blot, but not the overexpressed variants (Figure 3.13).
Figure 3.13: Detection of Survivin K129 acetylation by a specific antibody. Lysates from
293T cells transiently co-transfected with GFP-tagged Survivin mutants and Flag- or HA-tagged
acetyltransferases or empty vector (EV) were immunoblotted. Membranes were probed with
antibodies specific for Flag, HA, GFP or SurvK129Ac.
The SurvK129Ac antibody only detected specific bands at a molecular weight of ap-
prox. 15 kDa indicating endogenous Survivin. These bands only occurred when CBP-
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Flag was co-transfected. A transfection of other lysine acetyltransferases like p300,
PCAF or GCN5 did not result in a detectable Survivin K129 acetylation. In addition,
three unspecific bands were visible at approx. 30, 42 and 60 kDa, but no specific band
could be observed at 43 kDa, the molecular weight of the Survivin-GFP fusion pro-
tein.
To exclude that the C-terminal GFP tag (27 kDa), which is considerably bigger than
Survivin (16.5 kDa), disturbed the binding of the antibody, the experiment was repeated
comparing Survivin-GFP to Survivin constructs with small C-terminal expression tags
(Figure 3.14).
Figure 3.14: Influence of different C-terminal tags on Survivin K129 acetylation. Lysates
from 293T cells transiently co-transfected with GFP-, HA- or myc-tagged Survivin and the Flag-
tagged acetyltransferase CBP or empty vector (EV) were immunoblotted. Membranes were
probed with antibodies specific for Flag, Tubulin, SurvK129Ac, Surv or GAPDH.
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The SurvK129Ac antibody only detected bands in samples containing Survivin wt-HA
or Survivin wt-myc co-transfected with CBP-Flag at a molecular weight of approx.
15 kDa indicating that the detected protein was again endogenous Survivin and not
the transfected Survivin wt-HA (17.5 kDa) or Survivin wt-myc (17.7 kDa). In the sample
containing Survivin wt-GFP co-transfected with CBP, no band was visible.
Next, it was tested whether the antibody could detect overexpressed Survivin with an
N-terminal myc tag (Figure 3.15).
Figure 3.15: Detection of N-terminally tagged Survivin K129 acetylation. Lysates from
293T cells transiently co-transfected with myc-tagged Survivin and Flag-tagged CBP or empty
vector (EV) were immunoblotted. Membranes were probed with antibodies specific for Flag,
Tubulin, GAPDH, SurvK129Ac, Surv or myc.
In both samples in which CBP-Flag was overexpressed, the SurvK129Ac antibody de-
tected a band of a molecular weight of approx. 15 kDa irrespective of whether myc-
Survivin wt had been transfected or not.
The antibody was also tested in IF stainings of HeLa K cells (Figure 3.16).
In untransfected HeLa K cells, the SurvK129Ac antibody revealed a weak and het-
erogeneous nuclear staining. After transfection with myc-Survivin wt, the staining was
more prominent and still mainly nuclear, but also a weak cytoplasmic staining could be
observed.
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Figure 3.16: Cellular localization of K129 acetylated Survivin. HeLa K cells were transiently
transfected with myc-Survivin wt or left untransfected and fixed 24 h later. After permeabiliza-
tion, they were immunostained with antibodies specific for SurvK129Ac (red) and myc (green).
DNA was stained with Hoechst (blue). Images were taken with a Leica SP5 confocal micro-
scope. Scale bar, 20 µm (overview) and 5 µm (zoom), respectively.
As mentioned before, the correct localization and function of Survivin during mitosis
is dependent on its physical interaction with the other CPC members. To analyze this
binding biochemically by IP, 293T cells were co-transfected with Survivin wt-myc and
Borealin- or Aurora B-GFP, and the GFP-tagged proteins were immunoprecipitated
(Figure 3.17). CBP-Flag was co-transfected to enhance acetylation in general.
Co-transfection with GFP or empty vector serving as negative control demonstrated
that there was no unspecific binding of GFP microbeads alone or precipitated GFP
to Surv-myc. Borealin-GFP and Aurora B-GFP both could be precipitated, but overex-
pressed Surv-myc as well as endogenous SurvK129Ac were only co-immunoprecipitated
with Borealin.
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Figure 3.17: Interaction of endogenous K129 acetylated Survivin with Borealin. Lysates
from 293T cells transiently co-transfected with cDNAs encoding myc-tagged Survivin wt, Flag-
tagged CBP and the GFP-tagged CPC proteins Borealin or Aurora B (AurB) or with empty
vector (EV) were immunoprecipitated with magnetic beads coupled to a GFP antibody and
immunoblotted. Membranes were probed with antibodies specific for Flag, myc, GFP and
SurvK129Ac.
Next, the lysine deacetylase inhibitor TSA was used to enhance the general acetylation
level instead of overexpressing CBP. Moreover, the lysate containing Surv-myc and
Aurora B-GFP was incubated at 37 °C for 20 min before adding the antibody-coupled
microbeads. Also myc-tagged INCENP was included in the analysis (Figure 3.18).
As already shown before (Figure 3.17), Survivin was precipitated with Borealin-GFP,
but also with Aurora B-GFP and INCENP-myc. In the sample in which Aurora B-GFP,
INCENP-myc and Survivin-myc were expressed together, only INCENP, but not Sur-
vivin was recovered. In contrast to the results depicted in Figure 3.17, no interaction of
endogenous SurvK129Ac with Borealin or any other CPC member could be shown.
In a further experiment, cDNAs encoding GFP-tagged CPC proteins were co-transfect-
ed again with CBP-Flag to enhance acetylation. As the SurvK129Ac antibody only de-
tects the endogenous protein, overexpression of tagged Survivin was set aside in this
experiment. All lysates were incubated at 37 °C for 20 min before adding the antibody-
coupled microbeads. To accumulate mitotic cells, and thus, increase the amount of
assembled chromosomal passenger complexes, cells were treated with nocodazole,
which arrests them in prometaphase (Figure 3.19).
Endogenous Survivin precipitated with Borealin-, Aurora B- and INCENP-GFP. In asyn-
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Figure 3.18: Impact of TSA-enforced acetylation on SurvK129Ac interaction with mem-
bers of the CPC. 293T cells were transiently co-transfected with empty vector (EV) or with
cDNAs encoding myc- or HA-tagged Survivin and the GFP- or myc-tagged CPC proteins Bo-
realin (Bor), Aurora B (AurB) or INCENP (INC). 24 h after transfection, cells were treated with
100 nM TSA for 16 h. Lysates were immunoprecipitated (IP) with magnetic beads coupled to
a GFP- or myc-specific antibody and immunoblotted (WB). Membranes were probed with anti-
bodies specific for myc, HA, GFP and SurvK129Ac.
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Figure 3.19: Interaction of SurvK129Ac with members of the CPC in cells arrested in mi-
tosis. 293T cells were transiently co-transfected with empty vector (EV) or with cDNAs encod-
ing the GFP-tagged CPC proteins Survivin (Surv), Aurora B (AurB), Borealin (Bor) and INCENP
(INC) and with CBP-Flag. 8 h after transfection, cells were treated with 50 ng/mL nocodazole
for 16 h. Lysates were immunoprecipitated (IP) with magnetic beads coupled to a GFP-specific
antibody and immunoblotted (WB). Membranes were probed with antibodies specific for Flag,
GFP, AurB, Surv and SurvK129Ac.
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chronous as well as in mitotically arrested cells, the strongest interaction with Survivin
was found for Borealin-GFP, the weakest for Aurora B-GFP. Although an interaction of
Survivin with these CPC proteins as well as the expression of CBP-Flag was observed,
no SurvK129Ac was detected in the eluates. A dimerization of Survivin-GFP with the
endogenous protein was could not be detected.
IF stainings were performed to test for co-localization of SurvK129Ac with members
of the CPC. HeLa K cells were fixed, permeabilized, and immunostained with antibod-
ies specific for Survivin or SurvK129Ac and Aurora B, Borealin, INCENP or α-Tubulin
(Figure 3.20).
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Figure 3.20: Localization of endogenous K129 acetylated Survivin in mitosis. HeLa K
cells were fixed, permeabilized and immunostained with antibodies specific for Survivin or
SurvK129Ac (red) and Aurora B, Borealin, INCENP or α-Tubulin (green). DNA was stained with
Hoechst (blue). A) Interphase and prophase. B) Prometaphase and metaphase. C) Anaphase
and telophase. Images were taken with a Leica SP5 confocal microscope. Scale bar, 10 µm.
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Survivin localized primarily to the nucleus in interphase. During mitosis, the typical
chomosomal passenger staining pattern was observed: In prophase, when the chro-
matin condenses to form chromosomes, the CPC is initially found on chromosome
arms, but starts to accumulate at centromeres. It persists at centromeres in prometa-
phase and also in metaphase, when chomosomes align on the spindle equator forming
the characteristic metaphase plate. When the sister chromatids are pulled to opposite
spindle poles in anaphase, the CPC is no longer attached to centromeres, but translo-
cates to the spindle midzone and the cortex. In telophase, the CPC accumulates at
the cleavage furrow, and subsequently, at the midbody, which is located between the
separated and again partly decondensed chromatin. The staining of the other CPC
members Aurora B, Borealin and INCENP showed an exact co-localization with Sur-
vivin in all phases of mitosis. For SurvK129Ac, however, no such localization typical for
CPC proteins was observed.
To gain further insight into the role of Survivin acetylated at lysine 129 in mitosis, the
SurvK129 mutants were transfected in HeLa K cells and their localization in mitosis was
assessed by IF staining (Figure 3.21). It was observed that all of the Survivin mutants,
like wt Survivin, showed a staining typical for CPC proteins in all phases of mitosis.
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Figure 3.21: Localization of myc-tagged Survivin K129 mutants in mitosis. HeLa K cells
transiently transfected with myc-tagged Survivin variants were fixed, permeabilized and im-
munostained with a myc-specific antibody (green). DNA was stained with Hoechst (blue). A)
Interphase and prophase. B) Prometaphase and metaphase. C) Anaphase and telophase. Im-
ages were taken with a Leica SP5 confocal microscope. Scale bar, 10 µm.
108
3 RESULTS
3.3 Characterization of Survivin acetylation at other
lysine residues
3.3.1 Prediction of acetylation sites in Survivin
Lysine acetylation has emerged as a major post-translational modification comparable
to phosphorylation targeting not only histones and other nuclear proteins, but all types
of proteins throughout the cell. Multiple effects of acetylation on target proteins have
been reported including the regulation of protein interaction, function and localization
(Close et al., 2010; Sadoul et al., 2011). Therefore, we aimed to investigate whether
further of Survivin’s 16 lysine residues become acetylated, and which effects a possible
acetylation might have on the divers functions of the protein.
Table 3.1: Results of the prediction of acetylated lysine residues in Survivin.The most
promising values are emphasized.
Source Wang et al. (2010) PAIL ASEB ASEB
Acetylated by CBP CBP/p300 GCN5/PCAF
Position
15 0.0186 0.4180
23 x 0.1761 0.7494
78 0.50 0.0015 0.0899
79 0.69 0.3426 0.6256
90 x 1.82 0.2429 0.3626
91 0.69
103 0.46 0.6145
110 x 0.86 0.1740
112 x 1.09 0.0001 0.3798
115 x 1.22 0.0551 0.0694
120 x
121 x 0.0376 0.6780
122 x 0.53 0.0836 0.8724
129 x 0.56
130 x
To address this questions, first, an in silico analysis was performed using two acetyla-
tion prediction online tools, the PAIL tool and the ASEB tool, which allows KAT-specific
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prediction of acetylation sites (http://bioinfo.bjmu.edu.cn/huac/; Wang et al., 2012). Ta-
ble 3.1 summarizes the respective lysine residues from both predictions together with
the lysines Wang et al. (2010b) reported to be acteylated.
As the prediction tools are based on different mathematical algorithms, the results of
the analysis are by some means divergent. The score put out by PAIL increases with
rising probability for a lysine residue to be acetylated. In contrast, ASEB puts out P-
values which means that low values indicate a high acetylation probability. Unexpect-
edly, there were no values for lysine 129 in both ASEB predictions. This results from
the fact that ASEB prediction only works if the exact sequence coded by the Swiss-Prot
accession number is entered. In case of Survivin, this is a natural variant of the canon-
ical sequence which contains the aforementioned K129E mutation. Thus, the analysis
of the amino acid sequence containing a lysine at position 129, which is referred to as
Survivin wt in this thesis, was not possible. The predictions revealed that lysines 78,
90, 112 and 115 are promiment candidates for further analyses. In addition, some of
the lysine residues suggested to be acetylated by Wang et al. (2010b), especially those
located in vicinity to other potentially acetylated lysines, were also included in further
experiments. Since lysine to arginine and lysine to glutamine mutations are typically
used in studies analyzing protein acetylation, as already mentioned in section 3.1,
only these mutations were introduced. Mutations modifying acetylation at K90 were
of particular interest as it is located in the NES and the overlapping dimer interface
of Survivin. Therefore, also a K90E and a K90,91R double mutant were generated.
Figure 3.22 gives an overview on all myc-Survivin mutants cloned.
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Figure 3.22: Overview on the primary and secondary structure of Survivin illustrating
the positions of mutated lysine residues. The N-terminal BIR domain is depicted in blue,
the NES in orange and the C-terminal α-helix in red. The black line indicates the position of
the dimer interface. A) Amino acid sequence of Survivin wt. Mutated lysine residues are high-
lighted with a light blue box. Acetylation mimicking mutations are indicated in green, mutations
preventing acetylation are indicated in purple. Lysine residues Wang et al. (2010b) found to
be acetylated are marked with an asterisk. B) Domain organization of Survivin. C) Ribbon rep-
resentation of the Survivin monomer (Chantalat et al., 2000; PDB ID: 1E31). Mutated lysine
residues are depicted in stick representation in green. The Zn2+ion is shown as a cyan shpere.
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3.3.2 Effect of Survivin acetylation on its cellular localization
With the new myc-tagged Survivin mutants available, the analysis of their different
properties was carried out analogously to the examination of the SurvK129 mutants.
First of all, in order to investigate their cellular localization, the Survivin mutants were
expressed in HeLa K cells, and their localization was assessed by IF staining (Fig-
ure 3.23). All Survivin mutants exhibited the same localization: the bulk of overex-
pressed protein resided in the cytoplasm of the cells, a minor amount was present
in the nucleus and the nucleoli were completely spared. No clear difference appeared
in the ratio of cytoplasmic to nuclear protein between the Survivin variants. Only the
SurvK90E mutant (Figure 3.23A) showed a slightly decreased amount of nuclear pro-
tein compared to Survivin wt.
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Figure 3.23: Cellular localization of myc-tagged Survivin mutants. HeLa K cells transiently
transfected with myc-tagged Survivin variants were fixed, permeabilized and immunostained
with a myc-specific antibody (green). DNA was stained with Hoechst (blue). A) IF staining
of Survivin wt and the mutants SurvK78Q to SurvK90,91R. B) IF staining of the mutants
SurvK110,112,115Q to SurvK129,130R. Images were taken with a Leica SP5 confocal mi-
croscope. Scale bar, 20 µm (overview) and 10 µm (zoom), respectively.
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3.3.3 Involvement of acetylated Survivin in mitosis
Proper localization and function of Survivin and the CPC during the different phases of
mitosis is essential for accurate control and progression of cell division. Survivin, as a
part of the localization and regulation module of the CPC together with Borealin and
INCENP, forms numerous protein-protein interactions crucial for the localization and
stability of the complex. Some of the lysine residues which were identified as potential
acetylation sites have been shown to form electrostatic interactions within the CPC.
According to Jeyaprakash et al. (2007), lysine residues 110, 112, 120 and 121 are
critical for the stability of the CPC as K110 and K121 form electrostatic interactions
with amino acids in the helix of Borealin, while K112 and K120 build salt bridges with
amino acids in the helix of INCENP. The helices of Survivin, Borealin and INCENP
get in contact when the CPC assembles, forming a tight three-helical bundle, the core
complex of the CPC (Figure 3.24).
K78 has not been shown to form direct interactions with amino acids of other proteins,
but it is located within a region of Survivin’s BIR domain responsible for binding and
recognition of the N-terminus of histone H3 phosphorylated at threonine 3 (H3T3Ph)
(Jeyaprakash et al., 2011; Du et al., 2012). This interaction is necessary to recruit the
CPC to centromers (Kelly et al., 2010; Wang et al., 2010a). As already mentioned, K90
is located within Survivin’s classical NES. The binding of Survivin to CRM1 via its NES
does not only allow Survivin to shuttle between nucleus and cytoplasm, but is also
necessary for the proper localization and function of the CPC (Knauer et al., 2006).
To evaluate their localization in mitosis, the new myc-tagged Survivin variants were
transiently expressed in HeLa K cells, and their localization was assessed by IF staining
(Figure 3.25).
The microscopic analysis revealed no differences in the mitotic localization between
the Survivin mutants and Survivin wt. Of note, for some mutants, no cells in pro- and/or
anaphase were found, although the experiment was repeated several times.
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Figure 3.24: Schematic representation of the three-helix bundle essential for stable CPC
formation. Ribbon representation of the three-helical bundle formed by Survivin (red), Borealin
(blue) and INCENP (green)(Jeyaprakash et al., 2007; PDB ID: 2QFA). Amino acids forming salt
bridges with residues of one of the other proteins are depicted in stick representation (in the
same color as the protein). A) View on the helix bundle perpendicular to the helix axis. B) View
from the C-terminus of Survivin parallel to the helix axis.
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Figure 3.25: Localization of myc-tagged Survivin mutants in mitosis. HeLa K cells tran-
siently transfected with myc-tagged Survivin variants were fixed, permeabilized, and immunos-
tained with a myc-specific antibody (green). DNA was stained with Hoechst (blue). A) IF stain-
ing of Survivin wt and the mutants SurvK78Q to SurvK112R in interphase and prophase. B)
IF staining of Survivin wt and the mutants SurvK78Q to SurvK112R in prometaphase and
metaphase. C) IF staining of Survivin wt and the mutants SurvK78Q to SurvK112R in anaphase
and telophase. D) IF staining of the mutants SurvK115Q to SurvK129,130R in interphase and
prophase. E) IF staining of the mutants SurvK115Q to SurvK129,130R in prometaphase and
metaphase. F) IF staining of the mutants SurvK115Q to SurvK129,130R in anaphase and
telophase. Images were taken with a Leica SP5 confocal microscope. Scale bar, 10 µm.
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3.3.4 Effect of Survivin acetylation on its dimerization
While for a long time Survivin was considered to be existing and functioning only as a
dimer (Muchmore et al., 2000; Song et al., 2004), more recent studies demonstrated
that monomeric Survivin plays crucial roles in diverse cellular processes. It has been
shown that only the Survivin monomer can be part of the CPC (Jeyaprakash et al.,
2007), interact with CRM1 for its nuclear export (Engelsma et al., 2007), and that it
is also involved in the inhibition of caspase-dependent and -independent apoptosis
(Pavlyukov et al., 2011). Although important functions for monomeric as well as dimeric
Survivin in the nucleus and the cytoplasm have been reported, the mechanisms reg-
ulating its dimerization and subcellular localization are still not completely understood.
As mentioned before, Wang et al. (2010b) suggested that the acetylation of Survivin at
K129 functions as a switch between the momoneric and dimeric state of the protein.
To investigate whether a potential acetylation at lysine residues different from K129 is
also able to influence Survivin dimerization, the dimerization of the Survivin variants
was assessed by gel filtration using a Superdex 75 10/300 GL column (GE Healthcare
Life Sciences) (Figure 3.26A). Initially, the SurvK90R and SurvK90Q mutants were
analyzed since, as already mentioned, K90 is located in the dimer interface of Survivin,
thus mutations altering the biochemical properties of K90 could possibly interfere with
Survivin’s dimerization. For gel filtration experiments, recombinant, tag-free proteins
were produced as described in subsubsection 2.2.3.1 and subsection 3.2.3. Again, the
dimerization-deficient SurvF101AL102A mutant was used as negative control.
The elution profile of SurvK90R (red) mostly resembled that of Survivin wt (green) with
the dimer peak eluting at 9.5 mL and the monomer peak eluting at approx. 10.3 mL.
Only the height of the dimer peak was slightly lower than that of Survivin wt. The
peaks of SurvK90Q (orange) were both higher than that of Survivin wt, and their elution
volumes were slightly lower.
Again, the peaks were integrated and the monomer and dimer populations were de-
termined (Figure 3.26B). The quantification revealed 76.5 % dimeric protein in case of
SurvK90Q in comparison to 75 % in case of Survivin wt. With a percentage of 79.5 %
an increased dimerization was observed for SurvK90R.
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Figure 3.26: Dimerization of recombinant, untagged Survivin K90 mutants. A) Gel filtration
profiles of purified, tag-free Survivin mutants in PBS containing 2.5 mM β-mercaptoethanol.
Only the elution range between 8.5 and 11.5 mL is shown. A 280: absorption at 280 nm; AU:
absorption units. B) Quantification of Survivin dimerization. Monomer and dimer peaks of the
gel filtration profiles shown in A were integrated, and the sum of both integrals was set to 100 %.
n = 2; the error bars represent s.d.
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3.3.5 Analysis of the secondary structure of Survivin K90
mutants
The secondary structure of the SurvK90 mutants was also surveyed by CD spec-
troscopy (Figure 3.27) as already performed for the SurvK129 mutants. Both spectra
were similar to that of Survivin wt, with one maximum of the specific ellipticity at approx.
191 nm and two minima at 207 and 225 nm.
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Figure 3.27: CD spectra of recombinant, untagged Survivin K90 mutants. Far-UV circular
dichroism spectra of purified, tag-free Survivin mutants in 20 mM phosphate buffer containing
10 µM Zn2+ at 20 °C.
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Survivin plays crucial roles in various cellular processes. While some of its functions
are conducted by the Survivin monomer, others require the homodimer. However, the
mechanisms regulating Survivin dimerization are not understood yet. As Wang et al.
have claimed that the dimerization as well as the nuclear export of Survivin is regulated
by its acetylation at lysine 129, in this study, we first wanted to verify their results. While
we could confirm their findings concerning the SurvK129E mutant, for example its ex-
clusively cellular localization as well as its reduced tendency to form dimers, we could
not verify their assumption that the results obtained for SurvK129E can be conferred to
wt Survivin unmodified at K129. Furthermore, we aimed to investigate the role of Sur-
vivin acetylated at K129 in mitosis. Here, we found indications that acetylated Survivin
might be incorporated into the chromosomal passenger complex.
As lysine acetylation has emerged as a major post-translational modification capable
of altering the functions and interactions of proteins, we intended to identify further
acetylation sites within Survivin and the effects of a potential acetylation on Survivin’s
divers functions. However, the investigation of 15 Survivin mutants in which one to
three probably acetylated lysine residues were mutated to arginine or glutamine could
not identify potential candidates.
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4.1 Characterization of Survivin acetylation at lysine
129
4.1.1 Influence of the size and and position of different expression
tags on the cellular localization of the SurvivinK129
mutants
As lysine to arginine and lysine to glutamine mutations are conventionally used to mimic
an unmodified or acetylated lysine residue, respectively, initially, we decided to only
analyze Survivin wt and the SurvK129R and SurvK129Q mutants. Additionally, Wang
et al. (2010b) have reported that SurvK129R exhibited the same cellular localization
as SurvK129E, while SurvK129Q localized similar to SurvK129A. Thus, the typical
mutants should have been sufficient to analyze the effect of K129 acetylation. The
GFP tag was chosen as fluorescent fusion proteins can be easily examined for their
expression level and cellular localization without cell fixation and immunostaining. Ad-
ditionally, previous experiments revealed that GFP-tagged Survivin is able to rescue
the functions of endogenous Survivin depleted with siRNA indicating that, despite its
size, the GFP tag does not compromise Survivin’s functionality.
First analyses of the overall acetylation of GFP, GFP-tagged Survivin wt and both mu-
tants revealed that, in accordance to Wang et al. (2010b), acetylation of Surv wt-GFP
increased upon co-expression of the lysine acetyltransferases p300 and CBP (Fig-
ure 3.3). However, acetylated lysine residues were also detected in the isolated GFP
tag raising the question whether the increased acetylation levels were due to Survivin
or GFP acetylation, or both. Thus, for analyses of the general acetylation level using
an AcK antibody, Survivin variants with a lysine-free tag would be required.
Surprisingly, the analysis of the cellular localization of SurvK129R and SurvK129Q
in HeLa cells showed no differences between the GFP-tagged Survivin variants (Fig-
ure 3.4). Whereas Wang et al. (2010b) reported a nuclear localization for Survivin wt
and SurvK129Q and a cytoplasmic localization for SurvK129E, we observed that Sur-
vivin wt as well as both mutants predominantly localized to the cytoplasm. In contrast
to Wang et al. (2010b), who used Survivin mutants with an N-terminal myc tag, our
mutants were C-terminally tagged with GFP. Hence, the predominantly cytoplasmic lo-
calization of the Survivin-GFP variants could be due to the larger size of the proteins
compared to the myc-tagged variants. Nevertheless, LMB treatment of HeLa cells ex-
pressing the Survivin-GFP variants led to a nuclear accumulation of the proteins (data
not shown), demonstrating that Survivin-GFP can passively diffuse into the nucleus. In
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addition, a huge protein like GFP fused to the C-terminus of Survivin might mask the
α-helix, thus affecting the normal function and localization of Survivin. Due to the afore-
mentioned reasons and the finding that GFP itself is acetylated, Survivin wt and both
mutants were cloned with smaller C-terminal expression tags (myc and HA). However,
the cellular localization of the Survivin variants with smaller tags (Figure 3.5 and data
not shown) was comparable to that observed for the GFP-tagged proteins with the only
difference that the nuclear proportion of protein was slightly increased. This demon-
strates that the GFP tag was not the reason for the deviant results. Nevertheless, even
a small C-terminal tag could interfere with a mutational effect at position 129.
Therefore, Survivin wt as well as the SurvK129R and SurvK129Q mutant was finally
cloned with an N-terminal myc tag in order create the same conditions as reported
in the study by Wang et al. (2010b), although acetylation prediction revealed that the
lysine within the myc tag is likely to be acetylated if the tag is placed at the N-terminus
of the protein. Also the unconventional SurvK129E and SurvK129A mutants were in-
cluded in our study. To avoid staining artifacts as observed in Figure 3.5, an optimized
IF protocol including an extended permeabilization step was applied. In addition, a dif-
ferent strain of HeLa cells, HeLa Kyoto, was used for subsequent microscopic analyses,
as these cells have a larger cell body, they form an ordered monolayer and no staining
artifacts like membrane straining occur in IF experiments.
However, as discussed in subsection 4.1.2, the N-terminally myc-tagged mutants
SurvK129R and SurvK129Q exhibited an identical cellular localization as the mutants
with C-terminal myc or HA expression tags implying that the C-terminal tags were not
the reason why no differences could be observed in the cellular localization of the
acetylation mimicking (SurvK129Q) and the acetylation preventing (SurvK129R) mu-
tant.
4.1.2 Transferability of the results obtained for SurvivinK129E to
Survivin unmodified at lysine 129
The microscopic analysis of HeLa K cells expressing the myc-Survivin variants re-
vealed a predominantly cytoplasmic localization of Survivin wt, SurvK129R and
SurvK129Q (Figure 3.6). The second acetylation mimicking mutant, SurvK129A, also
exhibited a similar cellular distribution. Only SurvK129E, representing a natural variant
of Survivin in which the positively charged lysine at position 129 is exchanged by a neg-
atively charged glutamate, exhibited a clearly different localization as it was detected
exclusively in the cytoplasm. This hints towards a facilitated export of SurvK129E by
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the nuclear export receptor CRM1 as suggested by Wang et al. (2010b). However,
the contradictory findings for SurvK129E and SurvK129R were surprising since Wang
et al. (2010b) reported a predominantly cytoplasmic localization for SurvK129E, but
also for SurvK129R, arguing that this is caused by their acetylation abolishing function.
Our results, however, indicate that SurvK129E is not comparable to SurvK129R. In
contrast, our findings suggest that the effect observed for SurvK129E might not be due
to the inhibition of acetylation by the mutation as in that case the same effect should
be detectable for SurvK129R. The results obtained by IF experiments could be verified
by western blot analyses of lysates prepared from nuclear and cytoplasmic fractions of
cells expressing the Survivin variants.
Because Wang et al. (2010b) argued that SurvK129E forms less stable dimers than
wt Survivin, the homodimerization of the Survivin variants was investigated by IP ex-
periments in 293T cells (Figure 3.7). Again, contradictory results were obtained for
the acetylation abolishing mutants. While SurvK129R exhibited a dimerization capa-
bility similar to Survivin wt, SurvK129E preferentially existed as a monomer like the
dimerization-deficient SurvF101AL102A mutant. These findings again suggest that the
effects observed for SurvK129E are not based on a lack of acetylation at position 129.
Instead, they suggest that the presence of a negatively charged glutamate instead of a
positively charged lysine at this position alters protein-protein interactions, for instance
with CRM1. This impression is confirmed by the reduced dimerization tendency found
for SurvK129Q and SurvK129A. According to Wang et al. (2010b), acetylation at K129
facilitates the formation of Survivin dimers. Thus, the acetylation mimicking mutants
were supposed to preferentially exist as dimers like Survivin wt instead of exhibiting a
decreased dimerization. The SurvK129R mutant, which mimics Survivin unacetylated
at K129, however, formed dimers comparable to Survivin wt. Hence, contrary to the
findings of Wang et al. (2010b), our results suggest that acetylation at K129 impairs
Survivin dimerization rather than facilitating it.
IP experiments were accompanied by gel filtration analyses of recombinant, tag-free
Survivin variants. This allows to test in a cell-free background whether the introduced
mutations directly affect the homodimerization of the proteins (Figure 3.8). Due to dif-
ferent protein concentrations of the samples, the peaks of the elution profiles reached
different heights which impeded their comparison. Thus, the dimer and the monomer
peaks were integrated in order to obtain the percentage of dimeric and monomeric
Survivin. The quantitative analysis revealed that all Survivin variants predominantly ex-
isted as homodimers, except for the dimerization-deficient mutant SurvF101AL102A
serving as negative control. The monomer and dimer ratio was equal in all samples.
Only for SurvK129A, a slightly higher proportion of dimeric protein was determined,
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but in contrast to the other Survivin mutants, the protein was only analyzed once. As
expected, none of the mutations at position 129 directly interfered with the formation
of Survivin homodimers, as they are not positioned within the dimer interface (aa 6-10
and 89-102). Thus, the different dimerization capabilities of the mutants observed in
cell-based IP experiments are likely to be mediated by altered interactions with other
proteins, for example CRM1.
As Wang et al. (2010b) proposed that SurvK129E is exported from the nucleus more
efficiently than Survivin wt due to its enhanced interaction with CRM1, first of all, we in-
vestigated whether all myc-Survivin variants are exported in a CRM1-dependent man-
ner (Figure 3.9). Therefore, HeLa K cells expressing the myc-Survivin variants were
either treated with the CRM1 inhibitor leptomycin B, or left untreated, and the local-
ization of the Survivin variants was investigated microscopically. As expected, in un-
treated cells, all Survivin variants, except for SurvK129E, predominantly localized to
the cytoplasm as already depicted in Figure 3.6. LMB treatment led to a nuclear ac-
cumulation of Survivin wt as well as all SurvivinK129 variants demonstrating that their
export from the nucleus is mediated by CRM1. However, less protein accumulated
in the nucleus than in case of the positive control SurvNESmut-GFP, which exhibited
a strong nuclear enrichment already prior to CRM1 inhibition. This might be due to
the fact that, with their small molecular weight of 17.9 kDa, the myc-Survivin variants
can more easily exit the nucleus by passive diffusion than SurvNESmut-GFP (43 kDa).
Thus, to achieve a more distinct effect upon CRM1 inhibition not hampered by passive
diffusion as well as a better comparability, Survivin-GFP variants should be used for
this assay. SurvF101AL102A, which again served as positive control, exhibited a cellu-
lar distribution similar to that of Survivin wt in untreated cells, although Engelsma et al.
(2007) have shown that it undergoes enhanced CRM1 binding. This indicates that the
enhanced interaction of a Survivin mutant with CRM1 via its classical NES (aa 89-98)
does not seem to be sufficient for its complete exclusion from the nucleus as observed
in case of SurvK129E.
In order to quantify the interaction of the Survivin variants with CRM1, we performed
IP experiments in 293T cells. In a first approach, CRM1 was directly precipitated from
the lysates by its HA tag, and the co-immunoprecipitation of the myc- or GFP-tagged
Survivin variants was analyzed (Figure 3.10). In a second experiment, the Survivin
mutants were precipitated from the lysates, and the CRM1 co-IP was analyzed (Fig-
ure 3.11). The experiments did not provide consistent results. In addition, the results
have to be assessed as not meaningful as the positive as well as negative control did
not exhibit the expected results. SurvF101AL102A was used as positive control as En-
gelsma et al. (2007) have demonstrated an enhanced binding to CRM1. However, our
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interaction analysis showed a 55 % reduction in the interaction of SurvF101AL102A
with CRM1 compared to Survivin wt. In contrast, the negative control SurvNESmut,
which is unable to bind CRM1 due to mutations of two essential leucine residues within
its NES (Knauer et al., 2006), exhibited an only 28 % and 58 %, respectively, reduced
interaction with CRM1 compared to Survivin wt. The results indicate that either the IP
protocol or the quantification method have to be optimized in order to gain reliable re-
sults concerning the interaction of CRM1 with Survivin mutants. Perhaps the additional
incubation of the lysates for 20 min at 37 °C prior to the addition of antibody-coupled
microbeads should be omitted, though it improved the results for Survivin dimeriza-
tion IPs. Quantification could be improved by using secondary antibodies coupled to
near-infrared fluorescence dyes for western blotting allowing the direct detection and
quantification of protein bands with the Odyssey System (LI-COR Biotechnology). An-
other possibility to examine the CRM1-Survivin binding is an in vitro pulldown assay
using purified Survivin proteins and either purified or in vitro translated CRM1.
In order to exclude that conformational changes caused by the introduced mutation
are the reason for the altered behavior of the SurvK129E mutant, the secondary struc-
ture of the recombinant, tag-free Survivin variants was examined by CD spectroscopy
(Figure 3.12). Identical CD spectra were recorded for Survivin wt and the other vari-
ants showing one maximum of the specific ellipticity at approx. 191 nm and two minima
at 207 and 225 nm characteristic for proteins containing a high proportion of α-helical
structures. These results demonstrate that the facilitated nuclear export as well as the
reduced dimerization of SurvK129E are not due to an altered secondary structure of
the mutant. Only the spectrum of the dimerization-deficient SurvF101AL102A mutant
differed from the others as the negative peak at 225 nm was missing. This indicates
a reduced amount of α-helical structures probably due to a partial unwinding of the
C-terminal α-helix caused by the double mutation. CD measurements at a constant
wavelength of 209 nm (the wavelength at which one of the minima appears in the CD
spectrum of a protein α-helix) over a distinct temperature range (melting curves) could
reveal potential stability problems in the helix.
4.1.3 Emergence of a potential high-affinity export signal in the
C-terminus of Survivin as an explanation for the unique
behavior of the SurvivinK129E mutant
In summary, contrary to Wang et al. (2010b) who reported a predominatly cytoplas-
mic localization of SurvK129E and SurvK129R, we observed this localization for the
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SurvK129E mutant only. SurvK129R, however, exhibited a cellular localization com-
parable to Survivin wt and the mutants SurvK129Q and SurvK129A. Furthermore, we
could confirm that SurvK129E preferentially exists as a monomer, but again, different
results were obtained for SurvK129R which was shown to form dimers like Survivin wt.
The different results for SurvK129E and SurvK129R indicate that the facilitated export
and reduced dimerization of SurvK129E are unlikely to be caused by a lack of acetyla-
tion at position 129 because if that was the case, the effects should also be detectable
for SurvK129R. While the direct inhibition of dimerization as well as the disruption of
correct protein folding by the K129E mutation could be excluded as reasons for the
different results obtained for SurvK129E, an increased interaction with CRM1 could
provide a potential explanation. However, the comparison of the cellular localization
of SurvK129E with that of SurvF101AL102A, which, despite its enhanced interaction
with CRM1, localized like Survivin wt, suggests that the increased export of SurvK129E
leading to a complete absence of the protein from the nucleus is probably not mediated
by its classical NES, but occurs either NES-independently via adapter proteins, or is
mediated by a second, non-classical export motif. In fact, Rodriguez et al. (2002) have
reported that Surv119-142, which lacks the classical NES, is as efficiently exported
by CRM1 as Surv89-136 containing the NES. Nevertheless, full-length Survivin was
exported even more efficiently. Rodriguez et al. (2002) argued that the nuclear export
of Surv119-142 is likely to be mediated by NES containing adapter proteins confirming
the hypothesis that the K129E mutation could alter, and thus enhance the interaction
with such a protein leading to an increased export.
However, analysis of the amino acid sequence of Survivin’s C-terminus revealed the
presence of a cluster of hydrophobic amino acids between F124 and M141 hinting at
a potential export signal (Figure 4.1D). NESs are peptides of 8 to 15 amino acids con-
taining clusters of hydrophobic residues separated by spacers of other amino acids.
The classical consensus sequence is Φ1-X2,3-Φ2-X2,3-Φ3-X-Φ4, where Φ represents a
hydrophobic amino acid like leucine, valine, isoleucine, phenylalanine, or methionine,
and X can be any amino acid (Xu et al., 2012). However, the NES consensus is con-
tinuously updated and refined as recently by Güttler et al. (2010) or Xu et al. (2012).
Güttler et al. (2010), for example, redefined the NES consensus by analyzing struc-
tures of PKI-type and Rev-type NESs bound to CRM1. They proposed that, in addition
to the classical four hydrophobic residues Φ1 to Φ4, a fifth hydrophobic residue, Φ0,
can contribute to CRM1 binding as the NES binding site of CRM1 comprises five hy-
drophobic pockets. Furthermore, they stated characteristics for PKI-class as well as for
Rev-class export signals summarized in Figure 4.1A and B.
Taking these characteristics into account, a potential 5Φ PKI-class export motif can be
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Figure 4.1: Identification of a potential NES in the Survivin C-terminus. A) and B) Charac-
teristics of PKI-class and Rev-class NESs (modified after Güttler et al., 2010). C) Consensus
sequence for PKI-class NESs (Güttler et al., 2010). D) Amino acid sequence of the Survivin
C-terminus (aa 100-142) indicating hydrophobic amino acids (light blue). K129 is highlighted
in yellow. The position of the hypothesized NES is indicated by an orange box. Colors and
annotations were selected according to A.
located within Survivin’s C-terminus between A128 and M141 revealing a Φ0-X2-Φ1-
X3-Φ2-X2-Φ3-X2-Φ4 sequence (Figure 4.1D). Hence, except for the spacer between
Φ3 and Φ4, which is too long by one amino acid, this identified potential NES is con-
sistent with the consensus for PKI-class NESs (Figure 4.1C) defined by Güttler et al.
(2010). However, the proper composition and spacing of amino acids in the C-terminus
of a NES are critical for CRM1 binding. The mutation of the Φ3 and Φ4 positions to
alanine, for example, is sufficient to completely abolish the export activity of a NES
(Knauer et al., 2006; Güttler et al., 2010). In addition to the requirements for the Φ-
positions, Güttler et al. (2010) found that acidic residues are preferred in the spacer
between Φ0 and Φ1 as they engage in electrostatic interactions with K522 and K560
of the CRM1 NES binding pocket. In Survivin wt this is not the case as two lysine
residues are located in this position likely to undergo electrostatic repulsion with K522
and K560 of CRM1. The K129E mutation, however, alters this unfavorable condition
by exchanging at least one positively charged lysine residue with negatively charged
glutamate. Thus, a possible explanation for the observed facilitated CRM1-dependent
export of SurvK129E could be the conversion of a low-affinity NES in Survivin wt to a
high-affinity NES due to the exchange of lysine with glutamate. Similar effects elicited
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by the exchange of neutral residues with acidic amino acids within the Φ0-Φ1 spacer
have been reported by Güttler et al. (2010). Of course, this hypothesis has to be fur-
ther validated, for example by investigating the cellular localization as well as CRM1
interaction of SurvK129 mutants lacking amino acids 1-98 by IF and IP experiments.
Furthermore, microinjection of recombinant proteins consisting of the potential NES
flanked by an N-terminal GST and a C-terminal GFP tag into the nucleus of adherent,
mammalian cells would provide deeper insight into the functionality of the hypothesized
export signal.
The presence of a high-affinity NES in the C-terminal α-helix of Survivin, however,
does not per se explain the preferentially monomeric state of SurvK129E as this po-
tential export signal does not overlap with Survivin’s dimer interface (aa 6-10 and 89-
102). However, enhanced CRM1 binding to this site could probably sterically hamper
dimerization. One has also to take into consideration that the hydrophobic amino acids
representing the Φ positions of the potential C-terminal NES are the same as those en-
gaging in hydrophobic contacts with Borealin and INCENP within the three-helical bun-
dle that stabilizes the CPC (Figure 4.2). Hence, an enhanced CRM1 binding to this site
could probably interfere with CPC assembly. SurvK129E, though, localized correctly
in all phases of mitosis. However, the competition of CRM1 and Borealin/INCENP for
Survivin binding also occurs at the classical NES as Borealin and INCENP bind to Sur-
vivin’s dimer interface. This suggests that the binding of CRM1 and Borealin/INCENP,
although being mediated by the same amino acids, are temporally and/or spatially sep-
arated processes that do not affect each other.
Figure 4.2: Interactions of Survivin in the CPC core. Structure-based-sequence alignments
indicating amino acid conservation and interactions of Survivin with Borealin and INCENP. The
secondary structure elements are shown below the sequences. Conserved residues are high-
lighted in green. Above the sequences, colored circles identify residues involved in interactions
with Borealin (magenta circles) and INCENP (orange circles). hs: Homo sapiens, xl: Xenopus
laevis, dr: Danio rerio (modified after Jeyaprakash et al., 2007).
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4.1.4 Involvement of Survivin acetylated at lysine 129 in CPC
formation
In order to investigate the involvement of Survivin acetylated at K129 in mitosis, a topic
which has not been addressed in the study by Wang et al. (2010b), we intended to uti-
lize a commercially available primary antibody specific for SurvK129Ac, which had also
been used by Wang et al. (2010b). We assumed the SurvK129Ac antibody would offer
advantages over the aforementioned SurvK129Ac mimicking mutants since it directly
detects acetylated Survivin. Thus, it does not have to be considered whether any find-
ings are due to acetylation or simply to the introduced mutation as discussed above.
Wang et al. (2010b) could detect overexpressed acetylated myc-Survivin wt in western
blot, and an intense nuclear staining of endogenous SurvK129Ac in IF experiments.
Our tests of the SurvK129Ac antibody, however, revealed that overexpressed, tagged
Survivin is not recognized in western blot irrespective of the expression tag or its posi-
tion (Figure 3.13 - Figure 3.15). Only endogenous SurvK129Ac could be detected upon
CBP co-expression. Moreover, in IF stainings of untransfected HeLa K cells, or cells
transfected with myc-Survivin wt, only a weak, heterogeneous, predominantly nuclear
staining was detected (Figure 3.16), which, however, was more intense in transfected
cells indicating that the antibody might recognize overexpressed Survivin under native
conditions.
The antibody was first applied in IP analyses in 293T cells aiming to find out whether
SurvK129Ac engages in interactions with members of the chromosomal passenger
complex (Figure 3.17). We found that Borealin, which together with Survivin and
INCENP’s N-terminus belongs to the localization module of the CPC, interacts with
Survivin-myc as well as with endogenous SurvK129Ac. This was surprising as on
the one hand it is known that Survivin is a monomer within the CPC as Borealin and
INCENP occupy its dimer interface (Jeyaprakash et al., 2007), but on the other hand
Wang et al. (2010b) have claimed that SurvK129Ac preferentially exists as a dimer.
Our results, however, suggest that at least one portion of Survivin acetylated at K129
is present in a monomeric state and can be incorporated into the CPC. Together with
Aurora B, neither Survivin-myc nor SurvK129Ac could be co-precipitated. In case of
overexpressed Survivin-myc, this was unexpected. Though a direct interaction of both
proteins occurs only temporarily when Aurora B phosphorylates Survivin at T117, the
proteins are linked by INCENP within the CPC . However, this indirect interaction does
not seem to be sufficient to co-precipitate Survivin with Aurora B under the applied
conditions. Based on findings by Honda et al. (2003) who suggested that in mitosis,
the CPC is only stable if all members are present, a possible explanation could be
that the expression of endogenous Borealin and INCENP in this sample was not suffi-
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cient to form a detectable amount of assembled CPCs. Recent work by the Musacchio
group (personal communication), however, has shown that the CPC core comprising
Survivin, Borealin and INCENP’s N-terminus is also stable in the absence of Aurora B.
This suggests that Aurora B is possibly not only present and functional as a member of
the CPC, which might explain why Survivin could not be precipitated with the kinase.
With a further IP experiment, we wanted to verify the finding that Borealin interacts with
SurvK129Ac, and also wanted to include INCENP in the study (Figure 3.18). As for this
experiment the cells had to be transfected with three different plasmids, we decided
to enhance acetylation by treating the cells with TSA instead of transfecting them with
cDNA coding for CBP. Survivin was co-immunoprecipitated with Borealin and INCENP,
and the additional incubation for 20 min at 37 °C prior to the IP allowed the precipitation
of Survivin also with Aurora B. However, we could neither confirm the interaction of
Borealin with SurvK129Ac, nor could we detect an interaction of Aurora B or INCENP
with acetylated Survivin.
Thus, in another IP experiment, the conditions were changed again (Figure 3.19).
As the SurvK129Ac antibody only detects the endogenous protein, overexpression of
tagged Survivin was set aside. Additionally, transfection of CBP-encoding cDNA was
again applied to enhance acetylation, and all lysates were incubated for 20 min at 37 °C
before adding the micro beads. In order to arrest cells in prometaphase, thus increasing
the amount of assembled CPCs, cells were treated with nocodazole. While the analysis
of the IP with a GFP-specific antibody suggested a low IP efficiency, the analysis with
antibodies specific for Survivin and Aurora B showed intense bands for Survivin-GFP
and Aurora B-GFP, which hints towards a problem with the GFP-specific antibody. For
Borealin and INCENP, this was not tested due to the lack of specific antibodies working
in western blot. The IP revealed that, although endogenous wt Survivin co-precipitated
with Borealin, Aurora B and INCENP, SurvK129Ac does not seem to interact with these
CPC members. Dimerization of endogenous Survivin with Survivin-GFP could not be
detected. This is not surprising as Survivin-GFP homodimerization is likely to outbal-
ance the formation of heterodimers of Survivin-GFP with endogenous Survivin. The
results were similar in mitotically arrested and asynchronous cells.
In summary, the interaction of Borealin with Survivin acetylated at K129 could not be
verified. It has to be noted that the SurvK129Ac antibody used in the experiments
depicted in Figure 3.18 and Figure 3.19 was of a different lot than that used in the first
IP experiment (Figure 3.17). With the new lot, no SurvK129Ac could be detected in any
western blot analysis performed, not even in test experiments where cells were only
transfected with CBP, or treated with TSA. In addition, at the same time, the production
of the PVDF membrane used for western blotting was discontinued. Thus, for the latter
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IP experiments, a new membrane with a lower protein binding capacity had to be used.
It is therefore unclear whether the lack of a signal from the SurvK129Ac antibody is due
to a lack of interaction of Survivin acetylated at K129 with other CPC proteins, or if this
is caused by a technical problem with the new antibody lot or the PVDF membrane.
Hence, as a direct investigation of SurvK129Ac is not possible, IP analyses of the
interaction of CPC proteins with the SurvK129R and SurvK129Q mutants could provide
further insight into the involvement of SurvK129Ac in mitosis.
IP experiments were accompanied by IF stainings in order to analyze the localization
of SurvK129Ac in mitotic HeLa K cells and its co-localization with CPC members (Fig-
ure 3.20). This was again performed using the SurvK129Ac-specific antibody. While
Survivin showed a staining pattern typical for CPC proteins, and exhibited an exact co-
localization with Aurora B, Borealin and INCENP, for SurvK129Ac no such localization
could be observed. In interphase cells, the aforementioned weak, heterogeneous, pre-
dominantly nuclear staining was visible, whereas in mitotic cells, the staining was de-
tected in the whole cell, but DNA was spared. These findings indicate that SurvK129Ac
is not a part of the CPC, but as mentioned above, it is not clear whether the antibody
specific for SurvK129Ac yields reliable results.
In order to avoid using the SurvK129Ac antibody, but, nevertheless, obtain more in-
formation on a potential role of SurvK129Ac in mitosis, we analyzed the mitotic local-
ization of the myc-SurvK129 mutants in HeLa K cells (Figure 3.21). The experiment
revealed that all mutants localized like myc-Survivin wt. Concerning the SurvK129Q
mutant, which is supposed to mimic Survivin acetylated at K129, this suggests that
SurvK129Ac can be incorporated into the CPC. However, this finding is contradictory to
the results gained using the SurvK129Ac antibody and also to the theory by Wang et al.
(2010b) that SurvK129Ac predominantly exists as a dimer. In addition, as we found the
dimerization of SurvK129Q to be clearly reduced, it is not unlikely that SurvK129Q or
SurvK129Ac, respectively, can be a member of the CPC.
To verify this, IF experiments should be performed in the absence of endogenous Sur-
vivin as it might undo the effects of the mutants. To this end, endogenous Survivin
should be depleted with siRNA. As siRNA also has to be transfected into HeLa K cells,
and a simultaneous as well as a successive transient transfection of plasmid DNA and
siRNA dramatically reduces the transfection efficiency and viability of the cells, this
should be done in HeLa K cells stably expressing the Survivin variants. One way to
generate stably expressing HeLa K cells is via the Flp-In system (Life Technologies).
Here, the gene of interest is introduced into the cell genome with the help of the Sac-
charomyces cerevisiae DNA recombinase Flp. Another way to achieve a constitutive
expression of Survivin variants in HeLa K cells would be by lentiviral transduction tak-
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ing advantage of the ability of lentiviruses like HIV to stably integrate their own genome
into that of host cells.
4.2 Characterization of Survivin acetylation at other
lysine residues
We also aimed to investigate whether further of Survivin’s 16 lysine residues are acety-
lated, and which effects a possible acetylation might have on Survivin’s functions. To
this end, we performed acetylation predictions with two different online tools, and com-
pared the results with those obtained by mass spectrometric analyses performed by
Wang et al. (2010b) (Table 3.1). Furthermore, we wanted to identify acetylated lysine
residues by own mass spectrometric measurements. However, due to problems with
sample preparation this approach has not yet yielded any results. The Survivin proteins
to be analyzed were isolated from 293T lysates with antibody-coupled magnetic micro
beads using µMACS Isolation kits (Miltenyi Biotec). Precipitated proteins can be effi-
ciently eluted from the micro beads with a denaturing buffer containing DTT and SDS.
These substances have to be removed from the sample prior to mass spectrometric
measurements. However, sample purification could not be achieved without a loss of
the protein. Another way to elute precipitated proteins from the columns is with a non-
denaturing solution of triethylamine inducing a pH shift. This elution method, however,
did not yield a sufficient amount of protein. Therefore, sample preparation as well as
purification have to be improved.
Based on the findings of the in silico analysis, 15 new myc-tagged Survivin mutants
were cloned. Since lysine to arginine and lysine to glutamine mutations are typically
used in studies analyzing protein acetylation, only these mutations were introduced
with the exception of SurvK90E. We believed it would be interesting to analyze the
effect of a lysine to glutamate exchange within Survivin’s classical NES as it could, at
least to some extent, resemble the effect of the K129E mutation.
First of all, the cellular localization of the mutants was examined by IF stainings in
HeLa K cells (Figure 3.23). The experiments revealed that, except for SurvK90E, which
exhibited a reduced nuclear localization, the localization of all Survivin mutants resem-
bled that of Survivin wt. The finding that SurvK90E also showed a reduced nuclear
localization, albeit to a lesser extend than SurvK129E, confirms that the exchange of
a positively charged lysine with a negatively charged glutamate within a spacer se-
quence of a NES can indeed lead to facilitated CRM1 binding and nuclear export. As
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already argued concerning the the cellular localization of the SurvK129 mutants, the
results could be verified by performing fractionation experiments . In addition, the nu-
clear export of SurvK90E must be further analyzed to validate this theory. To test for
a facilitated export of SurvK90E, its NES could be expressed as a recombinant fusion
protein with GST and GFP, and microinjected into the nucleus of adherent cells. Its
interaction with CRM1 could be investigated on the one hand in cells by performing IP
experiments. On the other hand, the binding of recombinant SurvK90E or its NES to
in vitro translated or recombinant CRM1 could be analyzed by performing pull-down
assays.
As almost all of the newly cloned Survivin variants contained mutations possibly af-
fecting CPC localization as well as stability (see subsection 3.3.3) we aimed to ex-
amine their mitotic localization by IF experiments in HeLa K cells (Figure 3.25). The
analysis revealed that all Survivin mutants exhibited the same localization as Survivin
wt. This was especially unexpected for the mutants SurvK110,112,115Q, SurvK112Q,
and SurvK120-122Q as they contain lysine to glutamine mutations at positions which
have been demonstrated to engage in electrostatic interactions with aspartate or gluta-
mate residues of the helices of Borealin and INCENP (Jeyaprakash et al., 2007) (Fig-
ure 3.24). Thus, hampering these contacts either by removing lysine’s positive charge
by acetylation, or by exchanging lysine with glutamine, could likely lead to a destabi-
lization, or even disassembly of the three-helix bundle. However, only one electrostatic
contact to INCENP is lost in case of SurvivinK112Q, and one contact to INCENP as well
one to Borealin is abolished in case of SurvK110,112,115Q and SurvK120-122Q. This
might not be sufficient to destabilize the three-helical bundle as it is additionally sta-
bilized by hydrophobic interactions of other amino acids. Nevertheless, it would be in-
teresting to analyze the effect of a multiple K110,112,120,121Q mutation, which would
abrogate all of Survivin’s salt bridges to Borealin and INCENP within the three-helix
bundle. As mentioned above, effects which could be hidden by endogenous Survivin
could become more obvious when Survivin is depleted with siRNA.
Survivin plays crucial roles in divers cellular processes, for example in mitosis and
apoptosis. In some of these processes, Survivin is involved as a monomer, whereas
other functions are exerted by the dimer. However, it is still not completely understood
how the dimerization of Survivin is regulated. As PTMs can function as regulators of
protein-protein interactions, we aimed to test whether any of the new Survivin mutants
shows an altered dimerization due to the inhibition of post-translational modifications,
or the mimicry of acetylated lysine. Since mutations within the dimer interface could
most likely affect Survivin dimerization, initially, the SurvK90R and SurvK90Q mutants
were analyzed by gel filtration (Figure 3.26). SurvK90E was not analyzed as, at that
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point in time, the mutant had not been cloned into the GST-PreSc vector. The determi-
nation of the dimeric and monomeric proportion within the samples revealed that both
mutants predominantly form dimers like Survivin wt. An 1.5 % and 4.5 % increased
proportion of dimeric protein was found for SurvK90Q and SurvK90R, respectively,
compared to the wt protein. However, the differences were not significant. From these
results, it can be concluded that acetylation of Survivin at K90, as mimicked by the
SurvK90Q mutant, does not directly affect Survivin dimerization. In order to determine
its indirect effect on dimerization, which could be mediated by an alteration in CRM1
binding, IP analyses have to be performed.
The secondary structure of SurvK90R and SurvK90Q was analyzed by CD spec-
troscopy (Figure 3.27). Both mutants exhibited CD spectra identical to that of Sur-
vivin wt indicating that the introduced mutations do not hamper the folding of the pro-
teins. The stability of the mutants could be further investigated by recording CD melting
curves, for example at 209 nm.
In summary, concerning the SurvK129 mutants, we could not verify the findings re-
ported by Wang et al. (2010b). In contrast, our results indicate that the effect observed
for the SurvK129E mutant is not due to a lack of acetylation at K129, but is rather
caused by the emergence of a high-affinity NES in Survivin’s C-terminal α-helix. Fur-
thermore, our experiments suggest that acetylation at K129 rather impairs Survivin
dimerization than facilitating it. We have also found indications that Survivin acetylated
at K129 could be involved in mitosis. The investigations conducted in order to discover
further acetylation sites regulating Survivin’s localization or function could not identify
potential candidates. We could only show that, although K90 is located within Survivin’s
NES, its acetylation is unlikely to affect the protein’s dimerization. However, in order to
validate the obtained results and to gain a deeper understanding of how Survivin is
regulated by acetylation, further studies have to be performed as discussed in detail
above.
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Vector maps
The following figures depict the position of the Survivin cDNA in the pc3 or pET41-
GST-PreSc expression vectors.
Figure A.1: pc3-Survivin-GFP.
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Figure A.2: pc3-myc-Survivin.
Figure A.3: pET41-GST-PreSc-Survivin.
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